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Palladium based anti-cancer agents have been identified as potential replacements for known 
platinum based chemotherapeutics. However, only a limited number of these compounds have 
managed to progress beyond the laboratory due to a lack of understanding surrounding their mode 
of action and structure activity relationships. Hence, the aim of this study was to synthesize a small 
library of trans-Pd(II)-1-substituted-4-phenyl-1,2,3-triazolyl and N,N’-bidentate Pd(II)-1-substituted-
4-pyridyl-1,2,3-triazolyl complexes for evaluation against human breast cancer cell lines. The DNA 
interaction modes of the active compounds were investigated with DNA migration and DNA titration 
studies. 
A number of known (1a – 3a, 7a – 9a, 1b – 3b, 7b, 9b) and novel (4a – 6a, 4b – 6b, 8b) 1-substituted-
4-phenyl-1,2,3-triazole and 1-substituted-4-pyridyl-1,2,3-triazole ligands were synthesized, in 
moderate to good yields. The N-bound substituents were varied in order to investigate the effects of 
sterics, electronics and hydrophilicity on the cytotoxicity of the resulting complexes. All ligands were 
characterized using FTIR, 1H NMR and 13C NMR spectroscopy, as well as ESI-MS spectrometry. 
Elemental analysis was also employed to confirm the purity of the compounds. 
Complexation of 1a – 9a to Pd(II) yielded the trans-Pd(II)-phenyl-1,2,3-triazolyl complexes (T1a – 
T9a) in moderate to good yields. It was observed that these compounds dissociate in DMSO and an 
NMR study was conducted to confirm that ligand exchange indeed takes place. Complexation of 
ligands 1b – 9b to Pd(II) yielded the N,N’-bidentate-Pd(II)-pyridyl-1,2,3-triazolyl complexes (N1b – 
N9b) in moderate to good yields. Unlike the trans-Pd(II)-1-substituted-4-phenyl-1,2,3-triazolyl 
complexes, the N,N’-bidentate-Pd(II)-pyridyl-1,2,3-triazolyl complexes displayed no signs of ligand 
exchange in DMSO. Characterization of all complexes was carried out using FTIR, 1H and 13C NMR 
spectroscopy, ESI-MS and elemental analysis. 
The kinetic solubility in a 2 % (V/V) DMSO/PBS solution of all complexes was determined using a 
turbidimetric assay. It was found that all complexes were moderately soluble with the exception of 
complexes T2a, T7a, T9a and N1b. The cytotoxicity of these complexes were thus evaluated as 
suspensions. Owing to the ligand dissociation observed for complexes T1a – T9a, the cytotoxicity 
observed for the treatment of cells with these complexes cannot be ascribed to the activity of the 
original complexes but rather to a mixture of species in solution. 
The cytotoxicity of the complexes was evaluated employing a MTT Assay (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenylterazolium bromide assay) against breast adenocarcinoma cell lines MCF-7 and 
MDA-MB-231. Complex T8a displayed moderate cytotoxicity against MCF-7 (IC50 = 40.69 (± 1.1) 
µM), while none of the other complexes displayed any anti-cancer activity at the complex 
concentrations tested. 
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Subsequently, evaluation of the ligands against MCF-7 showed that ligands 1a – 4a displayed 
moderate cytotoxicity while 7a displayed anti-cancer activity (IC50 = 13.02 (± 1.2) µM) which is 
comparable to that of cisplatin. A structure-activity relationship in favour of the smaller N-bound 
substituents was established. 
DNA migration and titration studies revealed that ligands 1a – 4a displayed moderate intercalative 
character. Complex T8a displayed covalent binding in the DNA migration study, similar to that 
observed for cisplatin. Ligand 7a displayed weak intercalation based on the DNA migration study, 
but the DNA titration study revealed a potential multi-mode binding character. 
The affinity of the ligands towards DNA did not correlate directly with the IC50 values obtained. This 
potentially indicates that the pharmacological target of the cytotoxic ligands is probably not DNA, 
and thus requires further investigation.  
 
  




Kankerteenmiddels gebaseer op palladium is geïdentifiseer as moontlike plaasvervangers vir die 
bestaande platinum baseerde chemoterapeutiese middels. Tenspyte hiervan het slegs ‘n beperkte 
hoeveelheid palladium verbindings verder as die laboratorium gevorder, vermoedelik weens ‘n 
gebrek aan kennis rondom hul metode van aktiwiteit en struktuur-aktiwiteit verhoudings. Dus, die 
doel van hierdie studie was om ‘n reeks trans-Pd(II)-1-gesubstitueerde-4-feniel-1,2,3-triasoliel en 
N,N’-bidentate Pd(II)-1-gesubstitueerde-4-piridiel-1,2,3-triasoliel komplekse te evalueer as 
potensiële kankerteenmiddels, teen menslike borskanker sellyne. Die interaksie van die aktiewe 
verbindings met DNS is ook ondersoek deur middel van DNS migrasie en DNS titrasie studies. 
A aantal bekende (1a – 3a, 7a – 9a, 1b – 3b, 7b, 9b) en nuwe (4a – 6a, 4b – 6b, 8b) 1-
gesubstitueerde-4-feniel-1,2,3-triasool and 1-gesubstitueerde-4-piridiel-1,2,3-triasool ligande was 
gesintetiseer, in matige tot goeie opbrengs. Die N-gebonde substituente is gevarieer om die effek 
van steriese hindernis, elektroniese interaksies en hidrofiliesiteit op die sitotoksisiteit van die 
komplekse te ondersoek. Al die ligande is gekarakteriseer deur van FTIR, 1H KMR en 13C KMR 
spektroskopie, asook ESI-MS spektrometrie gebruik te maak. Die suiwerheid van die verbindings is 
deur mikroanaliese bepaal. 
Kompleksering van 1a – 9a aan ‘n Pd(II) sentrum, het die trans-Pd(II)-feniel-1,2,3-triasoliel 
komplekse (T1a – T9a) in matige to goeie opbrengs opgelewer. Daar is waargeneem dat hierdie 
komplekse in DMSO ligand uitruiling met die oplosmiddel ondergaan en ‘n KMR studie het bevestig 
dat liganduitruiling inderdaad wel in oplossing plaasvind. Kompleksering van ligande 1b – 9b aan ‘n 
Pd(II) sentrum, het die N,N’-bidentate-Pd(II)-piridiel-1,2,3-triasoliel komplekse (N1b – N9b) in matige 
tot goeie opbrengs opgelewer. Anders as in die geval van die trans-Pd(II)-feniel-1,2,3-triasoliel 
komplekse, toon die N,N’-bidentate-Pd(II)-piridiel-1,2,3-triasoliel komplekse geen tekens van 
liganduitruiling in DMSO nie. Alle komplekse is deur middel van FTIR, 1H en 13C KMR spektroskopie, 
ESI-MS spektrometrie en mikroanaliese gekarakteriseer. 
Die kinetiese oplosbaarbeid van al die komplekse in ‘n 2 % DMSO/PBS oplossing is met ‘n 
turbidimetriese toets vasgestel. Al die komplekse is matig oplosbaar met die uitsluiting van 
komplekse T2a, T7a, T9a en N1b. Die sitotoksisiteit van hierdie komplekse is dus bepaal met 
suspensies. As gevolg van die liganduitruiling wat vir komplekse T1a – T9a waargeneem is, kan die 
sitotoksisiteit wat vir hierdie komplekse bepaal is, nie die aktiwiteit van die oorspronklike komplekse 
toegeskryf word nie, maar eerder aan ‘n mengsel van spesies teenwoordig in die oplossing. 
Die sitotoksisiteit van die komplekse is ge-evalueer met ‘n MTT toets teen twee bors 
adenokarsinoom sellyne, MCF-7 en MDA-MB-231. Kompleks T8a het gematigde sitotoksisiteit teen 
MCF-7 (IK50 = 40.69 (± 1.1) µM) getoon, terwyl nie een van die ander komplekse enige antikanker 
aktiwiteit by die konsentrasies wat getoets is toon nie. 
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Daaropvolgende evaluasie van die ligande teen MCF-7 het aan die lig gebring dat ligande 1a – 4a 
gematigde sitotoksisiteit toon, terwyl ligand 7a antikanker aktiwiteit (IK50 = 13.02 (± 1.2) µM) 
vergelykbaar aan dié van sisplatien toon. ‘n Struktuur-aktiwiteit verhouding ten gunste van die kleiner 
substituente is vasgestel. 
DNS migrasie en titrasie studies het gewys dat ligande 1a – 4a gematigde interkalasie met DNS 
ondergaan. Kompleks T8a het kovalente binding aan DNS in die DNS migrasie studie getoon, 
soortgelyk aan dit gevind vir sisplatien. Ligand 7a het swak interkalasie in die DNS migrasie studie 
getoon, maar die DNS titrasie studie het getoon dat 7a moontlik ‘n veelvoudige binding karakter het. 
Die affiniteit van die ligande teenoor DNS stem nie ooreen met die IK50 waardes wat in die MTT toets 
bepaal is nie. Dit dui moontlik aan dat DNS nie die farmakologiese teiken van die sitotoksiese ligande 
is nie, en dat verdere ondersoek benodig word. 
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Chapter 1: Cancer treatments, the history 
of chemotherapy and anti-cancer 
palladium compounds 
Cancer is the second leading cause of death, after cardiovascular disease, worldwide with 5.5 % of 
all cancer related deaths in 2012 occurring in Sub-Saharan Africa.1,2 It is estimated that cancer will 
become the leading cause of death within the next decade.3 Currently, cancer related deaths account 
for 1 in 7 deaths worldwide.4 Tumour growth is can be translated as a single cell’s quest for 
immortality caused by a mutation in the DNA of the cell. This results in the obstruction of natural cell 
death pathways within the cell, resulting in uncontrolled proliferation. Ironically this quest would 
ultimately hasten the passing of the cell’s host.5 
1.1 The History of Cancer 
It is a common misconception that cancer is a modern disease that is accelerated through the ever 
increasing pace of life. Although the incidence of cancer in the modern world seems higher than that 
compared to the early 20th century, one has to consider the technological and medical advances that 
have enabled us to identify cancer at much earlier stages than before. In truth, cancer is an ancient 
foe that has haunted mankind since ancient times.  
The word ‘cancer’ has its roots in Ancient Greek. Hippocrates (460-370 BC) was the first to describe 
different tumours as karkinos, from the Greek for crab, presumably referring to the way in which 
tumours extend into the surrounding tissues. The Greek karkinos was later translated to the Latin 
cancer by Celsus, a Roman physician.2,6  
The first documented case of cancer comes from the Edwin Smith Papyrus, dated 3000 BC,6 which 
was copied from the writings of Imhotep, an ancient Egyptian healer. Under cure he wrote, “There is 
none.”5 Evidence of bone cancer was also found in the remains of Egyptian mummies, and breast 
cancer was described in their ancient writings from 1500 BC.2 
During the 16th to 18th centuries the understanding of medicine advanced dramatically with Giovanni 
Morgagni of Padua (1761) performing the first autopsies and relating illness to pathological findings. 
This change in rhetoric can be regarded as the initial period of the field of oncology, the study of 
cancer, and other theories as to the causes of cancer, such as the humoral theory, the lymph theory 
and the chronic irritation theory, were laid to rest.6 





The clinical treatment of cancer has changed and evolved over centuries and can thus be divided 
into three main branches: Surgery, Radiation and Chemotherapy. For the purposes of this thesis 
only chemotherapy will be discussed.  
1.2 The history and development of chemotherapeutic agents 
The German chemist, Paul Ehrlich, coined the term chemotherapy in the early 1900’s with reference 
to the use of chemicals to treat disease. Due to his research and experimentation on animal models, 
the use of arsenic containing compounds for the treatment of syphilis was proven in rabbit models.7 
Ehrlich’s interests expanded into anti-cancer treatments as well, with his lab screening aniline dyes 
for their anti-tumour activities. This led to the first primitive alkylating drugs to be used in anti-cancer 
therapy.2 
Surgery and radiotherapy dominated cancer treatment until the 1960’s, mainly due to their immediate 
visual results, but by the end of the 1960’s new studies had come to light that showed that the 
presence of micrometastases resulted in the recurrence of cancers treated with surgery and 
radiation.8 
Prior to World War II (1939-1945), the most exciting achievement in the field of cancer chemotherapy 
was the introduction of hormonal therapy by Charles Huggins in 1939. His hormonal treatment of 
men with prostate cancer showed positive responses, and earned him a Nobel Prize (1966).9 
WWII (1939-1945) launched a large number of research programmes aimed at drug discovery 
(antibiotics and antimalarial compounds) and nutritional research. Serendipitously some of this 
research led to the discovery of a large number of anti-cancer compounds. 
During a German Luftwaffe air raid on 2 December 1943, sulfur mustard gas was spilled on American 
troops in the Bari Harbour, Italy. It was later observed that the bone marrow and lymph nodes of the 
men exposed were severely depleted. The promising results from the subsequent research done by 
Goodman and Gilman in 1943 (the work was only published in 1946 although completed in 1943 
due to secrecy imposed on the researchers by the U.S. Office) resulted in the rapid synthesis and 
testing of various alkylating compounds. Thus nitrogen mustard, chlorambucil and 
cyclophosphamide came to be (Figure 1.1). Although this breakthrough was very exciting at the time, 
the remissions observed in patients turned out to be very brief and limited.5,7,8 






Figure 1.1: The alkylating agents based on nitrogen mustard.7 
Cancer chemotherapy thus follows a strange logic, that every poison might be a potential cure in 
disguise. 
The nutritional research programmes of that time discovered folic acid in green leafy vegetables and 
in 1937 folic acid was artificially synthesized for the first time. It was also discovered that a diet 
lacking in folic acid resulted in the same deficient bone marrow that was observed in the troops 
exposed to the mustard gas. This led a group of clinicians, Farber, Heinle and Welch, to believe that 
folic acid might have some anti-cancer properties. They tested their theory on children with 
leukaemia and unfortunately found that folic acid apparently accelerated cancer cell growth. 
Although this observation was later proven to be false, it led Farber in collaboration with Harriet Kilte 
to develop a series of folate antagonists that included aminopterin and amethopterin (now known as 
methotrexate). Farber tested these compounds in children with leukaemia in 1948 and the subjects 
showed complete remission. These compounds became the first of the anti-folates, an entire class 
of cancer chemotherapeutic drugs still used today (Figure 1.2).5,7,9 
 
Figure 1.2: Anti-metabolites based on folic acid.5,7 
The search for new antibiotics during the WWII period was based on the screening of various 
fermentation products. Along with the antibiotic activity of these compounds, the anti-tumour activity 
of certain agents was also investigated.9 This yielded actinomycin D, an antibiotic with significant 
anti-tumour properties. Unfortunately, actinomycin D was so toxic that its antibacterial uses were 
severely limited, but cancer treatment was born from poison. Sydney Farber tested actinomycin D 
on various mouse cancers in 1954, and found that even a small dose could thwart leukaemias, 
lymphomas and breast cancers. He thus started a trial in 1955 to test this new drug in children with 
various cancers, including Wilms’ tumour, a very rare kidney cancer. By the time Wilms’ tumour is 
detected, it usually has already metastasized to the lungs, where it can only be treated with radiation 





therapy and with only a small chance at success. The combination of actinomycin D and radiation 
proved to be highly effective against metastasized Wilms’ tumours and thus ultimately ‘cured’ that 
specific form of cancer.5 Actinomycin D was subsequently used for various paediatric cancers in the 
1950s and 1960s.7 
This was again the first drug of an entire class of anti-cancer antibiotics of which there is a large 
number still in use today (Figure 1.3). 
 
Figure 1.3: Anti-cancer antibiotics.5 
Anti-metabolites arose from the research initiated by the activity observed for nitrogen mustard and 
methotrexate. The same year Farber showed the anti-cancer activity of methotrexate, Hitchings and 
Elion isolated an adenine metabolism inhibitor. From this observation they developed two drugs, 6-
thioguanine and 6-mercaptopurine, that have been used in the treatment of leukaemia since 1951 
(Figure 1.4). Thiopurines and their analogues have found wide spread use for the treatment of other 
diseases, including herpes viral infections and immunosuppressive agents for organ transplants. 
Their work earned them a Nobel Prize in 1988.7 
Up until the mid-1950s most cancer chemotherapy was aimed at haematological cancers and not at 
solid tumours. It was not until Charles Heidelberger observed the increased use of uracil in rat 
hepatoma models that solid tumours became a chemotherapeutic target. By attaching a fluorine 
atom in the 5-position on the uracil base, he effectively ‘attacked’ the relevant biochemical pathway. 
His research yielded the first example of targeted therapy with the introduction of fluoropyrimidine 5-
fluorouracil (5-FU), as shown in Figure 1.4. 5-FU showed activity against a wide range of solid 
tumours and remains to today the main drug used in the treatment of colorectal cancer.5 






Figure 1.4: Anti-metabolites based on uracil7. 
The 1950s also yielded corticosteroids which produced brief remissions when used alone, but, in 
combination with some of the other drugs, prolonged remissions remarkably.7 
Despite the existence of the National Cancer Institute (NCI) in the USA during WWII, very little 
progress was made at the time on the front of new chemotherapy drugs. This was due to the 
repurposing of resources marked for the NCI into the war effort. The NCI’s contribution to the drug 
discovery programmes only became significant after the launch of the Cancer Chemotherapy 
National Service Center (CCNSC) in 1954. Between 1954 and 1964 the CCNSC tested nearly 
215000 potential anti-cancer drugs and became responsible for nearly all the drugs used at that time 
for the treatment of cancer.5,7,8 
One of the drugs tested by the CCNSC was a plant alkaloid ibenzmethyzin (renamed to 
procarbazine). The compound was isolated from Vinca rosea by the Eli Lilly Company in 1963 
(Figure 1.5). Two different groups showed the spectacular activity of procarbazine against leukaemia 
and Hodgkin’s lymphoma, Brunner and Young in 1967 and DeVita and colleagues in 1966 
respectively.5 The anti-cancer activity of these compounds were considered ground-breaking at the 
time due to the fact that they did not cause bone marrow depletion, as is observed for nitrogen 
mustard.10 Along with procarbazine, a number of other alkaloids were isolated as well, including 
vincristine and vinblastine.5 
 
Figure 1.5: The plant alkaloids isolated from the Vinca rosea by the Eli Lily Company.5 





All the drugs discovered up to that point were very useful, but ultimately inconsequential: they 
produced remissions, but the cancer would always return at some point. It thus became necessary 
to introduce combinational chemotherapy. Naturally this idea was met with severe scepticism, not 
only because it seemed to be a last desperate act, but also because it seemed unusually cruel to 
already vulnerable patients.5,7 
Despite the severe objections, a group of chemotherapists, including Emil Frei and Emil Freireich, 
at the NCI launched the first combination chemotherapy study in 1962 called VAMP. VAMP included 
vincristine, amethopterin, 6-mercaptopurine and prednisone and was found to increase the 
childhood leukaemia remission rates to 60 %. Unfortunately the combined toxic effects of all four 
drugs were nearly unbearable and clinicians had to improvise palliative care with platelet 
transfusions and the aggressive use of antibiotics.5,7 
VAMP was the first combinational therapy tested and became the standard of how we treat cancer 
today. Sadly, VAMP could not cross the blood-brain barrier and most of the children treated with 
VAMP returned with the leukaemia running rampant in their central nervous systems, ultimately 
dying due to an evolutionary mechanism that was supposed to protect them.5,7 
In 1963 Tom Frei started looking into different combinations of known chemotherapeutic drugs, drugs 
that would complement each other in their activity. He also changed his focus from leukaemia, a 
haematological cancer, to Hodgkin’s lymphoma, which would provide the perfect crossover to solid 
tumours. An added advantage of Hodgkin’s lymphoma was that it progressed locally, from lymph 
node to lymph node, and did not tend to end up in the brain like leukaemia. The NCI chemotherapists 
had also reached a crossroads of sorts: if they could cure metastatica Hodgkin’s lymphoma with 
aggressive combinational chemotherapy, then they could unequivocally prove that cancer can be 
cured through chemical intervention.5 
In 1964 DeVita, Zubrod, Frei and Freireich launched the MOMP (methotrexate, vincristine, nitrogen 
mustard and prednisone) trial on Hodgkin’s lymphoma patients. Later that same year DeVita 
modified the trial slightly by substituting methotrexate with the more powerful procarbazine, and thus 
launched the MOPP trial for the patients with the more advanced lymphomas. Predictably, the highly 
toxic drug regimens had nearly devastated the patients’ immune systems, leading to the first reported 
cases of PCP pneumonia, which would later be observed in AIDS sufferers.5,8 
The results were, however, positive and nearly all the patients entered long, durable remissions, the 
MOPP trial being the most promising. The MOMP trial results were presented at the AACR 
(American Association for Cancer Research) meeting in 1965 and MOPP in 1967, both showing 
positive results. By the 1970s Hodgkin’s lymphoma was generally considered ‘curable’ with the 
                                               
a Metastatic refers to cancers that have progressed beyond the initial organ toward other areas of the body. 





combination of radiation and chemotherapy.7 The NCI chemotherapists had finally proven that 
chemotherapy can cure cancer. 
The 1960s also yielded another important discovery in chemotherapy; the cytotoxic capabilities of 
cis-platinum (cis-dichlorodiaminoplatinum (II)). In 1965 Barnett Rosenberg investigated the biological 
effect of electricity on bacterial growth only to discover that the bacteria had stopped dividing entirely, 
but continued to grow into long filaments. At first this was thought to be due to the electrical current 
but it was later discovered that the platinum electrode had reacted with the growth medium to form 
a compound known as cis-platinum that was responsible for the static bacteria.11,5,12 More 
information on cis-platinum, commercially known as cisplatin, and other organometallic compounds 
used for chemotherapy will be given in Section 1.3.2. 
The 1970s heralded the age of adjuvant chemotherapy, where the drug would be used in addition 
to radiation and surgery even in early stage cancers. Naturally this was a point of much debate; 
should patients that have early stage cancers be exposed to potentially harmful drugs that they might 
not need? Although researchers began using adjuvant therapy on late stage breast cancer by the 
late 1960s, these programs were never studied within the confines of a clinical trial.7 
The two programs in question include L-PAM (the single use of L-phenylalanine mustard) and CMF 
(cyclophosphamide, methotrexate and 5-fluorouracil). L-PAM was only tested in an adjuvant 
capacity by the National Surgical Adjuvant Breast Project (NSABP) under leadership of Bernard 
Fisher and resulted in an optimistic publication in 1975. The CMF study was tested in an adjuvant 
capacity by the NCI along with the Istituto Nazionale Tumori in Italy under guidance of Gianni 
Bonadonna. The CMF study also yielded positive results and was published in 1976. The positive 
results from both trials expanded the scope of adjuvant chemotherapy to many different tumours and 
cascaded throughout oncology as the next most promising field.7,8 
In 1974 Lawrence Einhorn used the combination of cis-platinum, vinblastine and bleomycin to treat 
metastatic testicular cancer and subsequently increased the cure rate from 10 % to 60 %, as 
published in 1978.7 
Today, adjuvant chemotherapy is indicated for a wide variety of cancers including breast, colorectal, 
pancreatic and cervical cancer.8 
The 1970s also yielded the discovery of monoclonal antibodies that were only proven clinically useful 
in the 1990s. These antibodies do not work alone, but they do provide targeted chemotherapy when 
used in conjunction with chemotherapeutic agents and have thus become an integral part in 
combinational chemotherapy.13 
Targeted chemotherapy has become the main focus of current research. This includes the search 
for compounds that would target specific cellular targets characteristic of a specific cancer. This 





research finds its roots in the 1960s with the Special Virus Cancer Program (SVCP). Although the 
program did not meet its goals of identifying specific cancer causing viruses, it did however lead to 
the identification of oncogenes, suppressor oncogenes and new biological signalling pathways.5 
This enabled the recent development of the Bcr-Abl tyrosine kinase inhibitor, imatinib (commercially 
known as Gleevec), for the treatment of chronic myelocytic leukaemia (CML). CML is unique in that 
it is caused by a single defective kinase whereas most cancers result from multiple kinase 
abnormalities. This has thus opened a new field of research into kinase inhibitors and the Food and 
Drug Administration (FDA) has recently approved a small number of kinase inhibitors for the 
treatment of cancers heretofore resistant to all other forms of chemotherapy.7 
 
Figure 1.6: The first commercially available kinase inhibitor, imatinib5. 
Table 1.1 contains a summary of the different classes of chemotherapy drugs and their biological 
mechanisms.  
1.3 Transition metal compounds in anti-cancer chemotherapy 
Inorganic compounds were generally not considered suitable for anti-cancer chemotherapy since 
metals themselves were considered carcinogenic, thus the drug discovery focus prior to 1969 was 
mainly aimed at organic compounds. When Rosenberg and Van Camp demonstrated the potency 
of various platinum compounds in 1969, the drug discovery effort reorganised to incorporate more 
and more inorganic compounds.12,14 
1.3.1 General screening of metal compounds 
Prior to 1969 the interest in inorganic compounds and their salts was centred on the carcinogenicity 
of the compounds rather than their anti-cancer properties. A suspension of lead arsenate in benzene, 
known as Fowler’s suspension, was the first metal-based remedy to undergo extensive clinical 
testing. Unfortunately, the extensive toxicological studies that are used in modern medicine were not 





considered as acceptable protocol at the time and the true efficacy of the compound cannot be 
assessed by today’s standards.12 
Collier and Krause (1931) performed one of the most extensive early investigations into the anti-
cancer activities of various metal salts.15 No quantitative data were given but moderate activities of 
lead, chromium and manganese salts were described. Taylor and Carmichael (1953) tested several 
metal chlorides and nitrates but found that they were all generally ineffective. Geschickter and Reid 
(1947) tested oil soluble butylphthalate copper, nickel and cobalt complexes on humans.12 





Table 1.1: A summary of the various classes of chemotherapeutic drugs with their biological mechanisms and drawbacks. 
Type of anti-cancer agent Examples Biological mechanism Drawbacks 




Formation of an ethyleneammonium 
intermediate that forms covalent bonds to DNA 
on purine bases to induce apoptosis8. 
Brief remissions. 




Binds to folate dependent enzymes responsible 
for the synthesis of thymidylate and purines. 
Lack of those compounds induces apoptosis8. 
Severe bone-marrow toxicity. 











Inhibits cell proliferation by preventing 
microtubule polymerization8. 
Not as cytotoxic and thus needs to be 
used in combinational therapy. 




Formation of DNA-metal adducts leading to the 
formation of DNA crosslinks16. 
Severe neurotoxicity. 
Low water solubility. 
Emergence of platinum resistant 
cancers17.  
Monoclonal antibodies Rituximab 
Transtuzumab 
Disruption of the cancer cell signalling 
pathways13. 
Highly specific towards certain 
cancers resulting in highly expensive 
treatments13. 
Non-reproducible results18. 
Kinase inhibitors Imatinib 
Gefitinib 
Blocks kinase cascades linked to growth factor 
signalling pathways2. 
Emergence of resistance19. 
Narrow therapeutic indices20. 
  
                                               
b With the focus of platinum compounds. 
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They induced brief remissions in leukaemia patients lasting a mere 3 – 6 weeks and were required 
to increase the dosage 2 – 5 times before achieving a second remission.12 
Balo and Bangu (1957) prepared various complexes with Krebs cycle metabolites and found that 
iron ascorbate enhanced the tumour growth in mouse models, cadmium ascorbate inhibited tumour 
growth but was highly toxic and that manganese malate was the perfect intermediate concerning 
toxicity. But none of these compounds exceeded the potency of the already known organic 
compounds. 
The first known platinum and palladium compounds were tested by Krishner and colleagues in 1966. 
They tested various metals complexed to known anti-cancer compounds and identified five active 
compounds, three of which consisted of metals bound to 6-mercaptopurine (mp), an S-donor ligand. 
The palladium complex was Na2[Pd(mp)2Cl2]·5H2O and the platinum complex was 
Na2[Pt(mp)2Cl4]·2H2O. The premise was that the ligand should bind so strongly to the metal so as 
not to dissociate within a biological environment.12 
1.3.2 Platinum compounds 
Most anti-cancer research regarding transition metals has been performed on platinum containing 
compounds due to their high efficacy observed by Rosenberg and Van Camp in 1965. Like many 
anti-cancer discoveries, the discovery of the anti-tumour activity of cis-platinum was purely 
coincidental as previously stated.16 The image below contains the original photomicrographs of the 
effect cis-platinum has on bacterial growth. 
 
Figure 1.7: The original phase contrast photomicrographs of E. coli B x 600 published by Rosenberg et al.21 in 
1965.21 A) E. coli grown normally in a chemically defined medium. B) Filamentous bacteria grown in the same 
medium with the incorporation of 10 ppm cis-platinum. Cell division is completely inhibited resulting in the 
formation of bacterial filaments. 
Rosenberg and Van Camp went on to investigate the anti-tumour properties of various platinum 
complexes at length. Intuitively, they tested these compounds in mouse models and found that cis-





platinum completely inhibited the growth of Sarcoma-180.16 They compared the cytotoxicity of both 
Pt(II) and Pt(IV) with amino ligands and ethylenediamine ligands and ultimately concluded that the 
original cis-[Pt(NH3)2Cl2], commercially known today as cisplatin, was the most potent with a wide 
spectrum of activity.12,16 
Within a year of Rosenberg and Van Camp’s landmark study revealing the anti-cancer activity of 
cisplatin, additional reports of clinical trials conducted with the support of the NCI started to appear 
in literature. By 1973 it became clear that cisplatin was exceptionally useful in patients that were 
unresponsive to other chemotherapeutic agents.16 
As previously mentioned, Woodman et al.16 showed that cisplatin can be used in combination with 
other anti-cancer drugs resulting in increased anti-cancer activity. By mid-1974 Lawrence Einhorn’s 
group treated metastatic testicular cancer with a combination of cisplatin, vinblastine and bleomycin 
and thus increased the cure rate of metastatic testicular cancer from 10% to 60% by the end of the 
trial in 1978.7 
After the success achieved with cisplatin the research focus turned to analogues of cis-platinum in 
which both the neutral ligands and the charged ligands were investigated. An interesting observation 
of the chemistry of these compounds is the fact that the trans-isomer is usually inactive and mostly 
non-toxic when compared to cis-platinum. Thus the research focus remained on cis-platinum 
derivatives.12 
The mechanism through which cis-platinum interacts with biological surroundings was investigated 
some time ago by Reishus and Martin (1961) and Cleare et al. (1978).16 It is believed that the Cl-
ligands dissociate from the Pt-centre and that water, or a ligand species, would coordinate in their 
place, thus resulting in the hydrated Pt-complex being the active species responsible for the anti-
tumour activity observed.12 The ligand exchange follows the sequential exchange as shown in 
Equation 1.1.16 
𝑐𝑖𝑠𝑃𝑡(𝑁𝐻3)2𝐶𝑙2   
𝐻2𝑂
→   𝑐𝑖𝑠[𝑃𝑡(𝑁𝐻3)2𝐶𝑙(𝐻2𝑂)]
+ + 𝐶𝑙−  
𝐻2𝑂
→   𝑐𝑖𝑠𝑃𝑡[(𝑁𝐻3)2(𝐻2𝑂)2]
2+ +  2𝐶𝑙−          (1.1) 
The surprising cytotoxicity of cisplatin across a wide selection of cancers ignited a surge in the field 
of transition metal anti-cancer agents, thus resulting in various publications documenting the 
synthesis, application and biological interaction of platinum based anti-cancer compounds. Today 
there is a wide selection of cisplatin analogues commercially available, as shown in Figure 1.8. 






Figure 1.8: Cisplatin and various commercially available analogues17. 
Amid all the enthusiasm emanating from the discovery of cisplatin’s anti-cancer activity, there was a 
single problem with regards to the use of modern platinum compounds: cisplatin is severely toxic to 
kidneys. Clinicians had to improvise methods to prevent patients from losing total kidney function. 
This included hydrating patients before, during and after chemotherapy and allowing slow infusion 
rates which circumvented the severity of the kidney damage.16,22 
The global demand for platinum drugs has increased over the years, but there are some 
insurmountable side effects arising from the current platinum based drugs. Not only do these drugs 
lack specificity and are highly neurotoxic, but the increasing incidence of platinum resistant cancers 
has fuelled the search for alternative drugs.22,17 
Various transition metals have been screened in the process to find alternatives to platinum, and 
palladium has been identified as a promising candidate due to its similar coordination chemistry. 
Subsequently, a large amount of research has been done on organopalladium compounds.17 
1.3.3 Palladium compounds 
A comprehensive review on transition metals in chemotherapy, published in 197412, stated that there 
was little to no hope for palladium (II) complexes since their animal testing yielded poor results when 
compared to that of platinum (II) complexes. The author speculated that this is due to the increased 
reactivity of the complexes in vivo and that these compounds would only be successful anti-tumour 
agents in the presence of strongly deactivating ligands.12 
This was proven to be an erroneous assumption, since today there are many different palladium 
complexes that show significant anti-tumour activities. It has even been shown that some trans 
palladium (II) and palladium (IV) structures exhibit promising anti-cancer activity, thus disproving the 
initial generalization that a cis structure was crucial for anti-tumour activity.14 





Various palladium salts similar to that of cisplatin have been investigated for their anti-cancer 
activities, but none have been as successful as their platinum analogues.14 From the bulk of the 
research produced over the past five decades, it would appear that there are three distinct classes 
of Pd(II) anti-cancer compounds: trans-Pd(II) complexes, bidentate Pd(II) complexes and 
palladacycles. These will be discussed briefly below. 
1.3.3.1 Trans-Palladium (II) complexes 
Since the steric effects of a ligand could to a great extent govern the geometry around the metal 
centre, bulky monodentate ligands inevitably arrange themselves in trans positions around a d8 
palladium centre to result in a square planar geometry. It has been found that the trans-geometry 
around a palladium centre improves the cytotoxicity when compared to that of the cis-analogues, the 
opposite from what was observed for the platinum compounds.17 
One of the first trans-Pd(II) complexes that showed notable anti-cancer potential was put forward by 
Tušek-Božić et al. in 199123 (Figure 1.9). This was based on complexes of the type trans-[Pd(2-
dqmp)2X2] (2-dqmp = diethyl 2-quinolylmethylphosphonate and X = Cl or Br ) and have evaluated 
against epidermoid human carcinoma (KB) and murine leukaemia (L1210). It was found that the 
bromide analogues displayed higher cytotoxic activity against both cell lines than the chloride 
analogues, possibly due to the increased solubility of the bromide analogues, but the compounds 
were still not as effective as cisplatin.23 Although these results were not an improvement on the 
platinum analogues, this research provided the foundation for further investigations into the anti-
tumoural activity of trans-Pd(II) complexes. 
 
Figure 1.9: One of the first trans-Pd (II) complexes that showed notable anti-cancer activity, trans-Pd(II) 
bis(quinonylmethyl-phosponate).23 
Naturally-occurring ligands started to play a large role in drug discovery in the 1990s since the 
technological advancement of spectroscopy simplified structure elucidation. This resulted in the use 
of natural compounds as ligands, especially compounds that have already shown some biological 
activity such as the plant alkaloid harmine (7-methoxy-1-methyl-9H-pyrido[3,4-b]indole).17 





Al-Allaf and Rashan24 investigated the anti-cancer activity of trans-[Pd(harmine)(DMSO)Cl2] against 
P388, L1210 and K562 and found that the complex showed superior activity when compared to 
cisplatin, carboplatin, 5-FU and the ligand itself.24 
 
Figure 1.10: The trans-Pd(II) complex resulting from coordination to harmine and DMSO.24 
In 2002 Abu-Surrah et al.25 investigated the anti-cancer potential of an enantiomerically pure chiral 
trans-Pd (II) complex, trans-bis{endo-(1R)-1,7,7-trimethylbicyclo[2.2.1]-heptan-2-amino} 
palladium(II) dichloride. This compound performed worse than commercial platinum drugs with 
regards to the K562 and L929 cell lines but performed better than cisplatin and carboplatin in the 
HeLa cell line. The authors concluded that the compound had a higher non-specific toxicity than the 
platinum compounds which means that it would be a poor anti-cancer drug. It was however the first 
reported case of a chiral trans-Pd(II) complex.25 
 
Figure 1.11: The structure of the first chiral trans-Pd(II) complex evaluated against various cell lines25. 
In 2004 Gutiérrez and co-workers26 synthesized another chiral trans-Pd(II) complex from an α-
ketoimine, (S)-(-)-(1-phenylethylimino)benzyl-phenylketone, with the hope that the incorporation of 
various functional groups could help tailor the cytotoxic abilities of the subsequent drugs. The product 
unfortunately did not prove very promising since it also showed rather unselective cytotoxicity 
towards the PC-3, K562 and MCF-7 cancer cell lines, and resulted in higher IC50 values when 
compared to cisplatin.26 






Figure 1.12: The chiral α-ketoimine trans-Pd(II) complex.26 
To date, trans-Pd(II) complexes have always displayed lower cytotoxic ability when compared to 
known platinum drugs. The first true potential of trans-Pd(II) complexes only emerged in 2006 as 
demonstrated by Trávnícek and colleagues27 Substituted benzylaminopurine compounds have 
shown some ability to inhibit cyclin-dependent kinases (CDK), kinases that play a regulatory role in 
the cell cycle. This research group thus complexed a number of these compounds to palladium in 
cis- and trans-conformations and evaluated them against a number of cell lines. The trans-palladium 
complexes resulted in improved anti-cancer activity as compared to the platinum analogues and 
commercial compounds. The cis-palladium analogues were also tested and performed weaker than 
the trans-compounds, as expected from previous research.28,17,27 
Despite the many publications which conclude that trans-Pd analogues outperform the cis-Pd 
analogues, while the opposite is true for platinum compounds, there is, as yet, no definitive reason 
established for the difference in activity as related to the structure of the complexes. It has been 
speculated, but not proven, that the difference in activity is due to the way in which cisplatin interacts 
with DNA. The cytotoxicity of cisplatin is attributed to the formation of covalent bond between 
platinum and the N6 and N7 atoms of adjacent guanine base pairs on a single strand of DNA.29,30 
This mode of action relies on the cis structure of cisplatin. Since the mode of action of palladium 
complexes in general have not yet been established, the reason for the difference in activity between 
the cis-Pd and trans-Pd analogues is currently unknown, but preliminary indications are that the 
mode of action for these Pd-containing compounds differ from that of cisplatin. 






Figure 1.13: The benzylaminopurine based trans-Pd(II) complexes that showed very promising anti-tumoural 
activity.27 
A year later the same research group published the first trans-Pd(II) complex that showed selectivity, 
although the cytotoxicity of the complexes was not comparable to that of the commercial platinum 
compounds. The complex below showed selectivity towards malignant melanoma (G361) with an 
IC50 of 15 µM, as compared to that of cisplatin at 3 µM.31 
 
Figure 1.14: The structure of the first trans-Pd(II) complex that showed selectivity.31 
Up until this point the ligands used for complexation to the palladium centres were chosen for three 
distinct reasons: 1) ligands that are important in biological systems, such as organophosphorus 
ligands,23 2) ligands that occur naturally, such as the harmine ligand,24 and 3) ligands that have their 
own biological activity such as benzylaminopurine that is itself a kinase inhibitor.27 Soon it became 
apparent that certain types of ligands enhance the cytotoxic activity of the compounds while others 





diminish it and thus the research focus became more structure orientated, although no clear 
structure-activity relationships have been established. 
In literature, one of the more prominent ligand moieties are planar aromatic compounds. The first 
trans-Pd(II) complexes to be tested against ovarian cancer had hydroxyl-substituted pyridine 
ligands.32 The most effective compound among the three tested is shown below and performed 
better against cisplatin resistant ovarian cancer (A2780cisR) and picoplatin resistant ovarian cancer 
(A2780ZD0473R) than cisplatin itself. 
 
Figure 1.15: trans-Pd(2-hydroxypyridine)2Cl2, the first trans-Pd(II) complex to be evaluated against ovarian 
cancer.32 
Building on this research Huq and co-workers33 synthesized trans-Pd(II) complexes of the form trans-
PdL2Cl2 where L = 2-methylpyridine, imidazole and 1,2-α-imidazopyridine, of which the last was also 
significantly active against the ovarian cancer cell lines A2780, A2780cisR, A2780ZD0473R and SKOV-
3 (Sloan-Kettering HER2 3+ ovarian cancer). The most promising compound, trans-[Pd(1,2-α-
imidazopyridine)2Cl2] was less active than cisplatin, but the IC50 values are comparable to that of 
cisplatin, especially against the cisplatin resistant cell lines.33 
 
Figure 1.16: A trans-Pd(II) complex containing an imidazopyridine ligand that showed promising activity against 
ovarian cancer cell lines.33 
Continuing along this line of inquiry, Mendía and colleagues34 tested a series of PTA (1,3,5-triaza-7-
phosphadamantane) palladium(II) thionate complexes and also compared their antiproliferative 
activity against ovarian cancer to that of the platinum(II) analogues. By doing this, the group kept the 





concept of planarity with the thionate ligand but included a bulky phosphine ligand. This had a 
positive effect on the anti-cancer activity of the compound, by improving the IC50 values beyond that 
of cisplatin and better than those achieved by any of the other trans-Pd(II) complexes up to date.34 
 
Figure 1.17: Trans-[Pd(benzothiazole-2-thionate)2(PTA)2] had shown to be highly effective against ovarian 
cancer.34 
α-Keto-imines and α-diimines have also played an important role in the development of trans-Pd(II) 
complexes for anti-cancer purposes. This is due to the versatility regarding coordination and 
electronic effects that these compounds present.35 In the article published by Gutiérrez an co-
workers35 a number of cis and trans unsymmetrical α-diimine Pd(II) complexes were evaluated 
against a wide selection of cancer cell lines. To their disappointment it was found that none of their 
compounds displayed significant anti-cancer activity relative to cisplatin, but there were varying IC50 
values which could indicate a potential structure activity relationship.35 
 
Figure 1.18: Chiral Pd(II) complexes with α-diimine functionalities.35 
The final functionality that has improved the anti-cancer activity of trans-Pd(II) complexes is N-
heterocyclic carbenes (NHC). 
In 2007 Panda and colleagues36 explored the anti-cancer activities of palladium (II) N-heterocyclic 
carbene complexes, of which the complex that showed the most promise is shown in Figure 1.19. 





They found that the NHC complexes displayed significantly higher anti-cancer activities when 
compared to cisplatin and that they induced natural cell death, apoptosis. 
 
Figure 1.19: The Pd(II)-NHC complex that was first investigated in 2007. The complex showed remarkable anti-
cancer activity when compared to that of cisplatin against the same cell lines.36 
Building on this research, another group, Haque et al.37, decided to expand on it in 2013 by changing 
the substituents on the N-heterocyclic carbenes in order to investigate less sterically hindered 
substituents. Unfortunately their compounds, as shown in Figure 1.20, were not as active as those 
developed by Panda and colleagues36 and it is also clear that the structures of the carbenes have 
an unclear influence on the activity of the compounds. 
 
Figure 1.20: The two NHC-carbene complexes investigated by Haque et al.37 
In conclusion, trans-Pd(II) complexes have shown great promise in the field of anti-cancer activity 
with functionalities ranging from quinolones and α-diimines to pyridines and N-heterocyclic carbenes.  
From the complexes reviewed, a number of conclusions can be drawn. Firstly, the inclusion of planar 
moieties increases the cytotoxicity of the complexes. This is possibly due to the intercalation of the 
planar ligands with DNA. Secondly, bulkier ligands appear to increase the cytotoxicity of the 
complexes, possibly due to the fact that they cause a greater distortion of the DNA. Finally, it has 
been observed that complexation of the Pd-centre to a bioactive ligand, increases the anti-cancer 
activity of the ligand. 





Thus, it is clear that the ligand plays a very important role in the biological activity of the complex, 
but there is no definitive structure activity relationship that has become apparent yet. It is thus 
necessary to explore other ligand types in order to gather more information on these types of 
complexes.  
1.3.3.2 N,N-bidentate Palladium (II) complexes 
Trans-Pd(II) complexes have proven very useful but it remains necessary to explore the effect of the 
cis-isomers since the cis-Pt(II) complexes have proven so effective. As mentioned in the previous 
section, ligands surrounding Pd(II) centres prefer a trans-coordination due to steric constrains. 
Subsequently, multidentate ligands have enjoyed much attention due to their electronic and steric 
tailoring effects17. Naturally there are many different methods of chelation including N,N’- , N,S- , 
S,S’- , N,P- , and P,P’-coordinated compounds. For the purpose of this thesis, the focus will be on 
N,N’-bidentate ligands.17 
The most explored ligand types are 2,2’-bipyridyls and 1,10-phenanthrolines, since they provide a 
strong sterically constrained planar systems that are entropically favoured, due to the chelate 
effect.17 
One of the earliest N,N’-bidentate palladium(II) complexes were synthesized by Newkome et al.38 in 
1985, and although they did not investigate the cytotoxic capabilities of the compound, their research 
led to the investigation of N,N’-bidentate palladium(II) complexes as a class of cytotoxic drugs in 
their own right. 
 
Figure 1.21: The general structure of the first N,N-bidentate Pd(II) complexes.38 
In 1991 Mansouri-Torshizi et al.39 demonstrated that the inclusion of an oxygen leaving group 
somehow increases the anti-cancer activity of the complexes. Thus they studied the effects of 
incorporating selenite and tellurite into the Pd(II)-complexes on the anti-cancer activity of the 
compounds. The incorporation of the selenite greatly improved the anti-cancer activity of the 
complexes when compared to cisplatin.39 






Figure 1.22: Examples of the first N,N-bidentate complexes that showed significant anti-cancer activity against 
the P388 cell line.39 
Lin and colleagues40 demonstrated in 1998 that the planarity of the ligand increased the level of 
intercalation of the complex into the structure of DNA. They demonstrated this with a number of 
tetradentate 1,10-phenanthroline complexes (Figure 1.23) and showed that an increase in the steric 
bulk of the ligand resulted in higher cytotoxic activity against leukaemia, L1210, and liver carcinoma, 
Bel17402.40 
 
Figure 1.23: The general structure used by Lin and colleagues40 to investigate the effect of steric substituents on 
the anti-cancer activity of the complex. 
Building on the 2,2’-bipyridyl motif, Valentini et al.41 used a bioactive ligand, 4,4’-dinonyl-2,2’-
bipyridine, and a natural-occurring compound, curcumin , and complexed both to a Pd(II) centre. 
This resulted in a complex that showed higher IC50 values than pure curcumin, but induced a different 
cell death pathway in various different prostate cancer cell lines thus making the compound less 
toxic than the unbound curcumin. 






Figure 1.24: The structure of the complex resulting from the combination of curcumin and a bioactive 2,2'-bipyridyl 
ligand.41 
Another interesting 2,2’-bipyridyl complex (Figure 1.25) arose from the investigation by Gao and co-
workers42 into the effects of the carbon chain length on the anti-cancer activity of the compounds. 
They found that an increase in the carbon chain length of the benzene-alkyl dicarboxlate ligand leads 
to an increase in the anti-cancer activity of the compounds, thus indicating that the flexibility of the 
compound plays an important role in the intercalation of the compound into the DNA structure. They 
investigated carbon chain lengths of 1 to 3 carbon atoms. The exact role of the aliphatic chain was, 
however, not determined by these researchers.42 
 
Figure 1.25: The structure of the most potent compound investigated by Gao and co-workers.42 
Expanding upon the chelation of known biologically active compounds, Navarro-Ranninger and 
colleagues43 proceeded to chelate spermine and putrescine to palladium salts in order to produce a 
number of polyamine complexes. The most promising of their compounds used 1,4-butane diamine 
as a ligand, as shown in Figure 1.26. 






Figure 1.26: The spermine chelated Pd(II) complex.43 
Moving away from the 2,2’-bipyridyl motive, Lin and co-workers44 investigated a dimeric complex 
with Pd(II) centres stabilised by ethylenediamine bidentate ligands. They found a remarkably low 
IC50 value which prompted them to carry out further investigations in order to understand the way in 
which the electronics of the substituents influence the anti-cancer activity of the compound.44 
 
Figure 1.27: The dimeric complex that sparked the investigation into ethylenediamine type compounds.44 
By simplifying the structure, they found that with an increase in the electron donating abilities of the 
pyridine substituents, a marked decrease in the anti-cancer activity of the complex is observed.45 
The most promising complex showed an IC50 similar to that of cisplatin against the human leukaemia 
cell line, HL60 (Figure 1.28). 
 
Figure 1.28: One of the first ethylenediamine stabilized Pd(II) complexes to show significant anti-cancer activity.45 
Mansouri-Torshizi et al.46 synthesized an ethylenediamine stabilized quinolinato complex that 
showed significant anti-cancer activity against myelogenous leukaemia, K562, making it much more 
potent than any of the previous reported N,N’-bidentate complexes tested. 






Figure 1.29: A highly potent N,N-bidentate system, ethylenediamine 8-hydroxyquinolinato.46 
Mansouri-Torshizi et al.47 then proceeded to take some inspiration from their first anti-cancer 
compounds (Figure 1.22) to produce and test a 1,10-phenanthroline dithiocarbamate Pd(II) complex. 
The complex was also evaluated against K562 and was found to be less potent than the quinoline 
based complex mentioned above. This amended the previous assumption that the planarity of the 
ligand was the main anti-cancer instigator.47 
 
Figure 1.30: The 1,10-phenanthroline Pd(II) dithiocarbamate complex that showed significant anti-cancer activity.47 
The quinoline motif appeared again a few years later in the form of an iminophosphorane derived 
from 8-aminoquinoline ligand. Casini and co-workers.48 investigated a number of gold, palladium and 
platinum complexes with the ligand for both their anti-cancer activities and their luminescent 
properties. Figure 1.31 shows the N,N’-bidentate Pd(II) complex that displayed some anti-cancer 
activity. The study was unable to correlate the anti-cancer activity of the compound to the structure 
of the ligand, but it had become clear that although N,N’-bidentate ligands produce active anti-cancer 
complexes, they are not as active as the metallocycles of the same ligands.48 
 
Figure 1.31: The Pd(II) iminophosphorane that showed significant anti-cancer activity.48 





More recently, with the advent of copper catalysed ‘click’ chemistry (see Chapter 2), the use of 
pyridyl-1,2,3-triazole chelating ligands has become of increasing importance in coordination 
chemistry. By combining the azide and alkyne moieties, the opportunity for rapid library expansion 
is created. Trivedi and colleagues49 showed this with the incorporation of carbohydrate moieties into 
pyridyl-triazole N,N’-bidentate Pd(II) complexes. The use of carbohydrates in anti-cancer agents is 
well documented with compounds such as bleomycin (Figure 1.3), and thus helped the Pd(II) 
complexed compounds to show good anti-cancer activity.49 
 
Figure 1.32: The first pyridyl-1,2,3-triazole Pd(II) complexes used as anti-cancer agents.49 
In 2013 a separate group investigated the anti-cancer activity of similar compounds with imine 
functionalities rather than 1,2,3-triazoles. Katoaka and co-workers50 investigated palladium and 
platinum glycoconjugated imines against cisplatin resistant gastric cancer cell lines (Figure 1.33). 
Although their compounds were not as active as oxaliplatin, the palladium compounds were more 
active than the platinum compounds and effectively overcame the cisplatin resistance.50 Their work 
reiterated the importance of the Pd(II) centre stabilization.  
 
Figure 1.33: The glycoconjugated Pd(II) complexes with imine moieties tested against gastric cancer.50 
From the review above two conclusions can be made regarding N,N’-bidentate Pd(II) complexes. 
The first is that there are small structural features that seem to play a specific role in the structure-
activity relationships, but none that have been directly linked or proven consistently in various 
systems. The second is that the mode of Pd(II) stabilization greatly affects the anti-cancer activity of 
the compounds. This has also been the case with the trans-Pd(II) complexes discussed previously. 






It has been mentioned extensively that the stabilization of the Pd(II) centre plays a critical role in the 
anti-cancer activity of the compounds. Owing to this observation, it has been shown that Pd-C bonds 
are preferable to Pd-N bonds when it comes to anti-cancer activity, since the former withstand 
hydrolysis to a greater extent51, although there are some exceptions to the rule. Additionally, it has 
also been shown that palladacycles are not only more stable, but also show a more selective 
cytotoxicity that is not the case for platinum compounds.51 
Recently, a comprehensive review on the topic was published by Kapdi and Fairlamb.17 For this 
reason, only a handful of significant compounds will be discussed here. 
The first major publication in the field of anti-cancer palladacycles only came in 1993 by Higgins III 
et al.52 in which they evaluated twelve palladacycles with various scaffolds against seven different 
cell lines. The compounds that showed the most activity are shown in Figure 1.34. 
 
Figure 1.34: The compounds by Higgins et al.52 that showed the most activity against the respective cell lines 
listed. 
Ruiz et al.53 synthesized similar compounds by substituting the pyridine coordination site with a 
substituted amine. In addition to the amine substitution they incorporated a model nucleobase, 1-
methylcytosine, to make the compound more compatible with biological systems. The compound 
shown in Figure 1.35 displayed increased anti-cancer activity when compared to cisplatin under the 
same conditions. 
 
Figure 1.35: The palladacycle by Ruiz et al.53 that showed the best anti-cancer activity. 





The same C,N’-motif was reported previously by Travassos and colleagues51 in which they employed 
bis(diphenylphosphino) ethane (dppe) as a ligand with various modes of action (Figure 1.36). The 
compounds shown in Figure 1.36 were not especially active, but have served as the basis for many 
projects since. 
 
Figure 1.36: The different classes of compounds investigated by Travassos and colleagues51 and the resulting 
palladacycles tested. 
Ruiz et al.54 investigated palladacycles with 9-aminoacridine ligands against the leukaemia cell line, 
HL60. The inclusion of the acridine moiety was done in order to predisposition the compounds 
towards intercalation with DNA as its biological mechanism. They found that the palladacycles were 
more active than cisplatin under the same conditions. The two most potent compounds in this series 
are shown in Figure 1.37. 
 
Figure 1.37: The 9-aminoacridine palladacycles investigated by Ruiz et al.54 
The bis(diphenylphosphino) ethane (dppe) moiety appeared again in 2009 with the compounds 
investigated by Spencer et al.55 (Figure 1.38). The dinuclear compounds performed better than the 
monomeric compounds under the same conditions, and the bis(diphenylphosphino) ethane moieties 
performed better than the bis(diphenylphosphino) ferrocene (dppf) moieties, indicating that the type 
of bridging ligand is important. 






Figure 1.38: The dimeric compounds investigated by Spencer et al.55 
Another prominent moiety with palladacycles is the use of α-diimines to form pincer type 
palladacycles, as demonstrated by Gutiérrez and co-workers56 in 2009 (Figure 1.39). Although the 
cytotoxicity profiles of the compounds obtained were not as potent compared to cisplatin, the 
compounds showed some selectivity towards leukaemia and central nervous system (CNS) cancers 
as compared to prostate, colon and breast cancer. 
 
Figure 1.39: The α-diimines investigated by Gutiérrez and co-workers.56 
One of the most prominent issues with palladacycles is their low water solubility, which was 
overcome by Contel and colleagues57 with the use of water-soluble iminophosphorane ligands. Two 
of their most promising compounds are shown in Figure 1.40. DNA binding studies revealed that 
these compounds’ main target is not DNA, but rather human serum albumin (HSA), which is different 
from that of cisplatin and thus more favourable. With the advent of platinum resistant cancers, it is 
necessary to develop anti-cancer agents with biological mechanisms different from that of cisplatin 
in order to circumvent the rapid onset of resistant cancers. HSA is a carrier protein that has the ability 
to bind various therapeutic drugs, including metal cations and thus provides an ideal alternative anti-
cancer mechanism.57 






Figure 1.40: The water-soluble iminophosphorane palladacycles that showed improved anti-cancer activity when 
compared to cisplatin.57 
Recently our own research group investigated the cytotoxic capabilities of a dppe bridged 
palladacycle AJ5, basing the synthesis on the palladacycles investigated by Spencer et al.55 and 
Travassos and colleagues51 The in vitro and in vivo cytotoxicity of AJ5 have been fully investigated 
and indicate remarkably potent anti-cancer activity.58 This has sparked intense investigation into 
similar compounds. 
 
Figure 1.41: The binuclear palladacycle AJ5 which displayed highly potent activity against malignant melanoma 
cell lines.58 
The same year that AJ5 was published, an independent research group published their investigation 
into a number of benzylamines, two mononuclear compounds and one dinuclear compound (Figure 
1.42). Karami et al.59 found that the dinuclear compounds were generally more potent than their 
mononuclear counterparts. Nonetheless, all their compounds showed significant anti-cancer activity 
against various cell lines.  






Figure 1.42: The compounds investigated by Karami et al.59 
In 2014 Albert et al.60 investigated the effect of the co-ligand in dinuclear palladacycles with a range 
of differently substituted compounds. The most effective of their compounds is shown in Figure 1.43. 
Interestingly they found that the length of the co-linker chain does have a remarkable effect on the 
anti-cancer activity that can be contributed to the increased flexibility and lipophilicity of the molecule.  
 
Figure 1.43: The most effective compound investigated by Albert et al.60 
From the information above it appears that the dinuclear compounds outperform the mononuclear 
compounds when one simply considers the IC50 values. Since it is the metal adducts formed between 
the DNA and the compound that results in the cytotoxic effect observed, one should not only consider 
the IC50 value determined, but rather the metal centre to DNA ratio. When that is considered, the 
IC50 values of the dinuclear compounds can be considered as half that reported, which would mean 
that per metal centre the mononuclear compounds are more potent that the dinuclear compounds.  
In summary, Pd(II) compounds have found extensive use as anti-cancer agents, but the structure-
activity relationship is still vague. This necessitates further investigation into these compounds and 
the creation of larger libraries with the aim of generating enough data from which a more definitive 
structure-activity relationship can be elucidated. 





1.3.4 Structure-Activity Relationships 
As mentioned extensively throughout this chapter, the structure-activity relationships governing 
palladium based anti-cancer agents are vague and indefinite. In a comprehensive review by Alam 
and Huq61 published in 2016, a number of general structure-activity guidelines were presented based 
on the trends observed in literature. The most relevant conclusions are summarized below: 
1. In general, trans palladium complexes display greater anti-cancer activity than their cis 
counterparts. 
2. Bulkier ligands lead to increased activity due to a greater distortion of the DNA. 
3. Within a series of analogous palladium complexes, an increase in the lipophilicity of a 
complex generally leads to an increase in the anti-cancer activity of the complex. 
4. Chlorides are generally used as leaving groups in order to yield the active species in solution. 
These conclusions are still quite general and there are exceptions to the rule in all cases. It is thus 
important to focus more on the development of structure-activity relationships within a class or series 
of compounds 
1.4 Proposed compounds 
The proposed compounds for this project were trans-Pd(II) complexes and N,N’-bidentate Pd(II) 
complexes with 1,2,3-triazole scaffolds similar to that of Trivedi and co-workers.49  
The azide substituents were kept simple in order to investigate the steric, electronic and hydrophilic 
influences on the anti-cancer activities of the compounds. It was decided to investigate simple 
substituents, as their anti-cancer activity has, to the best of our knowledge, not been investigated, 
but more complex substituents, such as carbohydrate substituents, have been investigated before.49  
The general structures of the proposed compounds are shown in Figure 1.44. The trans-Pd(II)-1-
substituted-4-phenyl-1,2,3-triazolyl complexes and some of the N,N’-bidentate Pd(II)-1-substituted-
4-pyridyl-1,2,3-triazolyl complexes are to the best of our knowledge new. 
The structure of the ligands was chosen in such a manner as to utilize the 1,2,3-triazole as a 
coordinating ligand. 1,2,3-Triazoles are metabolically stable, have hydrogen bonding and 
coordination capabilities and are pharmacophores in their own right, thus making them suitable for 
medicinal applications.62 
The trans-Pd(II)-1,4-disubstituted-1,2,3-triazolyl complexes include a phenyl ring in the 4-position, 
as there is literature precedent which indicates that planar ligands facilitate DNA-binding interaction 
through intercalation. 





For the N,N’-bidentate Pd(II)-1,4-disubstituted-1,2,3-triazolyl complexes the phenyl ring was 
exchanged for a pyridine ring, as it would maintain the planar structure of the substituent while 
facilitating chelation to the metal centre. 
The N-bound substituents were varied in order to investigate the effect of sterics, hydrophilicity and 
electronics on the anticancer activity of the complexes. The choice of substituents is fully addressed 
in Chapter 2. 
 
Figure 1.44: The general structures of the proposed compounds. 
1.5 Aims and Objectives 
The aim of this project was to synthesized the two libraries of proposed complexes, as shown in 
Section 1.4, and to investigate their cytotoxicity against two breast cancer cell lines. 
In order to achieve this aim, the following objectives were identified: 
1. To synthesize of a series of 1,4-disubstituted 1,2,3-triazole ligands obtained from click 
chemistry methods. This includes the synthesis of the organo-azides used for the synthesis 
of the ligands. 
2. To synthesize and characterize the trans-Pd(II)-1-substituted-4-phenyl-1,2,3-triazolyl 
complexes. 
3. To synthesize and characterize the N,N’-bidentate Pd(II)-1-substituted-4-pyridyl-1,2,3-
triazolyl complexes. 
4. To investigate of the compounds’ interaction with DNA by utilizing UV-Vis spectrometry and 
horizontal gel electrophoresis. 
5. To assess the anti-cancer activity of the compounds against breast cancer cell lines (MCF-7 
and MDA-MB-231) with MTT Assays. 





1.6 Overview of thesis content by chapter 
Chapter 2: The synthesis and characterization of the ligands and their precursors are described in 
this chapter. 
Chapter 3: The synthesis and characterization of the trans-Pd(II)- and N,N’-bidentate Pd(II) 
complexes. 
Chapter 4: The investigation into the DNA binding modes of the compounds are discussed as well 
as the results from the in vitro testing on the breast cancer cell lines. 
Chapter 5: This chapter includes the final summary and concluding remarks of each preceding 
chapter as well as some suggestions for future work to be conducted.  
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Click chemistry is a term that is widely used to describe reactions that tend to conform to a number 
of specifications as outlined by Sharpless et al.1. These stipulate that a click reaction must take place 
under simple reaction conditions, use readily available starting materials, take place in a benign or 
readily removable solvent and finally result in simple product isolation1. 
When these conditions are considered, there are a number of reaction types that adhere to the 
criteria, such as cycloadditions, nucleophilic substitutions, non-aldol type carbonyl reactions and 
additions to multiple carbon-carbon bonds2. 
The most prominent of the so-called ‘click’ reactions, is the copper-catalysed 1,3-dipolar Huisgen 
cycloaddition (CuAAC). Traditionally the 1,3-dipolar Huisgen cycloaddition reaction is slow, requiring 
very high temperatures and long reaction times. Sharpless et al.1 demonstrated in 2001 that the 
reaction rates and conditions can be greatly improved with the addition of a Cu(I) catalyst in benign 
solvents such as water, thus ensuring that the reaction conditions conform to the click chemistry 
criteria.  
The 1,3-dipolar Huisgen cycloaddition utilizes an alkyne and an azide in the presence of a copper 
catalyst to afford a 1,4-disubstituted 1,2,3-triazole. Figure 2.1 shows the revised mechanism3 for a 
CuAAC reaction. The 1,5-disubstituted 1,2,3-triazole can also be obtained with the use of a 
ruthenium catalyst4,3.  
Since then, great strides have been made in the application of 1,2,3-triazoles in drug development2 
due to the fact that they provide the opportunity for rapid library expansion and have proven to ‘mimic’ 
known pharmacophores, thus making them biologically relevant. Recently, CuAAC 1,2,3-triazoles 
have also found application in materials science4, bioconjugation4 and photoelectronics5. 
1,2,3-Triazoles have also recently been described as a pharmacophore, as they can resist metabolic 
degradation and have hydrogen bonding capabilities, which are responsible for interactions with 
biomolecules and might improve aqueous solubility.6 There is thus a possibility that the ligands 
themselves might display some anti-cancer activity of their own. 
 






Figure 2.1: The revised mechanism for the CuAAC reaction as determined by Worrell et al.3 in 2013, showing the 
involvement of two different Cu-centres. 
As discussed in Section 1.6, this chapter contains the synthesis and characterization of the different 
triazole ligands and their precursors. This includes the synthesis of the various organoazides, 1-
substituted-4-phenyl-1,2,3-triazoles and 1-substituted-4-pyridyl-1,2,3-triazoles 
2.2 Results and Discussion 
2.2.1 Synthesis of organoazides precursors 
The azides chosen were selected in order to ultimately investigate the steric and electronic 
influences of the ligands on the anti-cancer activity of the complex. It was decided to investigate 
simple substituents, as their anti-cancer activity has, to the best of our knowledge, not been 
investigated, although complex substituents, such as carbohydrate functionalities have been 
investigated before.7 Azides 1 and 2 were selected for their electron donating abilities as well as 
steric bulk. Both azides are not explosive in nature and allows for a comparison between a flexible 
aliphatic chain versus the more rigid cyclohexane functionality. Azides 3 – 6 were chosen for their 
increasing hydrophilicity and hydrocarbon chain lengths. Azides 7 and 8 were chosen for their 
aromaticity and steric bulk. Azide 9 was chosen as it is strongly electron withdrawing while 7 is only 
weakly electron withdrawing. 
Organoazides are considered explosive and decompose with the release of nitrogen at the slightest 
external provocation such as heat, pressure or impact. Care was thus taken to synthesize azides 
that are not considered explosive. The general rule is that if the sum of carbon and oxygen atoms is 
less than threefold the number of nitrogen atoms, the organoazide is considered explosive. Equation 
2.1 shows the relationship required for the synthesis of non-explosive organoazides.8 There are 
however some exceptions to the rule. 







≥ 3             𝑁 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑎𝑡𝑜𝑚𝑠                                             (2.1) 
The synthesis of the organoazides was all based on literature procedures as outlined in the 
experimental section of this chapter (Section 2.4).  
The aliphatic and hydrophilic azides were prepared through the nucleophilic substitution of the 
halogen analogues, and the aromatic azides were prepared from the diazotization of the analogous 
amines with NaNO2, followed by the conversion of the diazonium salts into azides with the addition 
of NaN3. A summary of all the organoazides synthesized is shown in  
Table 2.1. 
Table 2.1: Summary of all the organoazides synthesized. 
Steric bulk Increased hydrophilicity Electronic effects 
   
 
FTIR provides the most valuable means of characterization regarding the synthesis of azides, due 
to the strong asymmetric N≡N stretch that can be observed around 2100 cm-1.9 For this reason, FTIR 
was used to track the synthesis of the azides and NMR was used to simply confirm that the organic 
structure had remained intact. 
  





The table below contains a comparison of the azide stretches of the various ligands synthesized. 
Table 2.2: A comparison of the N≡N stretches of each organoazide as observed with FTIR. 







7a 2123 (sym.), 2091 (asym.) 
8 2092 
9 2121 
a A split in the azide stretch was observed for this organoazide, which can be attributed to the symmetric and asymmetric stretches of the 
azide. 
It was observed that with a decrease in the electron donating ability of the substituent, an increase 
in the wavenumber for the azide stretch is observed. This can be attributed to a decrease in the 
stabilization of the azide, leading to an increase in the vibrational energy and thus an increase in the 
stretching frequency. 
2.2.2 Synthesis of 1,2,3-triazole ligands 
2.2.2.1 Substituted-phenyl-1,2,3-triazole ligands 
All substituted phenyl-1,2,3-triazole ligands prepared are summarized in Table 2.3. Of these, 4a, 5a 
and 6a are, to the best of our knowledge, new compounds.  
  





Table 2.3: A summary of the substituted phenyl-1,2,3-triazole ligands synthesized. Compound numbers in italics 
indicate novelty. 
   









The 1H NMR spectroscopic data for the ligands are summarized in Table 2.4. Additional analytical 
characterization are summarized in Table 2.5. 
From the 1H NMR spectroscopic data in Table 2.4 it should be noted that the triazole proton 
resonates as a singlet shifts downfield with a decrease in the electron donating ability of the N-
substituent. This corresponds to the trend that was observed with the N≡N stretch in the FTIR spectra 
of the azides, as discussed in Section 2.2.1, and also corresponds to the shift in the wavenumber of 
the C-H triazole stretch in the FTIR spectra of the ligands, as shown in Table 2.5. 









Aromatic region (ppm) 
Aliphatic region (ppm) 
CH3/CH2/CH OH 
1a 7.74 (s, 1H) 7.85-7.81 (m, 2H, 2 × CH Ar), 7.45-7.39 (m, 2H, 2 × CH Ar), 
7.35-7.29 (m, 1H, CH Ar) 
4.39 (t, 2H, 3J = 7.2 Hz, CH2), 1.94 (quint., 2H, 3J = 7.3 Hz, CH2), 
1.35-1.26 (m, 10H, 5 × CH2), 0.87 (t, 3H, 3J = 6.8 Hz, CH3) 
 
2a 7.76 (s, 1H) 7.81 (d, 2H, 3J = 8.0 Hz, 2 × CH Ar ), 7.42 (t, 2H, 3J = 7.5 Hz, 2 
× CH Ar), 7.32 (t, 1H, 3J = 7.2 Hz, CH Ar) 
2.28-1.93 (m, 4H, 2 × CH2), 1.82-1.76 (m, 2H, CH2), 1.54-1.44 (m, 
2H, CH2), 1.67 (s, 1H, CH), 1.36-1.29 (m, 2H, CH2) 
 
3a 7.76 (s, 1H) 7.61-7.59 (m, 2H, CH Ar), 7.34-7.26 (m, 3H, CH Ar), 4.43 (t, 3J = 4.8 Hz, 2H, CH2), 4.07 (bs, 2H, CH2) 4.43 (bs,1H) 
4a 7.93 (s, 1H) 7.77 (d, 3J = 8.0 Hz, 2H, CH Ar), 7.36 (t, 3J = 7.8 Hz, 2H, CH Ar), 
7.27 (t, 3J = 6.9 Hz, 1H, CH Ar) 
4.51 (t, 3J = 4.7 Hz, 2H, CH2), 3.84 (t, 3J = 5.4 Hz, 2H, CH2), 3.69 (t, 
3J = 4.5 Hz, 2H, CH2), 3.53 (t, 3J = 4.74 Hz, 2H, CH2) 
3.04 (s, 1H). 
5a 7.95 (s, 1H) 7.79-7.76 (m, 2H, CH Ar), 7.39-7.33 (m, 2H, CH Ar), 7.29-7.23 
(m, 1H, CH Ar), 
4.49 (t, 3J = 5.1 Hz, 2H, CH2), 3.82 (t, 3J = 5.1 Hz, 2H, CH2), 3.65 (t, 
3J = 4.6 Hz, 2H, CH2), 3.54 (s, 4H, 2 × CH2), 3.49 (t, 3J = 4.6 Hz, 
2H, CH2), 
3.14 (bs, 1H). 
6a 8.57 (s, 1H) 7.84 (dd, 2H, 3J = 7.5 Hz, CH Ar), 7.44 (dt, 2H, 3J = 7.6 Hz, CH 
Ar), 7.32 (dt, 1H, 3J = 7.3 Hz, CH Ar), 
4.38 (t, 2H, 3J = 7.0 Hz, CH2), 3.37 (q, 2H, 3J = 6.0 Hz, CH2), 1.86 
(quintet, 2H, 3J = 7.4 Hz, CH2), 1.40 (quintet, 2H, 3J = 7.0 Hz, CH2), 
1.35-1.24 (m, 4H, 2 × CH2) 
4.34 (t, 1H, 3J 
= 5.0 Hz) 
7ab 9.30 (s, 1H) 7.97-7.96 (m, 2H, 2 × CH Ar), 7.96-7.95 (m, 2H, 2 × CH Ar), 
7.66-7.62 (m, 2H, 2 × CH Ar), 7.54-7.49 (m, 3H, 2 × CH Ar + 
CH Ar overlapped), 7.39 (tt, 1H, 3J = 7.4 Hz, 4J = 1.2 Hz, CH Ar). 
  
8a 7.87 (s, 1H) 7.94-7.92 (m, 2H, 2 × CH Ar), 7.48-7.44 (m, 2H, 2 × CH Ar), 
7.38-7.34 (m, 1H, CH Ar), 7.32 (d, 1H, 3J = 7.4 Hz, CH Ar), 7.19 
(d, 2H, , 3J = 7.8 Hz, 2 × CH Ar) 
2.05 (s, 6H, 2 × CH3)  
9ab 9.53 (s, 1H) 8.51 (d, 2H, 3J = 8.8 Hz, 2 × CH Ar), 8.28 (d, 2H, 3J = 9.2 Hz, 2 
× CH Ar), 7.97 (d, 2H, 3J = 7.6 Hz, 2 × CH Ar), 7.53 (t, 2H, 3J = 
7.6 Hz, 2 × CH Ar), 7.42 (t, 1H, 3J = 7.4 Hz 
  
a All spectra run in CDCl3 at 25 °C, except where indicated. Chemical shifts reported as ppm values, referenced to the residual solvent peak  
b Spectrum run in DMSO-d6 at 25 °C  
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Table 2.5: The analytical data pertaining to the substituted-phenyl-1,2,3-triazole ligands. 
Compound Mp (°C)a FTIR C-H triazole stretch (cm-1)b ESI-MS [M + H]+ (m/z)c 
1a 80 – 81 3120 - 
2a 107 – 110 3125 227.1495 [M + H]+ 
3a 89 – 93 3130 189.0983 [M + H]+ 
4a 62 – 70 3129 234.1238 [M + H]+ 
5a 34- 36 3133 278.1506 [M + H]+ 
6a 97 – 98 3120 246.1602 [M + H]+ 
7a 188 – 190 3121 - 
8a 128 - 130 3132 - 
9a 238 - 239 3122 - 
a Reported as uncorrected. b Recorded neat with a ZnSe ATR accessory. c Reported fragments agree with the predicted spectra. 
For the purposes of this thesis, only the synthesis and characterization of 6a will be discussed in 
detail. The experimental procedures for all the ligands synthesized are reported in Section 2.4.3. 
The ligand, 6a, was synthesized via two different methods. The first was based on the synthesis 
described Romeo et al.10 which utilizes the traditional CuSO4·5H2O catalyst in the presence of 
sodium ascorbate. The second was based on the synthesis described by Man et al.11 which utilizes 
a less conventional Cu(PPh3)3Br catalyst. Both synthetic routes are shown in Scheme 2.1. 
 
Scheme 2.1: A representation of the synthetic schemes used to synthesize ligand 6a. i) follows the synthesis 
based on Romeo et al.10 and ii) follows the synthesis based on Man et al.11 
The synthesis published by Romeo et al.10 was used to synthesize 3a, with a reaction time of 4 hours 
and without chromatographic purification steps. The same conditions were followed for ligands 4a, 
5a and 6a but the reaction time had to be extended to 24 hours and the product had to be purified 
with column chromatography in order to remove the copper catalyst from the product. This did not 
conform to the principles of click chemistry and, in addition to this, very low yields (36 %) were 
achieved. 
The synthesis of 6a thus employed the procedure reported by Man and co-workers.11 The reported 
synthesis was previously used for siloxane functionalized triazole ligands and had to be kept 
completely water free in order to prevent the condensation of the siloxane functionalities. In the case 
of 6a the reaction time was changed from the reported 5 minutes to 30 minutes with the hope of 





increasing the yield of the product. There was no chromatographic purification required as the 
product could be purified with recrystallization from DCM:Et2O, without the copper contamination 
that was observed with the previous method, thus conforming to the click chemistry principles. The 
product was obtained in high purity and good yield (74 %). 
The product was characterized with FTIR, 1H NMR, 13C NMR, ESI-MS and elemental analysis. 
 
Figure 2.2: The FTIR spectrum of 6a with the signals assigned. All assignments were made in accordance with 
correlation tables compiled by Pavia et al.12 
The FTIR spectrum of 6a (Figure 2.2) shows that the triazole had formed with the appearance of the 
alkene C-H stretch at 3117 cm-1 and the appearance of the mono-substituted aromatic ring 
overtones12,13. 
The structure of the triazole was confirmed with 1H NMR since the triazole proton exhibits a very 
prominent singlet at 8.57 ppm, as shown in Figure 2.3. Interestingly, the proton on the hydroxyl group 
shows fine coupling to the neighbouring CH2, resulting in a triplet at 4.34 ppm. The structure was 
confirmed with 13C NMR (Figure 2.4). 
ESI-MS confirmed the formation of the product with the base peak representing the parent ion [M + 
H]+ at 246.1602 m/z (calculated at 246.1606 m/z). [M + Na]+ and [M + K]+ adducts were also identified 





















































































































































































Figure 2.3: The 1H NMR (600 MHz, DMSO-d6) spectrum of 6a. Assignments have been made according to the 
molecular structure as indicated. 
 
Figure 2.4: The 13C NMR (75 MHz, DMSO-d6) spectrum of 6a. Assignments have been made according to the 
molecular structure as indicated.






Figure 2.5: The ESI-MS spectrum of the product obtained with the predicted spectra for each identified signal. The prediction was performed on Molecular Weight 
Calculator freeware14  
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The elemental analysis of the 6a is summarized in Table 2.6.  
Table 2.6: The elemental analysis of 6a. 
 % C % H % N 
Calculated 67.4 7.41 17.7 
Found 67.3 7.17 16.8 
Molecular formula found: C14H19N3O·0.25H2O 
The ligand contained a small amount of water despite extensive in vacuo drying, and the percentage 
nitrogen is not within percentage error, but combined with all the other characterization techniques 
it can be concluded that the ligand was successfully synthesized. 
2.2.2.2 Substituted-pyridine-1,2,3-triazole ligands 
All substituted pyridine-1,2,3-triazole ligands are summarized in Table 2.7. Of these ligands 4b, 5b, 
6b and 8b are to the best of our knowledge new. 
Table 2.7: A summary of the substituted pyridine-1H-1,2,3-triazole ligands synthesized. Compound numbers of 
new ligands are indicated in italics. 
   














The 1H NMR characterization of the all the ligands synthesized is summarized in Table 2.9. 
Additional analytical characterization are summarized in Table 2.8. 
From the 1H NMR data in Table 2.9, a similar trend is observed as for the substituted-phenyl-1H-
1,2,3-triazole ligands. With a decrease in the donating ability of the substituent, derived from the 
original azide, there is an increase in the deshielding of the triazole proton. 
Table 2.8: The analytical data pertaining to the substituted-pyridyl-1,2,3-triazole ligands 
Compound Mp (°C)a FTIR C-H triazole stretch (cm-1)b ESI-MS [M + H]+ (m/z)c 
1b 75 – 77 3128 - 
2b 84 – 86 3061 - 
3b 108 – 109 3211 191.0928 [M + H]+ 
4b 53 – 54 3314 235.1192 [M + H]+ 
5b -d 3365 279.1457 [M + H]+ 
6b 70 – 72 3419 247.1553 [M + H]+ 
7b 90.- 91 3114 - 
8b -d 3051 251.1302 [M + H]+ 
9b 247 - 248 3126 - 
a Reported as uncorrected. b Recorded neat with a ZnSe ATR accessory. c Reported fragments agree with the predicted spectra.  
d Compounds isolated as viscous oils. 
 









Aromatic region (ppm) 
Aliphatic region (ppm) 
CH2/CH3/CH OH 
1b  8.04 (s, 1H) 8.45-8.44 (m, 1H, CH Ar), 8.55 (d, 1H, 3J = 7.9 Hz, CH Ar), 7.63 
(dd, 1H, 3J = 7.7 Hz, 4J = 1.8 Hz, CH Ar), 7.08 (dd, 1H, 3J = 7.4 
Hz, 4J = 1.1 Hz, CH Ar) 
4.28 (t, 2H, 3J = 7.2 Hz, CH2), 1.81 (qt, 2H, 3J = 7.2 Hz, CH2), 
1.20-1.12 (m, 10H, 5 × CH2), 0.74 (t, 3H, 3J = 7.1 Hz, CH2). 
 
2b 8.12-8.11 (m, 2H, 
CH Ar overlap 
CH triazole) 
8.50 (d, 1H, 3J = 4.5 Hz, CH Ar), 7.69 (dd, 1H, 3J = 7.7 Hz, 4J = 
1.7 Hz, CH Ar), 7.14 (m, 1H, CH Ar), 4.44 (tt, 1H, 3J = 11.7 Hz, 4J 
= 3.8 Hz, CH Ar) 
2.21-2.17 (m, 2H, CH2), 1.89-1.64 (m, 5H), 1.48-1.13 (m, 3H)  
3bb 8.54 (s, 1H) 8.60 (d, 1H, 3J = 4.4 Hz, CH Ar), 8.03 (dd, 1H, 3J = 8.0 Hz, CH 
Ar), 7.89 (dd, 1H, 3J = 7.7 Hz, CH Ar), 7.33 (dd, 1H, 3J = 7.0 Hz, 
CH Ar) 
4.48 (t, 2H, 3J = 5.5 Hz, CH2), 3.84 (q, 2H, 3J = 5.0 Hz, CH2) 5.07 (t, 1H, 3J 
= 5.2 Hz) 
4b 8.58 (s, 1H) 8.60-8.59 (m, 1H, CH Ar), 8.04 (dd, 1H, 3J = 7.9 Hz, 4J = 1.0 Hz, 
CH Ar), 7.89 (dd, 1H, 3J = 9.6 Hz, 4J = 1.8 Hz, CH Ar), 7.34 (dd, 
1H, 3J = 7.5 Hz, 4J = 1.1 Hz, CH Ar) 
4.63-4.60 (m, 4H, 2 × CH2), 3.88 (t, 2H, 3J = 5.3 Hz, CH2),  
3.49-3.44 (m, 5H,CH2 + OH) 
 
5b 8.58 (s, 1H) 8.46 (dd, 1H, 3J = 4.9 Hz, 4J = 0.9 Hz, CH Ar), 8.15 (dd, 1H, 3J = 
8.1 Hz, 4J = 0.95 Hz, CH Ar), 7.70 (dd, 1H, 3J = 7.5 Hz, 4J = 1.75 
Hz, CH Ar), 7.16 (dd, 1H, 3J = 7.5 Hz, 4J = 1.1 Hz, CH Ar) 
4.55 (t, 2H, 3J = 4.8 Hz, CH2), 3.83 (t, 2H, 3J = 4.8 Hz, CH2), 
3.72 (t, 2H, 3J = 4.4 Hz, CH2), 3.57 (s, 4H, 2 × CH2), 3.52 (t, 
2H, 3J = 4.4 Hz, CH2) 
5.02 (bs,1H), 
6bb 8.61 (s, 1H) 8.59 (dd, 1H, 3J = 1.7 Hz, 4J = 0.9 Hz, CH Ar), 8.03-8.02 (m, 1H, 
CH Ar), 7.88 (dd, 3J = 7.7 Hz, 4J = 1.9 Hz, CH Ar), 7.33 (dd, 1H, 
3J = 4.8 Hz, 4J = 1.2 Hz, CH Ar) 
4.42 (t, 2H, 3J = 7.1 Hz, CH2), 3.37 (q, 2H, 3J = 5.3 Hz, CH2), 
1.87 (quintet, 2H, 3J = 7.2 Hz, CH2), 1.39 (quintet, 2H, 3J = 
6.5 Hz, CH2), 1.34-1.22 (m, 4H, 2 × CH2). 
4.33 (t, 1H, 3J 
= 5.0 Hz) 
7bb 9.33 (s, 1H) 8.67-8.65 (m, 1H, CH Ar), 8.13 (dd, 1H, 3J = 7.9 Hz, 4J = 1.0 Hz, 
CH Ar), 8.04-8.01 (m, 2H, CH Ar), 7.95 (dd, 1H, 3J = 7.8 Hz, 4J = 
1.8 Hz, CH Ar), 7.64-7.60 (m, 2H, CH Ar), 7.52 (m, 1H, CH Ar), 
7.41 (dd, 1H, 3J = 4.8 Hz, 4J = 1.2 Hz, CH Ar) 
  
8bb 8.88 (s, 1H) 8.64-8.62 (m, 1H, CH Ar), 8.15 (d, 1H, 3J = 7.9 Hz, CH Ar), 7.94 
(dd, 1H, 3J = 7.8 Hz, 4J = 1.8 Hz, CH Ar), 7.44-7.36 (m, 2H, CH 
Ar), 7.31-7.29 (m, 2H, CH Ar) 
1.98 (s, 6H, 2 × CH3)  
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Aromatic region (ppm) 
Aliphatic region (ppm) 
CH2/CH3/CH OH 
9bb 9.55 (s, 1H) 8.69-8.67 (m, 1H, CH Ar), 8.46 (dd, 2H, 3J = 9.1 Hz, 4J = 2.1 Hz, 
CH Ar), 8.35 (dd, 2H, 3J = 9.2 Hz, 4J = 2.2 Hz, CH Ar), 8.14 (d, 
1H, 3J = 7.9 Hz, CH Ar), 7.97 (td, 1H, 3J = 7.7 Hz, 4J = 1.8 Hz, CH 
Ar), 7.43 (dd, 1H, 3J = 7.6 Hz, 4J = 1.2 Hz,  CH Ar) 
  
a All spectra run in CDCl3 at 25 °C, except where indicated. Chemical shifts reported as ppm values, referenced to the residual solvent peak 
b Spectrum run in DMSO-d6 at 25 °C 
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For the purposes of this thesis, only the synthesis of 4b will be discussed in detail. As with 6a, two 
different synthetic methods were used to synthesize 4b, of which the modified microwave assisted 
method yielded the purer product in better yield (Scheme 2.2). 
 
Scheme 2.2: A representation of the synthetic schemes used to synthesize ligand 6a. i) follows the synthesis 
based on Romeo et al.10 and ii) follows the synthesis based on Man et al.11 
The method reported by Romeo et al.10 yielded the product in a moderate yield (41 %) as a yellow 
oil with a small number of impurities. Using the procedure described by Man et al.11 and extending 
the reaction time to 30 minutes, the product was isolated in good yield (86 %) as an off-white powder. 
The difference between the two isolated products could possibly be ascribed to the chelation of the 
copper to the desired product, a phenomenon that is known to occur for these types of ligands15. 
The copper was not completely stripped from the ligand during the extraction step using the first 
method, thus resulting in a final product that consisted of free ligand and copper complexed ligand. 
The method reported by Man et al.11 utilizes a sterically hindered catalyst in a much lower molar 
ratio, thus circumventing the chelation problem and yielding a pure white powder rather than the 
impure yellow oil. 





 The compound (4b) was characterized with FTIR, 1H NMR and 13C NMR spectroscopy as well as 
ESI-MS and elemental analysis.  
 
Figure 2.6: The assigned FTIR spectrum of 4b. 
From the FTIR spectrum of 4b (Figure 2.6) it is evident that the desired product was synthesized. 
The appearance of the C-H triazole stretch at 3158 cm-1 indicates the formation of the triazole ring 
along with the disappearance of the azide stretch of the starting material at 2091 cm -1.  
The structure of the ligand was confirmed with 1H NMR, as shown in Figure 2.7, and was integrated 
relative to the triazole proton at 8.58 ppm. The integration of all the signals matched the molecular 
structure except for the multiplet at 3.49 – 3.44 ppm. This can be attributed to an overlap of the OH-
signal with that of the protons on the neighbouring carbon which results in a broader signal with a 
higher integration.  
13C NMR spectroscopy and ESI-MS were used to confirm the structure of the ligand, as shown in 
Figure 2.8 and Figure 2.9, respectively. 






Figure 2.7: The assigned 1H NMR (600 MHz, DMSO-d6) spectrum of 4b. Assignments have been made according 
to the molecular structure as indicated. 
 
Figure 2.8: The 13C NMR (600 MHz, DMSO-d6) spectrum of 4b.






Figure 2.9: The ESI-MS spectrum of the product obtained with the predicted spectra for each identified signal. The prediction was performed on Molecular Weight 
Calculator freeware14 
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The elemental analysis of the 4a is summarized in Table 2.6.  
Table 2.10: The elemental analysis of 4a. 
 % C % H % N 
Calculated 52.5 5.57 22.6 
Found 52.4 6.39 22.2 
Molecular formula found: C11H14N4O2·H2O 
 
As with ligand 6a, ligand 4b also contained a small amount of water despite extensive in vacuo 
drying. In this case the percentage hydrogen is not within experimental error, but combined with all 
the other characterization techniques it can be concluded that the ligand was successfully 
synthesized. 
2.3 Conclusion 
A number of known and new ligands were synthesized from their respective organoazide moieties, 
and fully characterized. Within both series of ligands, it was noted that a decrease in the electron 
donating abilities of the substituent lead to an increase in the deshielding of the triazole proton, as 
observed with 1H NMR. The ligands were then complexed to a Pd(II) precursor, as discussed in the 
next chapter. 
2.4 Experimental Section 
2.4.1 General Methods and Materials 
The synthetic procedures were all performed under standard Schlenk conditions in a nitrogen 
atmosphere unless otherwise noted. Literature procedures were used where indicated. All starting 
materials used were obtained from Merck and Sigma-Aldrich and used without additional purification. 
Solvents used were obtained from Merck, Protea Chemicals, Kimix and Sigma-Aldrich and purified 
accordingly. THF, DCM, hexane, and diethyl ether were purified and degassed with PureSolv Micro 
purifiers. Acetonitrile, methanol and ethanol were distilled over the appropriate drying agents. 
Acetonitrile was distilled over phosphorous pentoxide and both methanol and ethanol were distilled 
over magnesium filings and iodine. The copper catalyst, Cu(PPh3)3Br, was prepared using a 
literature procedure16. Where applicable, reactions were performed in a CEM Discover SP 
microwave reactor at a fixed voltage of 150 W. 
FTIR data was collected on a Thermo Nicolet 350 ATR-FTIR spectrometer with a Smart Performance 
ATR (Zn/Se) accessory. 1H NMR and 13C NMR spectroscopy were performed on 300, 400 and 600 
MHz Agilent NMR spectrometers as indicated. Chemical shifts were taken in reference to residual 





solvent peaks in which the compound was dissolved. Coupling constants (J) are reported in Hz. 
Mass Spectrometry data was collected on a Waters Synapt G2 mass spectrometer (ESI +, 15 V). 
Microanalysis was performed at the UCT Department of Chemistry on a Thermo Elemental Analyser 
CHNS-O instrument. Melting points were determined on a Bibby Stuart Scientific Melting Point 
Apparatus SMP3. 
2.4.2 Synthesis of azides 
2.4.2.1 Synthesis of 1: 1-azido-octane 
 Based on the synthesis published by Yao and Lear et al.17 NaN3 
(0.250 g, 3.85 mmol) was added to DMF (1.00 mL) and stirred 
vigorously in an inert atmosphere. To this 1-bromooctane (0.440 mL, 
2.54 mmol) was added drop wise. The reaction solution was allowed to stir at room temperature for 
23 h, after which TLC (eluted with EtOAc) indicated that the reaction has reached completion. The 
reaction mixture was diluted with water (20 mL) and the organic products extracted with EtOAc (5 × 
10 mL). The combined organic layers were washed with brine (10 mL) and dried over anhydrous 
MgSO4. After filtration the solvent was removed with rotary evaporation to yield a pale yellow oil 
(0.331 g, 84 %). FTIR (ATR): 2089 cm-1 (N≡N stretch). 1H NMR (600 MHz, CDCl3): δ (ppm) = 3.25 
(t, 2H, 3J = 7.2 Hz, CH2), 1.59 (quint, 2H, 3J = 7.1 Hz, CH2), 1.37-1.27 (m, 10H, 5 × CH2), 0.88 (t, 
3H, 3J = 7.0 Hz, CH3). 13C NMR (151 MHz, CDCl3): δ (ppm) = 51.62, 31.88, 29.28, 29.25, 28.97, 
26.85, 22.75, 14.17. The characterization data agrees with that reported in literature and the product 
was used without further purification. 
2.4.2.2 Synthesis of 2: 1-azidocyclohexyl 
 Based on the synthesis published by Renaud et al.18 Bromocyclohexane (0.500 mL, 
4.00 mmol) and NaN3 (0.650 g, 10.0 mmol) were added to DMF (20.0 mL). The 
saturated solution was allowed to stir at 80 °C for 18 h in an inert atmosphere. The 
reaction mixture was then diluted with EtOAc (20.0 mL) and washed with water (6 × 
10.0 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated 
under reduced pressure to yield a clear oil (0.412 g, 82 %). FTIR (ATR): 2085 cm-1 (N≡N stretch)). 
1H NMR (300 MHz, CDCl3): δ (ppm) = 3.30-3.22 (m, 1H, CH), 1.85-1.66 (m, 5H, CH2), 1.53-1.47 (m, 
1H, CH2), 1.36-1.26 (m, 4H, CH2). 13C NMR (75 MHz, CDCl3): δ (ppm) = 30.76, 25.22, 24.15, 0.92. 
The characterization data agrees with that reported in literature and the product was used without 
further purification. 
2.4.2.3 Synthesis of 3: 1-azido-ethanol 
 Based on the synthesis reported by Murphy et al.19 To a stirring solution of 2-
chloroethanol (0.380 mL, 5.74 mmol) in DMF (20.0 mL) was added NaN3 (0.523 g, 









cooling to room temperature, some DMF was removed on the rotary evaporator. The product was 
then extracted from the remaining solvent with Et2O (5 × 10.0 mL). The combined organic layers 
were washed with water (10 × 10.0 mL) dried over anhydrous MgSO4, and filtered. The solvent was 
then removed under reduced pressure to yield a clear colourless oil (0.464 g, 93 %). FTIR (ATR): 
2097 cm-1 (N≡N stretch). 1H NMR (400 MHz, CDCl3): δ (ppm) = 4.25 (bs, 1H, OH), 2.99 (t, 2H, 3J = 
5.0 Hz, CH2), 2.59 (t, 2H, 3J = 5.1 Hz, CH2). The characterization data agrees with that reported in 
literature and the product was used without further purification. 
2.4.2.4 Synthesis of 4: 2-(2-azido-ethoxy) ethanol 
 Synthesized according to a literature procedure20. 2-(2-chloroethoxy) ethanol 
(1.61 mL, 15.3 mmol) was added to a stirring solution of NaN3 (1.98 g, 30.5 
mmol) in water (6.35 mL). The solution was stirred at 90 °C for 16 h after 
which it was cooled to room temperature. The product was then extracted with DCM (5 × 5 mL). The 
organic phase was dried over anhydrous MgSO4 and the solvent removed under vacuum. A clear, 
colourless oil was obtained (1.75 g, 88 %). FTIR (ATR): 2091 cm -1(N≡N stretch). 1H NMR (400 MHz, 
CDCl3): δ (ppm) = 3.59-3.56 (m, 2H), 3.53 (t, 2H, J = 5.0 Hz), 3.44 (t, 2H, J = 4.7 Hz), 3.26 (t, 2H, J 
= 5.0 Hz), 3.19 (t, 1H, J = 5.8 Hz). 13C NMR (101 MHz, CDCl3): δ (ppm) = 72.05, 69.34, 60.95, 50.24. 
The characterization data agrees with that reported in literature and the product was used without 
further purification. 
2.4.2.5 Synthesis of 5: 2-(2-(2-azidoethoxy)ethoxy)ethanol 
Synthesized according to a literature procedure21. 2-(2-(2-
chloroethoxy)ethoxy)ethanol (0.860 mL, 6.00 mmol) was added to 
a stirring solution of NaN3 (0.780 g, 12.0 mmol) in DMF (8.00 mL). 
The solution was allowed to reflux at 90 °C for 24 h. Some of the DMF was then removed under 
vacuum. The remaining solution was then diluted with water (20 mL) and the product extracted with 
EtOAc (4 × 10 mL). The organic phase was then washed with brine (10.0 mL), dried over anhydrous 
MgSO4, filtered and the solvent removed under vacuum. A clear, slightly green oil was obtained 
(1.04 g, 96 %). FTIR (ATR): 2097 cm -1(N≡N stretch). 1H NMR (600 MHz, CDCl3): δ (ppm) = 3.66 
(bs, 1H, OH), 3.25-3.24 (m, 4H, 2 × CH2), 3.23-3.20 (m, 4H, 2 × CH2), 3.14 (t, 2H, 3J = 5.0 Hz, CH2), 
2.96 (t, 2H, 3J = 5.1 Hz, CH2). 13C NMR (101 MHz, CDCl3): δ (ppm) = 71.50, 69.21, 69.05, 68.65, 
59.93, 49.39.  The characterization data agrees with that reported in literature and the product was 
used without further purification. 
2.4.2.6 Synthesis of 6: 6-azidohexanol 
 Synthesized according to a literature procedure22. 6-chlorohexanol 
(0.466 mL, 3.49 mmol) was added to a stirring solution of NaN3 (0.567 g, 
8.725 mmol) in DMF (1.11 mL). The solution was then allowed to stir at 









washed with brine (5 × 5 mL) and water (5 × 5 mL). The organic layer was then dried over anhydrous 
MgSO4, filtered and the solvent removed under reduced pressure. A clear, off-white oil was obtained 
(0.362 g, 72 %). FTIR (ATR): 2087 cm-1 (N≡N stretch). 1H NMR (600 MHz, CDCl3): δ (ppm) = 3.45 
(t, 2H, 3J = 6.7 Hz, CH2), 3.30 (bs, 1H, OH), 3.13 (t, 2H, 
3J = 7.0 Hz, CH2), 1.48 (q, 2H, 
3J = 7.0 Hz, 
CH2), 1.42 (q, 2H, 
3J = 6.8 Hz, CH2), 1.29-1.22 (m, 4H, 2 × CH2). 13C NMR (151 MHz, CDCl3): δ 
(ppm) = 61.97, 51.10, 32.18, 28.53, 26.27, 25.10. The characterization data agrees with that reported 
in literature and the product was used without further purification. 
2.4.2.7 Synthesis of 7: 1-azidobenzene 
 Based on the synthesis reported by Ye et al.23 Aniline (0.382 mL, 4.20 mmol) was 
dissolved in rapidly stirring 10 % (v/v) HCl (5.0 mL) at 0 °C. NaNO2 (0.435 g, 6.30 
mmol) was dissolved in water (3 mL) and added dropwise over 10 minutes to the 
aniline solution. The reaction was allowed to stir at 0 °C for 30 minutes. NaN3 (1.09 
g, 16.8 mmol) was dissolved in water (3 mL) and added dropwise over 15 minutes to the reaction 
mixture. Each addition of the azide resulted in the reaction bubbling and foaming rapidly. The 
reaction mixture was then allowed to warm up to room temperature where it was stirred for 3 h until 
TLC (eluent 30 % EtOAc: PE) showed that the reaction had reached completion. EtOAc (20 mL) was 
added to the reaction mixture and stirred vigorously. The organic phase was then washed with water 
(5 × 15 mL). The organic phase was isolated, dried over Na2SO4, filtered and the solvent removed 
under reduced pressure. This yielded a yellow oil (0.462 g, 92.4 %). FTIR (ATR): 2123 cm-1 (N≡N 
sym. stretch), 2091 cm-1 (N=N=N asym. stretch). 1H NMR (600 MHz, CDCl3): δ (ppm) = 7.38-7.35 
(m, 2H, 2 × CH Ar), 7.16 (tt, 1H, 3J = 7.4 Hz, 4J = 1.1 Hz, CH Ar), 7.06-7.04 (m, 2H, 2 × CH Ar). The 
characterization data agrees with that reported in literature and the product was used without further 
purification. 
2.4.2.8 Synthesis of 8: 2-azido-1,3-dimethylbenzene 
 Synthesized according to a literature procedure24 2,6-dimethylaniline (1.54 mL, 12.5 
mmol) was dissolved in a 1:1 mixture of AcOH:H2O at 0 °C. A saturated aqueous 
solution of NaNO2 (1.294 g, 18.75 mmol) was added drop-wise to the solution. The 
solution was allowed to stir in air at 0 °C until all the starting material was confirmed 
consumed via TLC (eluent DCM). NaN3 (1.219 g, 18.75 mmol) was dissolved in water 
(3 mL) and the solution added dropwise over 15 minutes to the reaction mixture. Each addition of 
the azide resulted in the reaction bubbling and foaming vigorously. The solution was allowed to reach 
room temperature and then stirred for an additional 60 minutes. The solution was then diluted with 
H2O (15 mL) and Et2O (15 mL) which resulted in a bright red organic phase. The pH of the solution 
was adjusted to neutral with the addition of solid Na2CO3 and measured with universal indicator 
strips. The organic phase was then separated and the aqueous layer further extracted with Et2O (2 
× 15 mL). The combined organic phases were washed with H2O (10 mL) and saturated brine (10 
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mL), dried over anhydrous MgSO4, filtered and the solvent removed under reduced pressure to yield 
a dark yellow oil (1.41 g, 76 %). FTIR (ATR): 2092 cm-1 (N≡N stretch). 1H NMR (400 MHz, CDCl3): δ 
(ppm) = 7.06-7.02 (m, 3H, 3 × CH Ar), 2.39 (s, 6H, 2 × CH3). 13C NMR (75 MHz, CDCl3): δ (ppm) = 
136.97, 132.13, 128.86, 125.71, 18.15. The characterization data agrees with that reported in 
literature and the product was used without further purification. 
2.4.2.9 Synthesis of 9: 1-azido-4-nitrobenzene 
Based on synthesis published by Yao and Lear et al.17 4-nitroaniline (1.38 g, 
10.0 mmol) was dissolved in a 10 % (v/v) HCl at 0 °C. A saturated aqueous 
solution of NaNO2 (0.690 g, 10.0 mmol) was added to the solution. The solution 
was then allowed to stir in air at 0 °C until all the starting material had 
disappeared on TLC (eluted with 20 % (v/v) DCM:Hex). To the foaming mixture was added a 
saturated aqueous solution of NaN3 (1.219 g, 18.75 mmol), dropwise over 15 min. With each addition 
of the azide the solution bubbled furiously, forming white foam. In order for the solution to reach 
homogeneity, EtOAc (10 mL) was added to dissolve the foam, resulting in a biphasic system. After 
the addition of all the azide the solution was allowed to reach room temperature and then stirred for 
an additional hour. The product was then extracted with EtOAc (3 × 20 mL). The combined organic 
fractions were washed with brine (30 mL), dried over anhydrous MgSO4, filtered and the solvent 
removed. A bright yellow powder was obtained (1.419 g, 87 %). Melting point: 74-75 °C. FTIR (ATR): 
2120.90 cm-1 (N≡N stretch). 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.25-8.22 (m, 2H, 2 × CH Ar), 
7.26 - 7.12 (m, 2H, 2 × CH Ar). 13C NMR (151 MHz, CDCl3): δ (ppm) = 146.99, 144.76, 125.73, 
119.51. The characterization data agrees with that reported in literature and the product was used 
without further purification. 
2.4.3 Synthesis of substituted-phenyl-1,2,3-triazole ligands 
2.4.3.1 Synthesis of 1a: 1-octyl-4-phenyl-1,2,3-triazole 
 Based on synthesis published by Hu et al.25 
Phenylacetylene (0.162 L, 1.48 mmol) and 
compound 1 (286 mg, 1.48 mmol) were added to 
DIPEA (0.011 mL, 0.062 mmol), HOAc (0.004 mL, 
0.062 mmol) and CuI (0.0059 g, 0.031 mmol) in DCM 
(1.0 mL). The solution was allowed to stir at 25 °C for 
24 h. The solution was filtered through a 0.45 µm syringe filter to remove the copper precipitate that 
had formed and the solvent removed on a rotary evaporator. The product was purified with a short 
silica column to remove any residual copper catalyst (30% EtOAc: PE (40-60°C). The relevant 
fractions were collected and the solvent removed to yield a white powder (0.240 g, 63 %). Mp = 80-
81 °C (lit. 78-80 °C) FTIR (ATR): 3120 cm-1 (C-H triazole stretch). 1H NMR (300 MHz, CDCl3): δ 
(ppm) = 7.85-7.81 (m, 2H, 2 × CH Ar), 7.74 (s, 1H, CH triazole), 7.45-7.39 (m, 2H, 2 × CH Ar), 7.35-
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7.29 (m, 1H, CH Ar), 4.39 (t, 2H, 3J = 7.2 Hz, CH2), 1.94 (quint., 2H, 3J = 7.3 Hz, CH2), 1.35-1.26 (m, 
10H, 5 × CH2), 0.87 (t, 3H, 3J = 6.8 Hz, CH3). 13C NMR (75 MHz, CDCl3): δ (ppm) = 147.85 (C quat.), 
130.88 (C quat.), 128.95 (2 × CH Ar), 128.19 (CH triazole), 125.82 (2 × CH Ar), 119.49 (CH Ar), 
50.58, 31.84, 30.50, 29.18, 26.65, 22.73, 14.19 (7 × CH2), 1.16 (CH3). The characterization data 
agrees with that reported in literature. 
2.4.3.2 Synthesis of 2a: 1-cyclohexyl-4-phenyl-1H-1,2,3-triazole 
 Based on synthesis published by Hu et al.25 Phenylacetylene (0.111 
mL, 1.00 mmol) and compound 2 (0.076 g, 0.607 mmol) were added 
to DIPEA (0.007 mL, 0.04 mmol), HOAc (0.0023 mL, 0.04 mmol) and 
CuI (0.0038 g, 0.02 mmol) in DCM (1.0 mL). The solution was 
allowed to stir at 25 °C for 24 h in an inert atmosphere. The solution 
was then filtered through a syringe filter to remove the copper impurity. The solvent was removed 
under vacuum to yield an off-white powder. The product was purified via column chromatography 
(30 % EtOAc: PE (40-60°C)) to yield a white powder (0.116 g, 84 %). Mp = 107-110 °C (lit. 106-
110.0°C). FTIR (ATR): 3125 cm-1 (C-H triazole stretch). 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.81 
(d, 2H, 3J = 8.0 Hz, 2 × CH Ar ), 7.76 (s, 1H, CH triazole), 7.42 (t, 2H, 3J = 7.5 Hz, 2 × CH Ar), 7.32 
(t, 1H, 3J = 7.2 Hz, CH Ar), 2.28-1.93 (m, 4H, 2 × CH2), 1.82-1.76 (m, 2H, CH2), 1.67 (s, 1H, CH), 
1.54-1.44 (m, 2H, CH2), 1.36-1.29 (m, 2H, CH2). 13C NMR (101 MHz, CDCl3): δ (ppm) =147.35, 
130.99, 128.86, 128.03, 125.71, 117.40, 60.22, 33.68, 25.27, 25.23. ESI-MS: found: 227.1495 [M + 
H]+ (calc. 227.3093). The characterization data agrees with that reported in literature. 
2.4.3.3 Synthesis of 3a: 2-(4-phenyl-1H-1,2,3-triazol-1-yl)ethanol 
 Based on synthesis published by Romeo at al.10 Phenylacetylene 
(0.120 mL, 1.10 mmol), compound 3 (0.087 g, 1.00 mmol) and Et3N 
(0.139 mL, 1.00 mmol) were added to iPrOH (1.15 mL). In a separate 
container CuSO4·5H2O (0.065 g, 0.26 mmol) was reduced with 
sodium ascorbate (0.103 g, 0.52 mmol) in water (1.15 mL). The 
copper solution was then added to the isopropanol solution. The reaction mixture was allowed to stir 
at 25 °C for 24 h. The solution was filtered through a syringe filter to remove the copper impurity and 
the iPrOH was removed under reduced pressure. The residue obtained was then diluted with water 
(20 mL) and the product was extracted with EtOAc (5 × 10 mL). The organic phase was dried over 
anhydrous MgSO4, filtered and the solvent removed under reduced pressure. This resulted in a 
yellow oil that was purified via column chromatography (5 % Et3N: EtOAc) to yield a white powder 
(0.101 g, 53 %). Mp = 89-93 °C (lit. 89-92°C). FTIR (ATR): 3130 cm-1 (C-H triazole stretch). 1H NMR 
(400 MHz, CDCl3): δ (ppm) = 7.76 (s, 1H, CH triazole), 7.61-7.59 (m, 2H, CH Ar), 7.34-7.26 (m, 3H, 
CH Ar), 4.43 (t, J = 4.8 Hz, 2H, CH2), 4.43 (bs overlapped, 1H, OH), 4.07 (bs, 2H, CH2). 13C NMR 
(151 MHz, CDCl3): δ (ppm) = 147.37, 130.25, 128.88, 128.21, 125.58, 121.17, 61.10, 53.14. ESI-
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MS: found: 189.0983 m/z [M + H]+ (calc. 189.2169). The characterization data agrees with that 
reported in literature. 
2.4.3.4 Synthesis of 4a: 2-[2-(4-phenyl-1H-1,2,3-triazolyl)ethoxy]ethanol 
Synthesized using the same method as for compound 3a 
(Section 2.4.3.3).  A lustrous golden powder was obtained 
(0.176 g, 76 %). Mp = 62-70 °C. FTIR (ATR): 3129 cm-1 (C-
H triazole stretch). 1H NMR (400 MHz, CDCl3): δ (ppm)= 
7.93 (s, 1H, CH triazole), 7.77 (d, 3J = 8.0 Hz, 2H, CH Ar), 
7.36 (t, 3J = 7.8 Hz, 2H, CH Ar), 7.27 (t, 3J = 6.9 Hz, 1H, CH Ar), 4.51 (t, 3J = 4.7 Hz, 2H, CH2), 3.84 
(t, 3J = 5.4 Hz, 2H, CH2), 3.69 (t, 3J = 4.5 Hz, 2H, CH2), 3.53 (t, 3J = 4.74 Hz, 2H, CH2), 3.04 (s, 1H, 
OH). 13C NMR (101 MHz, CDCl3): δ (ppm) = 147.66, 130.54, 128.82, 128.11, 125.67, 120.98, 72.69, 
69.27, 61.47, 50.30. ESI-MS: found: 234.1238 m/z [M + H]+ (calc. 233.1164), 256.1053 m/z [M + 
Na]+ (calc. 256.1062). Elemental analysis: % Found (% calc.) for C12H15N3O2: C: 61.36 (61.79); H: 
6.63 (6.48); N: 17.32 (18.01). 
2.4.3.5 Synthesis of 5a: 2-(2-[2-(4-phenyl-1H-1,2,3-triazolyl)ethoxy]ethoxy)ethanol 
Synthesized using the same method as used for 
compound 3a (Section 2.4.3.3). A hygroscopic 
white solid was obtained (0.251 g, 91 %). Mp = 
34-36 °C. FTIR (ATR) = 3133 cm-1 (C-H triazole 
stretch), 3364 (O-H stretch). 1H NMR (300 MHz, 
CDCl3): δ (ppm) = 7.95 (s, 1H, CH triazole), 7.79-
7.76 (m, 2H, CH Ar), 7.39-7.33 (m, 2H, CH Ar), 7.29-7.23 (m, 1H, CH Ar), 4.49 (t, 3J = 5.1 Hz, 2H, 
CH2), 3.82 (t, 3J = 5.1 Hz, 2H, CH2), 3.65 (t, 3J = 4.6 Hz, 2H, CH2), 3.54 (s, 4H, 2 × CH2), 3.49 (t, 3J 
= 4.6 Hz, 2H, CH2), 3.14 (bs, 1H, OH). 13C NMR (101 MHz, CDCl3): δ (ppm) = 147.42 (C quat.), 
130.49 (C quat.), 128.71 (2 × CH Ar), 127.96 (CH triazole), 125.52 (2 × CH Ar), 121.03 (CH Ar), 
72.43, 70.39, 70.05, 69.27, 61.36, 50.13 (6 × CH2). ESI-MS: found: 278.1506 m/z [M + H]+ (calc. 
278.1505), 300.1324 m/z [M + Na]+ (calc. 300.1324). Elemental analysis: % Found (% calc.) for 
C14H19N3O3·H2O: C: 56.94 (57.72); H: 7.16 (6.49); N: 14.22 (13.98). 
2.4.3.6 General synthesis of 6a, 7a and 9a 
The synthesis is based on a procedure described by Man and co-workers.11 The azide (1 eq.), 2-
ethynylpyridine (1 eq.) and Cu(PPh3)3Br (0.005 mmol) were added to a solvent system of THF:Et3N 
(1:1, 500 µL:500µL) in a 10 mL microwave reactor tube. The reaction mixture was irradiated for 30 
minutes at 100 °C under nitrogen. The solvent was removed under reduced pressure. The resulting 
residue was washed with Et2O and the solvent decanted. The solvent was removed to yield the crude 
product. The product was then recrystallized from DCM:Et2O to produce the purified product. 
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2.4.3.6.1 Synthesis of 6a: 6-(4-phenyl-1H-1,2,3-triazol-1-yl)hexan-1-ol 
White opalescent flakes were isolated (0.132 g, 74 %). 
Mp = 97 – 98 °C. FTIR (ATR): 3208 cm-1 (O-H stretch), 
3120 cm-1 (C-H triazole). 1H NMR (600 MHz, DMSO-
d6): δ (ppm) = 8.57 (s, 1H, CH triazole), 7.84 (dd, 2H, 3J 
= 7.5 Hz, 2 × CH Ar), 7.44 (dt, 2H, 3J = 7.6 Hz, 2 × CH 
Ar), 7.32 (dt, 1H, 3J = 7.3 Hz, CH Ar), 4.38 (t, 2H, 3J = 7.0 Hz, CH2), 4.34 (t, 1H, 3J = 5.0 Hz, OH), 
3.37 (q, 2H, 3J = 6.0 Hz, CH2), 1.86 (quintet, 2H, 3J = 7.4 Hz, CH2), 1.40 (quintet, 2H, 3J = 7.0 Hz, 
CH2), 1.35-1.24 (m, 4H, 2 × CH2). 13C NMR (75 MHz, DMSO-d6): δ (ppm) = 146.24 (C quat.), 130.87 
(C quat.), 128.86 (2 × CH2), 127.75 (CH triazole), 125.08 (2 × CH Ar), 121.20 (CH Ar), 60.55 (CH2), 
49.49 (CH2), 32.28 (CH2), 29.67 (CH2), 25.75 (CH2), 24.91 (CH2). ESI-MS: found: 246.1602 m/z [M 
+ H]+ (calc. 246.1606), 268.1418 m/z [M + Na]+ (calc. 268.1426), 284.1163 m/z [M + K]+ (calc. 
284.1165). Elemental analysis: % Found (% calc.) for C14H19N3O·0.25H2O: C: 67.31 (67.38); H: 7.17 
(7.41); N: 16.82 (17.73). 
2.4.3.6.2 Synthesis of 7a: 1,4-diphenyl-1H-1,2,3-triazole 
White opalescent flakes were isolated (0.127 g, 57 %). Mp = 188-
190 °C (lit. 184-186 °C). FTIR (ATR): 3121 cm-1 (C-H triazole). 1H 
NMR (600 MHz, DMSO-d6): δ (ppm) = 9.30 (s, 1H, CH triazole), 7.97-
7.96 (m, 2H, 2 × CH Ar), 7.96-7.95 (m, 2H, 2 × CH Ar), 7.66-7.62 
(m, 2H, 2 × CH Ar), 7.54-7.49 (m, 3H, 2 × CH Ar + CH Ar 
overlapped), 7.39 (tt, 1H, 3J = 7.4 Hz, 4J = 1.2 Hz, CH Ar). 13C NMR 
(151 MHz, DMSO-d6): δ (ppm) = 147.30, 136.64, 130.24, 129.94, 129.00, 128.72, 128.24, 125.36, 
125.31, 120.03, 119.98, 119.63, 119.59. The characterization data agrees with that reported in 
literature. 
2.4.3.6.3 Synthesis of 9a: 1-(4-nitrophenyl)-4-phenyl-1H-1,2,3-triazole 
Orange powder isolated (0.243 g, 91 %). Mp = 238 – 239 °C 
(lit. 237-238 °C). FTIR (ATR): 3122 cm-1 (C-H triazole stretch), 
1597 cm-1 (N=O stretch), 1347 cm-1 (N=O stretch). 1H NMR 
(600 MHz, DMSO-d6): δ (ppm) = 9.53 (s, 1H, CH triazole), 8.51 
(d, 2H, 3J = 8.8 Hz, 2 × CH Ar), 8.28 (d, 2H, 3J = 9.2 Hz, 2 × 
CH Ar), 7.97 (d, 2H, 3J = 7.6 Hz, 2 × CH Ar), 7.53 (t, 2H, 3J = 
7.6 Hz, 2 × CH Ar), 7.42 (t, 1H, 3J = 7.4 Hz, CH Ar). 13C NMR (101 MHz, DMSO-d6): δ (ppm) = 
147.83 (C quat), 146.71 (C quat), 140.86 (C quat), 122.77 (C quat), 129.09 (2 × CH Ar), 128.56 (CH 
Ar), 125.67 (2 × CH Ar), 125.42 (2 × CH Ar), 120.46 (2 × CH Ar), 120.01 (CH triazole). The 









2.4.3.7 Synthesis of 8a: 1-(2,6-dimethylphenyl)-4-phenyl-1H-1,2,3-triazole 
Synthesized according to a literature procedure26. Phenylacetylene 
(0.362 mL, 3.30 mmol), azide 8 (0.456 g, 3.10 mmol), CuSO4·5H2O 
(0.899 g, 3.60 mmol) and sodium ascorbate (1.43 g, 7.20 mmol) were 
added to the solvent system of tBuOH: H2O (4:1, 20 mL: 5.0 mL) and 
stirred at 25 °C for 43 hours. After 43 h the tBuOH was removed 
under reduced pressure and the resulting residue diluted with water 
(20 mL). The product was extracted with EtOAc (5 × 20 mL) and the combined organic fractions 
were washed with saturated NH4Cl (25 mL). The organic phase was dried over MgSO4, filtered and 
the solvent removed under reduced pressure. The product was then purified with silica gel 
chromatography (column length 12 cm) in petroleum ether (40 – 60 °C) with increasing amounts of 
EtOAc. The relevant fractions were combined and the solvent removed under reduced pressure to 
yield an opalescent orange powder (0.635 g, 82 %). Mp = 128 - 130 °C. FTIR (ATR): 3132 cm-1 (C-
H triazole stretch). 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.94-7.92 (m, 2H, 2 × CH Ar), 7.87 (s, 1H, 
CH triazole), 7.48-7.44 (m, 2H, 2 × CH Ar), 7.38-7.34 (m, 1H, CH Ar), 7.32 (d, 1H, 3J = 7.4 Hz, CH 
Ar), 7.19 (d, 2H, , 3J = 7.8 Hz, 2 × CH Ar), 2.05 (s, 6H, 2 × CH3). 13C NMR (75 MHz, CDCl3): δ (ppm) 
= 147.66, 135.94, 135.48, 130.41, 130.08, 128.95, 128.49, 128.33, 125.76, 121.34, 17.43. The 
characterization data agrees with that reported in literature. 
2.4.4 Synthesis of substituted-pyridine-1H-1,2,3-triazole ligands 
2.4.4.1 Synthesis of 1b: 2-(1-octyl-1H-1,2,3-triazol-4-yl) pyridine 
Synthesized according to a literature procedure27. To 
a stirring solution of 2-ethynylpyridine (0.607 L, 6.0 
mmol) in DMF:H2O (4:1, 15 mL) was added Na2CO3 
(0.650 g, 6.0 mmol), NaN3 (0.470 g, 7.2 mmol), 
CuSO4·5H2O (0.300 g, 1.2 mmol) and sodium acetate 
(1.05 g, 6.0 mmol). 1-bromo-octane (1.14 mL, 6.6 mmol) was added to this solution. The reaction 
was allowed to stir at 95 °C for 20 h. The reaction mixture was washed with disodium-EDTA (1M, 
100 mL) in order to remove the copper catalyst. The product was extracted with DCM (5 × 20 mL). 
The combined organic phases were washed with water (100 mL) and brine (100 mL), and then dried 
over anhydrous MgSO4, filtered, and the solvent removed under reduced vacuum. The product was 
then purified by means of silica gel chromatography (eluted with DCM followed by 10 % acetone in 
DCM). The relevant fractions were collected and the solvent removed under reduced vacuum. This 
yielded an off-white powder (0.607 g, 48 %). Melting point: 75 -77°C. FTIR (ATR): 3128 cm-1 (C-H 
triazole). 1H NMR (600 MHz, CDCl3): δ (ppm) = 8.45-8.44 (m, 1H, CH Ar), 8.55 (d, 1H, 3J = 7.9 Hz, 
CH Ar),8.04 (s, 1H, CH triazole), 7.63 (dd, 1H, 3J = 7.7 Hz, 4J = 1.8 Hz, CH Ar), 7.08 (dd, 1H,  3J = 
7.4 Hz, 4J = 1.1 Hz, CH Ar), 4.28 (t, 2H, 3J = 7.2 Hz, CH2), 1.81 (qt, 2H, 3J = 7.2 Hz, CH2), 1.20-1.12 
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(m, 10H, 5 × CH2), 0.74 (t, 3H, 3J = 7.1 Hz, CH2). 13C NMR (151 MHz, CDCl3): δ (ppm) = 150.32, 
149.21, 148.15, 136.68, 122.58, 121.17, 119.98, 50.32, 31.54, 30.09, 28.87, 28.80, 26.30, 22.43, 
13.90. The characterization data agrees with that reported in literature. 
2.4.4.2 Synthesis of 2b: 2-(1-cyclohexyl-1H-1,2,3-triazol-4-yl) pyridine 
Based on the synthesis published by Sarkar et al.28 The azide 2 
(0.250 g, 2.00 mmol) and 2-ethynylpyridine (0.202 mL, 2.00 mmol) 
were added to a solvent system of DCM: H2O: 
tBuOH (2.5 mL: 2.5 
mL: 5.0 mL) while stirring. To this was added CuSO4·5H2O (0.025 g, 
0.10 mmol), sodium ascorbate (0.079 g, 0.40 mmol) and DIPEA 
(0.00348 mL, 0.02 mmol). The solution was allowed to reflux at 50 °C for 48h. Water (50 mL) was 
added to quench the solution and the product was extracted with DCM (3 × 20 mL). The organic 
phase was then dried over anhydrous Na2SO4, filtered, and the solvent removed under reduced 
pressure. The product was then purified with silica gel chromatography (eluted with DCM followed 
by 10 % acetone in DCM). The solvent was removed under reduced pressure to yield an off white 
powder (0.145 g, 32 %). Melting point: 84 - 86 °C. FTIR (ATR): 3061 cm-1 (C-H triazole). 1H NMR 
(300 MHz, CDCl3): δ (ppm) = 8.50 (d, 1H, 3J = 4.5 Hz, CH Ar), 8.12-8.11 (m, 2H, CH Ar overlap CH 
triazole), 7.69 (dd, 1H, 3J = 7.7 Hz, 4J = 1.7 Hz, CH Ar), 7.14 (m, 1H, CH Ar), 4.44 (tt, 1H, 3J = 11.7 
Hz, 4J = 3.8 Hz, CH Ar), 2.21-2.17 (m, 2H, CH2), 1.89-1.64 (m, 5H, CH2), 1.48-1.13 (m, 3H, CH2). 
13C NMR (75 MHz, CDCl3): δ (ppm) = 150.51, 149.29, 147.85, 136.85, 122.67, 120.09, 119.66, 
60.13, 33.51, 25.11. The characterization agrees with literature. 
2.4.4.3 General synthesis of 3b – 6b. 
The synthesis is based on a procedure described by Man et al.11 The azide (1 eq.), 2-ethynylpyridine 
(1 eq.) and Cu(PPh3)3Br (0.005 mmol) were added to a solvent system of THF:Et3N (1:1, 500 
µL:500µL) in a 10 mL microwave reactor tube. The reaction mixture was irradiated for 30 minutes at 
100 °C under nitrogen. The solvent was removed under reduced pressure. The resulting residue 
was washed with Et2O and the solvent decanted. The solvent was removed to yield the crude 
product. The product was then recrystallized from DCM:Et2O to produce the purified product. 
2.4.4.3.1 Synthesis of 3b: 2-[4-(pyridine-2-yl)-1H-1,2,3-triazol-1-yl] ethan-1-ol 
Pale brown crystals were isolated (0.171 g, 90 %). Mp = 108 – 109 
°C. FTIR (ATR): 3211 cm-1 (O-H stretch), 3132 cm-1 (C-H triazole). 1H 
NMR (600 MHz, DMSO-d6): δ (ppm) = 8.60 (d, 1H, 3J = 4.4 Hz, CH 
Ar), 8.54 (s, 1H, CH triazole), 8.03 (dd, 1H, 3J = 8.0 Hz, CH Ar), 7.89 
(dd, 1H, 3J = 7.7 Hz, CH Ar), 7.33 (dd, 1H, 3J = 7.0 Hz, CH Ar), 5.07 
(t, 1H, 3J = 5.2 Hz, OH), 4.48 (t, 2H, 3J = 5.5 Hz, CH2), 3.84 (q, 2H, 3J = 5.0 Hz, CH2). 13C NMR (151 
MHz, DMSO-d6): δ (ppm) = 150.12 (C quat.), 149.55 (CH triazole), 147.01 (C quat.), 137.14 (CH Ar), 
123.60 (CH Ar), 122.83 (CH Ar), 119.30 (CH Ar), 59.79 (CH2), 52.36 (CH2). ESI-MS: found: 191.0928 
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m/z [M + H]+ (calc. 191.0933), 213.0747 m/z [M + Na]+ (calc. 213.0752). Elemental analysis: % 
Found (% calc.) for C9H10N4O: C: 57.03 (56.68); H: 4.85 (5.29); N: 29.16 (29.35). 
2.4.4.3.2 Synthesis of 4b: 2-{2-[4-(pyridine-2-yl)-1H-1,2,3-triazol-1-yl]ethoxy}ethan-1-ol 
 An off white powder was isolated (0.201 g, 86 %). Mp = 53 
- 54 °C. FTIR (ATR): 3314 cm-1 (O-H stretch), 3155 cm-1 (C-
H triazole). 1H NMR (600 MHz, CDCl3): δ (ppm) = 8.60-8.59 
(m, 1H, CH Ar), 8.58 (s, 1H, CH triazole), 8.04 (dd, 1H, 3J 
= 7.9 Hz, 4J = 1.0 Hz, CH Ar), 7.89 (dd, 1H, 3J = 9.6 Hz, 4J 
= 1.8 Hz, CH Ar), 7.34 (dd, 1H, 3J = 7.5 Hz, 4J = 1.1 Hz, CH 
Ar), 4.63-4.60 (m, 4H, 2 × CH2), 3.88 (t, 2H, 3J = 5.3 Hz, CH2),  3.49-3.44 (m, 5H,CH2 + OH). 13C 
NMR (600 MHz, CDCl3): δ (ppm) = 150.05 (C quat.), 149.56 (CH triazole), 147.13 (C quat.), 137.15 
(CH Ar), 123.57 (CH Ar), 122.88 (CH Ar), 119.37 (CH Ar), 72.08 (CH2), 68.62 (CH2), 60.11 (CH2), 
49.65 (CH2). ESI-MS: found: 235.1192 m/z [M + H]+ (calc. 235.1195), 257.1006 m/z [M + Na]+ (calc. 
257.1014), 273.0749 m/z [M + K]+ (calc. 273.0754). Elemental analysis: % Found (% calc.) for 
C11H14N4O2·H2O: C: 52.37 (52.50); H: 6.39 (5.57); N: 22.21 (22.62). 
2.4.4.3.3 Synthesis of 5b: 2-(2-{2-[4-(pyridine-2-yl)-1H-1,2,3-triazol-1-yl]ethoxy}ethoxy)ethan-1-ol 
A brown oil was obtained after the Et2O was 
removed (0.151 g, 84 %). FTIR (ATR): 3365 cm-
1 (O-H stretch), 1112 and 1060 cm-1 (overlapping 
C-O stretches). 1H NMR (600 MHz, CDCl3): δ 
(ppm) = 8.58 (s, 1H, CH triazole), 8.46 (dd, 1H, 3J 
= 4.9 Hz, 4J = 0.9 Hz, CH Ar), 8.15 (dd, 1H, 3J = 8.1 Hz, 4J = 0.95 Hz, CH Ar), 7.70 (dd, 1H, 3J = 7.5 
Hz, 4J = 1.75 Hz, CH Ar), 7.16 (dd, 1H, 3J = 7.5 Hz, 4J = 1.1 Hz, CH Ar), 5.02 (bs, O-H), 4.55 (t, 2H, 
3J = 4.8 Hz, CH2), 3.83 (t, 2H, 3J = 4.8 Hz, CH2), 3.72 (t, 2H, 3J = 4.4 Hz, CH2), 3.57 (s, 4H, 2 × CH2), 
3.52 (t, 2H, 3J = 4.4 Hz, CH2). 13C NMR (600 MHz, CDCl3): δ (ppm) = 150.26 (C quat.), 148.87 (CH 
triazole), 147.60 (C quat.), 137.35 (CH Ar), 123.77 (CH Ar), 122.79 (CH Ar), 120.48 (CH Ar), 72.85 
(CH2), 70.10 (CH2), 70.08 (CH2), 68.98 (CH2), 61.27 (CH2), 50.12 (CH2). ESI-MS: found: 279.1457 
m/z [M + H]+ (calc. 279.1457). Elemental analysis: % Found (% calc.) for C13H18N4O3·2 EtOAc: C: 
53.55 (53.51); H: 5.96 (7.09); N: 13.00 (13.14). 
2.4.4.3.4 Synthesis of 6b: 6-[4-(pyridine-2-yl)-1H-1,2,3-triazol-1-yl] hexan-1-ol 
Fine white crystals were obtained (0.213 g, 86 %). Mp = 
70 - 72 °C. FTIR (ATR): 3419 cm-1 (O-H stretch), 3127 
cm-1 (CH triazole). 1H NMR (600 MHz, DMSO-d6): δ 
(ppm) = 8.61 (s, 1H, CH triazole), 8.59 (dd, 1H, 3J = 1.7 
Hz, 4J = 0.9 Hz, CH Ar), 8.03-8.02 (m, 1H, CH Ar), 7.88 









4.8 Hz, 4J = 1.2 Hz, CH Ar), 4.42 (t, 2H, 3J = 7.1 Hz, CH2), 4.33 (t, 1H, 3J = 5.0 Hz, OH), 3.37 (q, 2H, 
3J = 5.3 Hz, CH2), 1.87 (quintet, 2H, 3J = 7.2 Hz, CH2), 1.39 (quintet, 2H, 3J = 6.5 Hz, CH2), 1.34-
1.22 (m, 4H, 2 × CH2). 13C NMR (75 MHz, DMSO-d6): δ (ppm) = 150.09 (C quat.), 149.55 (CH 
triazole), 147.15 (C quat.), 137.15 (CH Ar), 123.13 (CH Ar), 122.88 (CH Ar), 119.35 (CH Ar), 60.55 
(CH2), 49.54 (CH2), 32.30 (CH2), 29.68 (CH2), 25.72 (CH2), 24.90 (CH2). ESI-MS: found: 247.1553 
m/z [M + H]+ (calc. 247.1559), 269.1374 m/z [M + Na]+ (calc. 269.1378). Elemental analysis: % 
Found (% calc.) for C13H18N4O: C: 63.39 (63.33); H: 7.37 (6.91); N: 22.75 (24.71).  
2.4.4.4 Synthesis of 7b: 2-(1-phenyl-1H-1,2,3-triazol-4-yl)pyridine 
Based on the synthesis reported by Crowly et al.29 Phenylboronic acid 
(0.279 g, 2.88 mmol), NaN3 (0.800 g, 12.3 mmol) and Cu(OAc)2·H2O 
(0.164 g, 0.820 mmol) were added to MeOH (5.0 mL) and allowed to 
reflux at 55 °C for 2 hours. After 2 hours, sodium ascorbate (0.174 g, 
0.880 mmol) and 2-ethynylpyridine (0.245 mL, 2.42 mmol) were 
added to the reaction mixture. The reaction was then allowed to stir at 25 °C for 16 hours. The 
reaction was then quenched with 1.5 M Na2EDTA/NaOH at pH = 8 (300 mL) and stirred for 1 hour. 
The solution was filtered through a Büchner filter and the yellow precipitate suspended in 25% NH3 
solution (50 mL). The organic compounds were then extracted with DCM (2 × 20 mL). The combined 
organic fractions were dried over anhydrous MgSO4, filtered and the solvent removed under reduced 
pressure. This yielded an off white powder (0.223 g, 41 %). Mp: 90 – 91 °C (lit. 90-91°C). FTIR 
(ATR): 3114 cm-1 (C-H triazole stretch).1H NMR (300 MHz, DMSO-d6): δ (ppm) = 9.33 (s, 1H, CH 
triazole), 8.67-8.65 (m, 1H, CH Ar), 8.13 (dd, 1H, 3J = 7.9 Hz, 4J = 1.0 Hz, CH Ar), 8.04-8.01 (m, 2H, 
CH Ar phenyl ring), 7.95 (dd, 1H, 3J = 7.8 Hz, 4J = 1.8 Hz, CH Ar), 7.64-7.60 (m, 2H, CH Ar phenyl 
ring), 7.52 (m, 1H, CH Ar phenyl ring), 7.41 (dd, 1H, 3J = 4.8 Hz, 4J = 1.2 Hz, CH Ar). 13C NMR (75 
MHz, DMSO-d6): δ (ppm) = 149.67 (CH triazole), 149.50 (C quat.), 148.20 (C quat), 137.34 (CH Ar), 
136.56 (C quat.), 129.90 (2 × CH Ar), 128.84 (CH Ar), 123.35 (CH Ar), 121.24 (CH Ar), 120.19 (2 × 
CH Ar), 119.81 (CH Ar). The characterization data agrees with that reported in literature. 
2.4.4.5 Synthesis of 8b: 2-[1-(2,6-dimethylphenyl)-1H-1,2,3-triazol-4-yl]pyridine 
Based on the synthesis reported by Sarkar et al.30 The azide 8 (0.294 
g, 2.00 mmol) and 2-ethynylpyridine (0.202 mL, 2.00 mmol) were 
added to a solvent system of DCM: H2O: 
tBuOH (2.5 mL: 2.5 mL: 5.0 
mL). To the rapidly stirring mixture was added CuSO4·5H2O (0.025 
g, 0.10 mmol), sodium ascorbate (0.079 g, 0.40 mmol) and DIPEA 
(0.0035 mL, 0.02 mmol). The reaction mixture was allowed to stir at 
room temperature for 48 hours after which it was diluted with H2O (50 mL). The organic compounds 
were extracted with DCM (3 × 20 mL) and the combined organic fractions washed with H2O (20 mL) 
and saturated NH4Cl (20 mL). The organic phase was then dried over anhydrous Na2SO4, filtered 
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and the solvent removed under reduced pressure. The resulting viscous red oil was purified with 
silica gel chromatography (eluted with DCM followed by 10 % acetone in DCM). The solvent was 
removed under reduced pressure to yield a viscous red oil (0.230 g, 46 %). FTIR (ATR): 3051 cm-1 
(C-H triazole stretch). 1H NMR (300 MHz, DMSO-d6): δ (ppm): 8.88 (s, 1H, CH triazole), 8.64-8.62 
(m, 1H, CH Ar), 8.15 (d, 1H, 3J = 7.9 Hz, CH Ar), 7.94 (dd, 1H, 3J = 7.8 Hz, 4J = 1.8 Hz, CH Ar), 7.44-
7.36 (m, 2H, CH Ar), 7.31-7.29 (m, 2H, CH Ar), 1.98 (s, 6H, 2 × CH3). 13C NMR (75 MHz, DMSO-
d6): δ (ppm) = 149.78, 149.61, 147.39, 137.27, 135.76, 134.87, 130.02, 028.40, 125.08, 123.17, 
119.72, 16.95. ESI-MS: found: 251.1302 m/z [M + H]+ (calc. 251.1297). Elemental analysis: % Found 
(% calc.) for C15H14N4: C: 70.60 (70.78); H: 5.41 (5.57); N: 21.56 (21.92). 
2.4.4.6 Synthesis of 9b: 2-[1-(4-nitrophenyl)-1H-1,2,3-4-yl]pyridine 
Synthesized according to a literature procedure15. The azide 9 
(1.38 g, 8.350 mmol) was added to rapidly stirring MeCN (30 
mL) to which was added 2-ethynylpyridine (0.770 mL, 7.59 
mmol), Cu(OAc)2·H2O (0.300 g, 4.510 mmol) and sodium 
ascorbate (0.600 g, 3.05 mmol). The solution was allowed to 
stir for 24 hours at room temperature. The reaction mixture was 
diluted with CH3Cl (50 mL) and washed with Na2EDTA (1M) (2 × 50 mL). The organic compounds 
were extracted with CH3Cl (3 × 10 mL) and the combined organic phases washed with H2O (50 mL) 
and brine (50 mL). The organic phase was dried over anhydrous MgSO4, filtered and the solvent 
removed under reduced pressure. The resulting red powder was purified with silica gel 
chromatography (eluted with DCM followed by 10 % acetone in DCM). The solvent was removed 
under reduced pressure to yield a yellow powder (0.729 g, 36 %). Mp: 247 – 248 °C. FTIR (ATR): 
3126 cm-1 (C-H triazole stretch). 1H NMR (600 MHz, DMSO-d6): δ (ppm) = 9.55 (s, 1H, CH triazole), 
8.69-8.67 (m, 1H, CH Ar), 8.46 (dd, 2H, 3J = 9.25 Hz, 4J = 1.92 Hz, CH Ar), 8.35 (dd, 2H, 3J = 8.83 
Hz, 4J = 2.25 Hz, CH Ar), 8.14 (d, 1H, 3J = 8.08 Hz, CH Ar), 7.97 (td, 1H, 3J = 7.66 Hz, 4J = 1.74 Hz, 
CH Ar), 7.43 (dd, 1H, 3J = 7.53 Hz, 4J = 1.13 Hz, CH Ar). 13C NMR (101 MHz, DMSO-d6): δ (ppm) = 
149.80, 149.05, 148.69, 146.83, 140.80, 137.46, 125.53, 123.64, 121.79, 120.81, 120.00. The 
characterization agrees with literature. 
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Chapter 3: Synthesis and Characterization 
of trans- and N,N’-bidentate Pd(II) 
complexes 
3.1 Introduction 
As discussed in Chapter 1, palladium complexes have been investigated extensively as anti-cancer 
agents. It is thus prudent to revisit the most relevant literature examples and discuss their studies in 
more detail. 
3.1.1 Trans-Pd(II) complexes based on 1-substituted-4-phenyl-1,2,3-triazolyl 
ligands 
From Chapter 1 it is clear that the structures of trans-Pd(II) complexes are highly varied and that 
there are no clear structure-activity-relationships established as of yet. To the best of our knowledge, 
no trans-Pd(II) complexes with substituted-1,2,3-triazole ligands have been evaluated for their anti-
cancer activities, but there are a few examples of these compounds reported in literature. 
Owing to the discovery of the CuAAC reaction, there has been an exponential increase in the number 
of 1,4-disubstituted-1,2,3-triazole compounds synthesized. Despite the popularity of these 
compounds, investigation into their coordination properties has surprisingly not kept pace, although 
these compounds have the potential for a wide array of coordination modes (Figure 3.1).1 
 
Figure 3.1: The various coordination modes of 1,4-substituted-1,2,3-triazole ligands. 
Only coordination modes A, C and D have been observed. Coordination to N3 is preferred over N2 
due to the fact that N3 is more electron rich than N2.1,2 
Additionally, the CH-acidity in position 5 gives the 1,2,3-triazole a hydrogen bond donor-strength 
similar to a prototypical amide, depending on its substituents. Owing to the triazole’s aromatic 
character it is thus an ideal moiety for bioinorganic applications, as it allows for simultaneous 
hydrogen bonding and metal coordination.3  
Van Koten and co-workers4 published the first complexes with substituted-1,2,3-triazoles as 
monodentate ligands. It was shown that the electronic and steric characteristics of the ligands can 





easily be tuned and that these characteristics influence the coordination behaviour of the ligands. 
With the inclusion of an electron withdrawing substituent on the N1-atom of the triazole, the 
coordination strength of the ligand decreased, while the reverse was true for an electron donating 
substituent. This was established by using competition experiments between the complex and a 
number of commonly used Lewis bases, such as PPh3 and DMSO. It was shown that the strength 
of the 1,2,3-triazole coordination bond is similar to that of pyridine, depending on the substituents on 
the triazole ring (Figure 3.2).4 
 
Figure 3.2: A) The first monodentate 1,4-disubstituted-1,2,3-triazole Pd(II) complex synthesized by Van Koten and 
co-workers.4 and B) the crystal structure obtained for the product. 
Astruc and co-workers5 synthesized the first monodentate triazole complex of the type PdL2X2 
complex in 2008 with a ferrocenyl substituent on the triazole ring. This complex was not evaluated 
for any anti-cancer activity, but, nevertheless, displayed interesting 1H NMR characteristics (see 
Section 3.2.1.1). 
 
Figure 3.3: A) The PdL2X2 complex synthesized by Astruc and co-workers5 and B) the crystal structure obtained 
of the complex. 
More recently Crowley and McMorran.6 showed that these trans-Pd(II) complexes can be 
manipulated into supramolecular structures. They started out by showing that the Pd(II) centre can 





sterically accommodate up to four disubstituted-1,2,3-triazole ligands, and exploited this 
phenomenon to prepare quadruply stranded helicate cages (Figure 3.4).6 
 
Figure 3.4: The complexes investigated by Crowley and McMorran.1 with 1) the disubstituted complex and 2) the 
crystal structure of the tetra substituted complex. 
The examples briefly discussed above are the most structurally relevant trans-Pd(II) complexes with 
disubstituted-1,2,3-triazole ligands to date, but none of them have been evaluated as anti-cancer 
agents, nor have they found application in other fields. This motivated us to investigate the same 
type of complexes for their anti-cancer activity. 
3.1.2 N,N’-bidentate Pd(II) complexes based on 1-substituted-4-pyridyl-1,2,3-
triazolyl ligands 
Unlike the substituted-1,2,3-triazolyl trans-Pd(II) complexes, there are examples of N,N’-bidentate 
substituted-1,2,3-triazolyl Pd(II) complexes in the literature as discussed in Chapter 1 (Section 
1.3.3.2). Although no structure-activity relationship has been established for these compounds, there 
have been a few promising candidates. 
The most recent examples of N,N’-bidentate substituted-1,2,3-triazolyl Pd(II) complexes used as 
antiproliferative agents were published by Trivedi et al.7 in which they synthesized a number of N,N’-
bidentate-1,2,3-triazolyl Pd(II) complexes with carbohydrate substituents. These complexes showed 
significant anti-cancer activity against a number of cancer cell lines while the ligands themselves 
were non-toxic.7 The structures investigated are shown in Table 3.1. 
  





Table 3.1: The carbohydrate substituted-pyridyl-1,2,3-triazole Pd(II) complexes investigated by Trivedi et al.7 for 
their anti-cancer activity. 
 
R = 
    
 
Cell line A B C D E 
 IC50 (µM) IC50 (µM) IC50 (µM) IC50 (µM) IC50 (µM) 
A549 6.4 -a 7.7 6.9 - 
Neuro2a 7.8 5.6 7.1 - - 
HeLa 8.3 7.9 - 9.2 - 
MDA-MBA-231 9.9 7.9 - 12.1 - 
MCF-7 5.5 8.9 - - - 
a Inactive at concentrations evaluated. 
Although it was shown that the carbohydrate moiety was necessary for the anti-cancer activity 
displayed7, there is to the best of our knowledge no literature that investigates the steric, solubility or 
electronic effects on the anti-cancer activity of the compounds. 
This chapter covers the synthesis and characterization of the trans- and N,N’-bidentate Pd(II) 
complexes derived from substituted-phenyl- and pyridyl 1,2,3-triazolyl ligands, respectively, reported 
in Chapter 2. 
3.2 Results and Discussion 
3.2.1 Trans-Pd(II) complexes based on 1-substituted-4-phenyl-1,2,3-triazolyl 
ligands 
All the trans-Pd(II) complexes synthesized are to the best of our knowledge new and were 
synthesized in a similar manner (see Section 3.4.2).  
The complexes were synthesized by reacting the ligand with (MeCN)2PdCl2 at room temperature. All 
complexes were isolated in moderate to good yields as indicated in Scheme 3.1. 
 






T1a: R = Octyl (65 %) 
T2a: R = Cyclohexyl (63 %) 
T3a: R = Ethanol (95 %) 
T4a: R = 2-(2-ethoxy) ethanol (87 %) 
T5a: R = 2-(2-(2-ethoxy) ethoxy) ethanol (90 %) 
T6a: R = Hexanol (60 %) 
T7a: R = Phenyl (76 %) 
T8a: R = 2,6-dimethylphenyl (63 %) 
T9a: R = 4-nitrophenyl (90 %) 
 
Scheme 3.1: The general structure of the trans-Pd(II) substituted-phenyl-1,2,3-triazolyl complexes synthesized, 
with the percentage yield indicated in brackets. 
The complexation of the ligands to the Pd-precursor was monitored with FTIR spectroscopy, where 
a small shift in the C-H triazole stretch was observed upon the formation of the complex, as shown 
in Table 3.2. Ideally, the N=N stretch would result in the best confirmation of complexation and 
indication of bond strength. Unfortunately, the N=N signal is very weak in FTIR spectra and 15N 
substitution is required for unambiguous assignment.8 Thus the C-H triazole stretch was monitored. 
Complexes T1a, T2a and T5a were soluble in DCM, CHCl3 and DMSO while all of the other 
complexes prepared were only soluble in DMSO.  
There is no trend in the FTIR shift of the C-H triazole signals upon complexation, so complexation 
had to be confirmed with 1H NMR spectroscopy. However, it appeared that the complexes were in 
equilibrium with uncoordinated ligand in solution, as shown in Figure 3.5 with T4a as example. 
Irrespective of the batch of compound and concentration of the NMR sample, the ratio between the 
complex signals and the dissociated ligand signal remained the same. This phenomenon was 
investigated in more detail with a short NMR study, as discussed in Section 3.2.1.1. 






Figure 3.5: The 1H NMR (600 MHz, DMSO-d6) of T4a with the dissociated ligand indicated in purple, and the complex in orange. Assignment aided by Marvin Suite prediction 
software. 
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Table 3.2: Characterization data of the trans-Pd(II) substituted-phenyl-1,2,3-triazolyl complexes with a comparison 
of the FTIR C–H triazole stretch between the ligand and the corresponding complex. 
Compound Mp (°C) 
FTIR C-H triazole stretch (cm-1) ESI-MS (m/z) 
Metal complexes Ligands  
T1a 180 – 181 3128 3120 435.2332 [M – L]+ 
T2a 155 – 157 3134 3125 597.1552 [M – Cl]+ 
T3a 239 – 240 3130 3130 521.0526 [M – Cl]+ 
T4a 191a 3098 3129 609.1058 [M – Cl]+ 
T5a 131 – 132 3129 3133 697.1556 [M – Cl]+ 
T6a 123 – 124 3096 3120 633.1762 [M – Cl]+ 
T7a 160a 3114 3121 619.1668 [M – H]+ 
T8a 213a 3132 3132 426.1011 [M – L]+ 
T9a 304 – 305b 3126 3122 638.9197 [M – 2Cl]- 
a Decomposition without melting 
b Decomposition with melting 
 
The ESI mass spectra of these complexes generally showed the daughter ions, [M – Cl]+. The 
detection of fragments of this type is not unusual as they are normally observed for Pd-Cl 
compounds.9 It was also noted that performing the mass spectral analysis at low cone voltages, 
yielded spectra which showed ions that could only be assigned to ligand fragments. An increase in 
the cone voltage resulted in increased fragmentation which allowed for the identification of the [M – 
Cl]+ fragments.  
Figure 3.6 shows the assigned ESI mass spectrum of complex T4a with the predicted spectra of 
each identified fragment superimposed onto the spectrum. The base peak has been assigned to the 
[M – 2Cl – H]+ daughter ion while the parent ion [M – H]+ is visible at 643.0611 m/z. Since the complex 
is only soluble in DMSO, the [M – Cl + DMSO]+ ion is also observed at 685.1174 m/z. The acetonitrile 
adduct to the [M – Cl]+ daughter ion has also been identified at 650.1307 m/z. All identified fragments 
displayed the expected isotope clusters for Pd-containing complexes. 






Figure 3.6: The ESI-MS spectrum of T4a obtained, with the predicted spectra for each identified signal. The prediction was performed on Molecular Weight Calculator 
freeware.10
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The elemental analysis of the trans-Pd(II) complexes revealed the PdL2Cl2 nature of these 
compounds with the results summarized in Table 3.3 
Table 3.3: A summary of the elemental analysis results obtained for the trans-Pd(II) complexes. 
 Calculated Found Molecular formula calculated for: 
 % C % H % N % C % H % N  
T1a 55.54 6.70 12.14 55.57 6.69 12.43 C32H46Cl2N6Pd 
T2a 52.47 5.50 13.11 52.37 5.27 13.11 C28H34Cl2N6Pd·0.5H2O 
T3a 42.15 3.93 14.57 42.49 3.75 14.80 C20H22Cl2N6Pd·0.25DCM 
T4a 44.77 4.70 13.05 44.76 4.91 12.58 C24H30O4Cl2N6Pd 
T5a 45.05 5.15 11.16 45.43 5.47 10.16 C28H38O6N6Cl2Pd 
T6a 47.20 5.44 11.49 46.89 5.28 10.97 C28H38Cl2N6PdO2·0.75DCM 
T7a 40.05 3.15 8.76 39.66 2.89 8.40 C28H22Cl2N6Pd·4DCM 
T8a 56.86 4.47 12.43 56.22 4.87 10.92 C32H30Cl2N6Pd 
T9a 46.89 2.83 15.55 47.27 2.65 14.61 C28H20N8O4PdCl2·0.125DCM 
 
As with the elemental analysis of the ligands in Chapter 2, there is in some cases a discrepancy 
between the calculated % N and that found. There are also trace amounts of solvent present in some 
of the samples despite extensive drying. Combined with the other characterization results, it can be 
concluded that the intended trans-Pd(II) complexes have been successfully synthesized. 
It is, however, necessary to mention that the exact geometry of the complexes have not been 
confirmed, as we were unable to obtain a crystal structure. There are a number of isomers that could 
be present for the PdL2Cl2 complexes, as shown in Figure 3.7 with T1a as an example. The 
complexes synthesized are described as trans-Pd(II) complexes since bulky monodentate ligands 
generally result in a trans geometry around the Pd-centre, due to steric influences playing the 
determining role in the geometry of the complexes.11,12 In solution, it is possible that any one of these 
isomers are present, although a trans geometry is preferred, and further investigation in this regard 
is required. 
 
Figure 3.7: The various conformational isomers that are possible for the PdL2Cl2 complexes. 
  





3.2.1.1 NMR study on trans-Pd(II) phenyl-1,2,3-triazolyl complexes 
As mentioned in Section 3.2.1, it was observed that the substituted-1,2,3-triazolyl trans-Pd(II) 
complexes dissociate in DMSO. This phenomenon was observed with varying degrees of ligand 
dissociation/exchange depending on the nature of the substituents.  
The extent of dissociation was greater for complexes with electron withdrawing aromatic N-bound 
substituents, than for aliphatic groups, as shown in Figure 3.8. This could possibly be attributed to 
the decrease in the electron density around the coordinating N-atom caused by the electron 
withdrawing nature of the aromatic substituents, ultimately leading to a lower coordination ability of 
the ligand. This phenomenon has been studied previously and it was found that the coordination 
strength of the triazole depends on the C- and N-bound substituents, and increases in the order 
phenyl < H < benzyl < alkyl. 3,4 
 
Figure 3.8: A comparison of the aromatic region of the 1H NMR spectra of T2a, with an aliphatic substituent, and 
T7a, with an aromatic substituent. The signals attributed to the complex of T7a are shown in grey blocks. 
To the best of our knowledge, there is a single literature precedent for this phenomenon as 
documented by Astruc and co-workers5 for ferrocenyl-1,2,3-triazolyl complexes. Ligand 
dissociation/exchange was confirmed with the addition of varying equivalents of Pd-precursor to a 
solution of the ligand in DMSO-d6. The results of their experiment are shown in Figure 3.9. Ligand 
dissociation was still observed at a ratio of 2 equivalents Pd-precursor to ligand.5 






Figure 3.9: The 1H NMR spectroscopy experiment conducted by Astruc and co-workers5 in which they dissolved 
their ligand in DMSO-d6 and added sequential amounts of (C6H5CN)2PdCl2: (A) ligand alone, (B) 1eq. of ligand and 
0.5eq. of (C6H5CN)2PdCl2, (C) 1eq. of ligand with 1eq. of (C6H5CN)2PdCl2. (D) 1eq. of ligand and 1.5eq. of 
(C6H5CN)2PdCl2, (E) 1eq. of ligand and 2eq. of (C6H5CN)2PdCl2. 
The experiment outlined by Astruc and co-workers5 was performed with the T4a system. This was 
done by preparing a sample of the corresponding ligand 4a in DMSO-d6 and adding increasing molar 
equivalents of (MeCN)2PdCl2 in order to monitor the effect on the 1H NMR spectrum. The resulting 
spectra are shown in Figure 3.10 and the experimental details are given in Section 3.4.4. 






Figure 3.10: The results from the (MeCN)2PdCl2 addition to 1 eq. 4a experiments. Since the ratio of ligand to metal in the complex is 2:1, the addition of 0.5 eq. of the Pd-
precursor would result in the complex ratio.
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As seen in Figure 3.10, with each addition of the Pd-precursor to the ligand sample, there is an 
increase in the intensity of the signals associated with the complex and a corresponding decrease 
in the signals associated with the ligand, similar to what was reported by Astruc and co-workers5. It 
was noted that despite the addition of 1.5 eq. Pd-precursor to the ligand, three times the 
stoichiometric ratio, there are still free ligand signals observed. At 1.5 eq. Pd-precursor, the NMR 
sample became so concentrated that precipitation of the Pd-precursor was observed and the 
experiment could not be continued. 
The effect of temperature was also investigated by running a variable temperature experiment on 
T4a. Since the sample was only soluble in DMSO, low temperature NMR was not practical, thus only 
20 °C, 40 °C and 60 °C 1H NMR experiments were performed. The resulting spectra are shown in 
Figure 3.11. 
 
Figure 3.11: The 1H NMR spectroscopy variable temperature experiment of T4a. The ligand CH-triazole is shown 
in purple and the complex CH-triazole is shown in orange. 
The variable temperature NMR spectra (Figure 3.11) shows a pronounced increase in the 
dissociation with an increase in temperature, evidenced by the decrease of the complex signals and 
an increase in the free ligand signals, as expected. There is also a marked loss of fine coupling and 
broadening in the signals with an increase in temperature. 
The next logical question was whether this process is reversible, i.e. could the formation of the 
complex in solution be reversed to bring about ligand dissociation by diluting the saturated NMR 
sample again. The results from this experiment are shown in Figure 3.12 where the concentration of 
the Pd-precursor is used to indicate the process. 






Figure 3.12: The results from the addition-dilution experiment performed in order to determine the reversibility of the process. 
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The addition-dilution experiment indicated that the dissociation of the ligand from the saturated 
solution will take place upon dilution of the sample with additional DMSO-d6. Upon dilution, the 
complex signals decrease and the ligand signals increase once more. 
From the addition-dilution experiment a few interesting observations were made, as shown in Figure 
3.13. It was observed that with an increase in the Pd-concentration there is a decrease in the intensity 
of the ligand CH-triazole signal with a corresponding increase in the complex CH triazole signal, as 
is expected. This is coupled with a very slight (0.0004 ppm) upfield shift of the signals for both the 
complex and the free ligand. The opposite is observed when the sample is diluted, and the signals 
return to their usual positions. 
As for the aromatic signals, there is a remarkable decrease in the fine coupling of the ligand signals 
upon addition of (MeCN)2PdCl2 and a general broadening of the signals throughout the spectrum. It 
should also be noted that the signals for protons 2 and 6 (according to the numbering scheme in 
Figure 3.5) shifts drastically from 7.84 ppm for the free ligand, to 8.43 ppm for the complex. This is 
interesting when taking into consideration that the downfield shift for the CH triazole signal is only 
0.22 ppm. This would indicate that the complexation of the metal centre to the ligand has a greater 
effect on the two signals of the adjacent phenyl ring than on the triazole itself. 
The final observation pertains to the solvents present within the NMR sample, i.e. the residual DMSO 
signal and the H2O signal. In the case of the latter, this could potentially be employed to probe any 
interaction of the complex and water. This could be useful since these products are aimed at a 
biological application, which usually takes place in aqueous media. Interestingly, in the 1H NMR 
spectra of these complexes in DMSO, the H2O signal shifts downfield with an increase in the Pd-
precursor concentration and upfield upon dilution, a trend that is the opposite from the other ligand 
and complex signals. This interaction with H2O indicates that the complex might not stable in the 
presence of H2O and some species in solution could potentially be attributed to the aqua complexes. 
As for the residual DMSO signal, only a loss in fine coupling is observed with an increase in the Pd-
precursor concentration. Upon dilution the fine coupling returns. 
Due to the fact that these spectra are referenced relative to the residual DMSO signal, any shift in 
this signal is not discernible. It is reasonably expected that, upon ligand dissociation, the vacant sites 
on the Pd-centre would be occupied by DMSO-molecules, thus resulting in the formation of 
(DMSO)2PdCl2. Theoretically, this should result in a shift of the residual DMSO signals, which cannot 
be observed using this particular setup. 
It thus became necessary to repeat the above process using an external reference. It was also 
decided to switch to an analogous complex that is soluble in both DMSO and CDCl3 in order to 
investigate the effect of dissociation in a system where the DMSO is not in excess, and to investigate 
whether the phenomenon observed will hold in a different solvent system. The addition-dilution 





experiment was thus repeated on the T2a system with CDCl3 as an external reference. The resulting 
spectra are shown in Figure 3.14. 
 
Figure 3.13: A collection of the interesting changes observed in the NMR spectrum of 4a arranged according to 
increasing Pd-precursor concentration. 
From Figure 3.14, it is also seen that the ligand signals decrease as the complex signals increase 
with the addition of the Pd-precursor and the opposite is observed upon dilution, similar to what was 
observed for the T4a system. 
It was interesting to note that the external CDCl3 signals appeared at 6.72 ppm (indicated in grey in 
Figure 3.14) rather than the expected 8.32 ppm13, where it should occur if the CDCl3 is in contact 
with the DMSO-d6. Nevertheless, the spectra were all referenced to the signal at 6.72 ppm in order 
to investigate the effect the Pd-precursor addition has on the residual DMSO-d6 shift. 






Figure 3.14: The 1H NMR spectra of the addition-dilution experiment of 2a with the addition of (MeCN)2PdCl2 in order to synthesize T2a in situ.
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The more relevant signals from the addition-dilution study on the T2a system have been summarized 
in Figure 3.15. 
 
Figure 3.15: A collection of the interesting changes observed in the addition-dilution experiment of the T2a 
system, arranged according to the Pd-precursor concentration. 
It was found that the trends observed for the T4a system were also observed with the T2a system. 
The signal of the CH cyclohexyl substituent is included in Figure 3.15 since it clearly shows the 
disappearance of fine coupling present in the spectrum of the ligand as the intensity of the signals 
assigned to complex increases. A slight upfield shift of the complex signals are also observed as the 
Pd-precursor concentration increases and the reversal of the process is seen upon dilution. 
Owing to the external referencing used, a similar shift is now observed in the residual DMSO signal. 
It is assumed that this is due to the coordination of the DMSO to the metal centre. 
In addition to the signals arising from the free ligand and the complex, there is a third set of signals 
that mimics the complex signals (indicated within orange ovals in Figure 3.15). Similarly, Astruc and 
co-workers5 observed the same low intensity signals in their system and hypothesized that it could 
be due to a chloro-bridged dimer forming in solution.14,15 This hypothesis is still not completely 
proven, but since the ratio of the third set of signals to that of the complex and the ligand remain the 
same irrespective of the Pd-concentration, it is unlikely that they can be attributed to the mono-
substituted (DMSO)Pd(L)Cl2 species.5 





Since the T2a complex is also soluble in CDCl3 where ligand dissociation is not observed, it was 
decided that the effect of the addition of DMSO to the system would be investigated as well, since it 
would be interesting to see at which concentration the ligand is displaced from the metal centre. In 
CDCl3 the signals for the aromatic rings are broad and lack fine structure, which could potentially be 
the exchange of the ligands around the metal centre. A summary of the resulting spectra is shown 
in Figure 3.16. 
 
Figure 3.16: A summary of the spectra obtained for the addition of DMSO to T2a in CDCl3. 
As seen in Figure 3.16, even the addition of one equivalent DMSO to the complex in solution results 
in the formation of new species in solution. This is accompanied by a small upfield shift for all the 
complex signals, apart from the CH-triazole signal (7.65 – 7.67 ppm) which has a slight downfield 
shift. The most noticeable shift is that of the water signal which shifts downfield from 1.58 ppm to 
2.23 ppm as the concentration of DMSO increases. This could be attributed to the hydrogen bonding 
interaction between DMSO and water. 
When one considers the products that could form during a ligand dissociation/exchange process, 
the number of possible interactions become more difficult to distinguish from the NMR spectrum 
alone. Owing to the presence of water in the DMSO-d6 solvent, the complexes also have the potential 
to form the aqua-species with the loss of a labile Cl- ion. A summary of all the potential species that 
could be present is shown in Scheme 3.2, with the addition of the chloro-bridged species. 






Scheme 3.2: A) a summary of all the species that could potentially be present when T2a is dissolved in DMSO and 
B) the structure of the proposed chloro-bridged dimer that could form in solution. 
Since the aim of these compounds were to be evaluated as anti-cancer agents, their stability in 
DMSO was crucial. The protocol for evaluating the anti-cancer activity involves the preparation of a 
stock solution of the compound in DMSO (see Chapter 4). If any ligand dissociation and subsequent 
solvent coordination occurs, then any anti-cancer activity that is observed is more than likely not 
attributable to the original palladium complex alone, but rather to a combination of species present 
within the solution. Additionally, the extent of ligand dissociation has an influence on the 
concentration of each of the possible components. Should the intact complex have any anti-cancer 
activity of its own, its concentration within the dissociated solution could be lower than the detection 
limit, thus resulting in false negatives. 
The DMSO-mediated dissociation of N-coordinating ligands in drug-like molecules is generally not 
reported and thus this presumably results in inaccurate representation of biological activity, as 





discussed by Gasser and co-workers.16 To the best of our knowledge, the complete ligand 
dissociation of N-containing ligands has only been documented for Ru-complexes.17 
From the NMR study it can thus be concluded that in the case of the trans-Pd(II) phenyl-1,2,3-triazolyl 
complexes the extent of ligand dissociation should be considered when interpreting anti-cancer 
assay results. This will be discussed in more detail in Chapter 4. 
3.2.2 N,N’-bidentate Pd(II) pyridyl-1,2,3-triazolyl complexes derived from 
pyridyl-1,2,3-triazolyl ligands 
The N,N’-bidentate complexes are to the best of our knowledge all new, except for N7b which has 
been reported previously18 but not investigated for its activity as an anti-cancer agent. 
The synthesis of these compounds was similar to that of the trans-Pd(II) phenyl-1,2,3-triazolyl 
complexes (Section 3.2.1) and is summarized in Section 3.4.3.1. All complexes were isolated in 
moderate to good yields, as indicated in Scheme 3.3, and all complexes were only soluble in DMSO.  
 
N1b: R = Octyl (82 %) 
N2b: R = Cyclohexyl (78 %) 
N3b: R = Ethanol (87 %) 
N4b: R = 2-(2-ethoxy) ethanol (88 %) 
N5b: R = 2-(2-(2-ethoxy) ethoxy) ethanol (36 %) 
N6b: R = Hexanol (89 %) 
N7b: R = Phenyl (88 %) 
N8b: R = 2,6-dimethylphenyl (77 %) 
N9b: R = 4-nitrophenyl (86 %) 
 
Scheme 3.3: The general structure of the N,N’-bidentate Pd(II) pyridyl-1,2,3-triazolyl complexes synthesized with 
the percentage yields indicated in brackets. 
The reaction of the ligands with the Pd-precursor, (MeCN)2PdCl2, was monitored with FTIR and 1H 
NMR spectroscopy, where a significant shift in the CH-triazole proton signal was observed following 
complex formation. The FTIR and 1H NMR characterization data for the N,N’-bidentate complexes 
are summarized in Table 3.4 and Table 3.5 respectively.  





Table 3.4: Characterization data for the N,N’-bidentate-Pd(II) pyridyl-1,2,3-triazolyl complexes with a comparison 
of the FTIR C–H triazole stretch between the ligand and the corresponding complex. 
Compound Mp (°C) 
FTIR C-H triazole stretch (cm-1) ESI-MS (m/z) 
Metal complexes Ligands  
N1b 279 - 280 3080 3128 459.01 [M + Na]+ 
N2b 304b 3087 3061 428.97 [M + Na]+ 
N3b 249a 3091 3211 297.00 [M – 2Cl + H]+ 
N4b 202 - 203 3090 3314 376.98 [M – Cl]+ 
N5b 160 – 161 3099 3365 421.01 [M – Cl]+ 
N6b 220 - 221 3095 3419 389.02 [M – Cl]+ 
N7b 252a 3593 3114 362.96 [M – Cl]+ 
N8b 327a 3117 3051 434.02 [M + Li]+ 
N9b 335b 3135 3126 450.97 [M + Li]+ 
a Decomposition without melting 
b Decomposition with melting 
There is no apparent correlation between the C-H triazole stretch of the ligand and the complex for 
the compounds with the aliphatic tethers (N1b and N2b). For the aromatic complexes, N7b, N8b 
and N9b, there is an increase in the frequency of the C-H triazole band while the opposite can be 
seen for the complexes with the hydrophilic tethers, N3b, N4b, N5b and N6b. 
Upon complexation, a distinct downfield shift in the CH triazole singlet was observed in the 1H NMR 
spectra, as illustrated in Table 3.5. This can be attributed to the shift of electron density from the N3-
atom to the metal centre, which results in a decrease in electron density around the triazole proton. 
This results in a downfield shift or the triazole proton resonance. 
Table 3.5: A comparison of the 1H NMR signals of the CH triazole peaks of the ligands and the N,N’-bidentate Pd(II) 
complexes. 
Substituted Pyridine-1,2,3-triazolyl ligands N,N’-bidentate Pd(II)-pyridyl-1,2,3-triazolyl complexes 
Ligand CH triazole (ppm) Complex CH triazole (ppm) 
1b  8.04 (s, 1H) N1b 9.21 (s, 1H) 
2bb 8.12-8.11 (m, 2H, CH Ar overlap CH triazole) N2b 9.30 (s, 1H) 
3b 8.60 (s, 1H) N3b 9.20 (s, 1H) 
4b 8.58 (s, 1H) N4b 9.19 (s, 1H) 
5bb 8.58 (s, 1H) N5b 9.16 (s, 1H) 
6b 8.61 (s, 1H) N6b 9.22 (s, 1H) 
7b 9.33 (s, 1H) N7b 9.88 (s, 1H) 
8b 8.88 (s, 1H) N8b 9.47 (s, 1H) 
9b 9.55 (s, 1H) N9b 10.10 (s, 1H) 
a All spectra run in DMSO-d6 at 25 °C, except where indicated. Chemical shifts reported as ppm values, referenced to the residual solvent signal 
b Spectrum recorded in CDCl3 at 25 °C 









Aromatic region (ppm) 
Aliphatic region (ppm) 
CH2/CH3/CH OH 
N1b 9.21 (s, 1H) 8.96 (d, 1H, 3J = 5.3 Hz, CH Ar), 8.30 (dd, 1H, 3J = 7.6 Hz, 4J = 1.4 Hz, 
CH Ar), 8.15 (d, 1H, 3J = 7.5 Hz, CH Ar). 
7.69 (m, 1H, CH2), 1.91-1.88 (m, 2H, CH2), 1.30-1.24 
(m, 10H, 5 × CH2), 0.85 (t, 3H, 3J = 7.0 Hz, CH3) 
 
N2b 9.30 (s, 1H) 8.95 (d, 1H, 3J = 5.7 Hz, CH Ar), 8.30 (ddd, 1H, 3J = 7.6 Hz, 4J = 1.2 Hz, 
CH Ar), 8.12 (d, 1H, 3J = 7.9 Hz, CH Ar). 
4.72 (tt, 1H, 3J = 11.3 Hz, 4J = 3.9 Hz, CH), 2.21-2.18 
(m, 2H, CH2), 1.86-1.67 (m, 5H, 2 × CH2), 1.53-1.43 (m, 
2H, CH2), 1.31-1.20 (m, 1H, CH) 
 
N3b 9.20 (s, 1H) 8.98 (d, 1H, 3J = 5.5 Hz, CH Ar), 8.30 (t, 1H, 3J = 7.5 Hz, CH Ar), 8.24 (d, 
1H, 3J = 7.7 Hz, CH Ar), 7.69 (t, 1H, 3J = 7.1 Hz, CH Ar). 
4.62 (t, 2H, 3J = 5.1 Hz, CH2), 3.85 (m, 2H, CH2). 5.22 (bs, 1H) 
N4b 9.19 (s, 1H) 8.96-8.94 (m, 1H, CH Ar), 8.30 (dd, 1H, 3J = 7.7 Hz, 4J = 1.4 Hz, CH Ar), 
8.21-8.19 (dd, 1H, CH Ar), 7.68 (dd, 1H, 3J = 8.9 Hz, 4J = 1.5 Hz, CH Ar). 
4.55 (t, 2H, 3J = 4.9 Hz, CH2), 3.90 (t, 2H, 3J = 4.9 Hz, 
CH2), 3.49 (s, 4H, 2 × CH2) 
 
N5b 9.16 (s, 1H) 8.98 (d, 1H, 3J = 5.2 Hz, CH Ar), 8.29 (td, 1H, 3J = 7.7 Hz, 4J = 1.1 Hz, 
CH Ar), 8.23 (d, 1H, 3J = 7.3 Hz, CH Ar), 7.70 (td, 1H, 3J = 7.4 Hz, 4J = 
1.4 Hz, CH Ar) 
4.77 (t, 2H, 3J = 4.8 Hz, CH2), 3.90 (t, 2H, 3J = 4.9 Hz, 
CH2), 3.60-3.57 (m, 2H, CH2), 3.53-3.50 (m, 2H, CH2), 
3.49-3.44 (m, 2H, CH2), 3.40-3.38 (m, 2H, CH2) 
4.58 (t, 1H, 3J = 5.5 Hz) 
N6b 9.22 (s, 1H) 8.96 (d, 1H, 3J = 6.0 Hz, CH Ar), 8.29 (t, 1H, 3J = 7.8 Hz, CH Ar), 8.16 (d, 
1H, 3J = 7.8 Hz, CH Ar), 7.68 (t, 1H, 3J = 7.2 Hz, CH Ar). 
4.56 (t, 2H, 3J = 7.1 Hz, CH2), 3.38 (q, 2H, 3J = 6.3 Hz, 
CH2), 1.90 (multiplet, 2H, CH2), 1.44-1.39 (m, 2H, CH2), 
1.36-1.31 (m, 4H, 2 × CH2). 
4.34 (t, 1H, 3J = 5.2 Hz) 
N7b 9.88 (s, 1H) 9.04-9.02 (m, 1H, CH Ar), 8.38 (dd, 1H, 3J = 7.8 Hz, 4J = 1.4 Hz, CH Ar), 
8.19-8.16 (m, 1H, CH Ar), 7.94-7.90 (m, 2H, 2 × CH Ar), 7.78-7.66 (m, 
4H, 4 × CH Ar). 
  
N8b 9.47 (s, 1H) 9.04 (d, 1H, 3J = 6.2 Hz, CH Ar), 8.35 (dd, 1H, 3J = 7.8 Hz, 4J = 1.3 Hz, 
CH Ar), 8.14 (d, 1H, 3J = 7.5 Hz, CH Ar), 7.78-7.73 (m, 1H, CH Ar), 7.55-
7.50 (m, 1H, CH Ar), 7.38 (d, 2H, 3J = 7.8 Hz, 2 × CH Ar). 
2.06 (s, 6H, 2 × CH3)  
N9b 10.09 (s, 1H) 8.97 (d, 1H, 3J = 5.5 Hz, CH Ar), 8.58 – 8.55 (m, 2H, 2 × CH Ar), 8.38 
(td, 1H, 3J = 7.9 Hz, 4J = 1.5 Hz, CH Ar), 8.21 – 8.18 (m, 3H, 3 × CH Ar), 
7.75 (td, 1H, 3J = 7.3 Hz, 4J = 1.3 Hz, CH Ar). 
  
a All spectra run in DMSO-d6 at 25 °C, except where indicated. Chemical shifts reported as ppm values, referenced to the residual solvent peak 
Stellenbosch University  https://scholar.sun.ac.za





The ESI-MS spectra of the complexes typically yielded the [M – Cl]+ fragments, which is commonly 
observed for Pd-Cl compounds. The loss of chloride is brought on by the protonation of the mass 
ion, followed by the loss of HCl.9 The [M – Cl + MeCN]+ fragments were also observed and a possible 
fragmentation pattern, using complex N7b as an example, is shown in Scheme 3.4 in order to 
illustrate the loss of the chloride ion and the formation of the [M – Cl + MeCN]+ fragment. 
Assuming that the Pd-N (triazole) bond has not been severed (as indicated by the [M + H]+ fragment 
in Scheme 3.4), it is expected that the proton would reside on the medial N-atom, as it is the next 
most basic atom, after the coordinating proximal N-atom.1,2,3 
Additionally, a Na adduct was also observed in some cases. The observed fragments displayed the 
characteristic isotopic clusters expected for Pd(II) complexes. An example of a typical ESI-MS 
spectrum for the N,N’-bidentate Pd(II) pyridyl-1,2,3-triazolyl complexes is shown in Figure 3.17. 
 
Scheme 3.4: The fragmentation pattern observed for the N,N'-bidentate Pd(II) pyridyl-1,2,3-triazolyl complexes, 
with N7b as an example. 
 






Figure 3.17: The ESI-MS spectrum of N7b obtained with the predicted spectra for each identified signal. The prediction was performed on Molecular Weight Calculator 
freeware.10 
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The identity of the complexes was also confirmed with elemental analysis, as summarized in Table 
3.7. Efforts to obtain single crystals suitable for single crystal X-ray diffraction (SCXRD) analysis 
were fruitless as amorphous powders were obtained in all cases. A summary of the elemental 
analysis is given in Table 3.7.  
Table 3.7: A summary of the elemental analysis results of all the N,N'-bidentate Pd(II)-complexes. 
 Calculated Found Molecular formula found 
 % C % H % N % C % H % N  
N1b 41.35 5.09 12.86 41.01 4.84 12.40 C15H22Cl2N4Pd 
N2b 38.49 3.98 13.81 38.12 4.17 12.44 C13H16Cl2N4Pd 
N3b 28.04 3.14 15.27 28.34 3.32 14.53 C9H10Cl2N4Pd·H2O 
N4b 38.49 3.98 13.81 38.12 4.17 12.44 C13H16O2Cl2N4Pd 
N5b 31.11 3.73 10.36 30.79 3.30 10.67 C13H18O2Cl2N4Pd 
N6b 36.47 4.36 13.09 36.12 5.41 14.16 C13H18Cl2N4O2Pd·0.25H2O 
N7b 37.80 2.80 13.56 37.60 2.27 14.10 C13H10Cl2N4Pd·0.75H2O 
N8b 42.13 3.30 13.10 40.32 2.84 12.01 C15H14Cl2N4Pd 
N9b 34.17 2.06 15.04 34.59 1.71 14.42 C13H9N5O2PdCl2·0.25DCM 
 
In the cases of N3b, N6b and N7b trace amounts of water was detected despite extensive in vacuo 
drying. 
3.3 Conclusion 
The trans-Pd(II) phenyl-1,2,3-triazolyl complexes and N,N’-bidentate Pd(II) pyridyl-1,2,3-triazolyl 
complexes were both successfully synthesized and characterized. It was noted that the 1,2,3-triazole 
ligands of the trans-Pd(II) complexes dissociated in DMSO and that the extent of dissociation is 
dependent on the N-bound substituents of the 1,2,3-triazole ring, with aromatic substituents leading 
to a greater extent of dissociation than the aliphatic and hydrophilic substituents. As discussed in 
Section 3.2.1.1, it is suspected that the increase in the electron withdrawing capabilities of the 
aromatic R-groups result in a decrease in the electron donating abilities of the coordinating proximal 
N-atom. This results in a weakening of the coordination strength of the N-atom, which increases the 
extent of ligand dissociation observed. This phenomenon has been studied previously and it was 
found that the coordination strength of the triazole depends on the C- and N-bound substituents, and 
increases in the order phenyl < H < benzyl < alkyl. 3,4 





3.4 Experimental Section 
3.4.1 General Methods and Materials 
The synthetic procedures were all performed under standard Schlenk conditions under a nitrogen 
atmosphere unless otherwise noted. Literature procedures were used where indicated. All starting 
materials used were obtained from Merck and Sigma-Aldrich and used without additional purification. 
Solvents used were obtained from Merck, Protea Chemicals, Kimix and Sigma-Aldrich and purified 
accordingly. THF, DCM, hexane, and diethyl ether were dried and degassed using PureSolv Micro 
purifiers. Acetonitrile, methanol and ethanol were distilled over the appropriate drying agents. 
Acetonitrile was distilled over phosphorous pentoxide and both methanol and ethanol were distilled 
over magnesium filings and iodine. The Pd(II) precursor, (MeCN)2PdCl2, was prepared according to 
a literature procedure19. 
FTIR data was collected on a Thermo Nicolet 350 ATR-FTIR spectrometer with a Smart Performance 
ATR (Zn/Se) attachment. 1H NMR and 13C NMR spectroscopy experiments were performed on 300, 
400 and 600 MHz Agilent NMR spectrometers as indicated. Chemical shifts were recorded in 
reference to the residual solvent signals. The coupling constants (J) are reported in Hz. ESI Mass 
Spectra were recorded in positive mode, unless otherwise stated, using a Waters Synapt G2 mass 
spectrometer and employing a cone voltage of 15 V unless otherwise noted. Microanalysis was 
performed at the University of Cape Town’s Department of Chemistry on an Thermo Scientific Flash 
2000 CHNS-O Analyzer. Melting points were determined on a Bibby Stuart Scientific Melting Point 
Apparatus SMP3. 
3.4.2 Synthesis of trans-Pd(II) complexes based on 1-substituted-4-phenyl-1,2,3-
triazolyl ligands 
3.4.2.1 General synthesis for trans-Pd(II) phenyl-1,2,3-triazolyl complexes 
(MeCN)2PdCl2 (1 eq.) was dissolved in DCM (9.0 mL) at 25 °C. A solution of the ligand (2 eq.) 
dissolved in DCM (1.0 mL) was added to a solution of the Pd-precursor. The reaction mixture was 
allowed to stir at 25 °C for 2-4 hours after which the resulting precipitate was filtered off. The 
precipitate was washed with DCM (3 × 2 mL) to remove any residual ligand and Pd-precursor, 
followed by Et2O (3 × 2 mL) in order to remove the residual solvent. The product was then dried 
under vacuum overnight. 





3.4.2.1.1 Synthesis of T1a 
An opalescent yellow powder was 
recrystallized by layering hexane onto a 
DCM solution of the compound (0.093 g, 
65 %). Mp = 180 – 181 °C. FTIR (ATR): 
3128.45 cm1 (C-H triazole stretch). 1H 
NMR (600 MHz, DMSO-d6): δ (ppm) = 
8.81 (s, 1H CH triazole), 8.44 (d, 2H, 3J 
= 7.6 Hz, 2 × CH Ar), 7.61 (t, 2H, 3J = 7.5 Hz, 2 × CH Ar), 7.53 (t, 1H, 3J = 7.4 Hz, CH Ar), 4.53 – 
4.48 (m, 2H, CH2), 1.90 – 1.83 (m, 3H, CH2 + CH), 1.27-1.22 (m, 14H, 5 × CH2), 0.84 (t, 3H, 3J = 7.0 
Hz, CH3), (severe overlap with dissociated ligand signals). 13C NMR (151 MHz, DMSO-d6): δ (ppm) 
= 147.03 (C quat), 129.47 (C quat), 128.94 (2 × CH Ar), 127.77 (2 × CH Ar), 127.45 (CH triazole), 
124.87 (CH Ar), 51.42 (CH2), 31.11 (CH2), 29.04 (CH2), 29.01 (CH2), 28.45 (CH2), 28.22 (CH2), 25.58 
(CH2), 13.91 (CH3), (severe overlap with dissociated ligand signals). ESI-MS: found: 435.2332 m/z 
[M – L]+ (calc. 435.0296 m/z). Elemental analysis: % Found (% calc.) for C32H46Cl2N6Pd: C: 55.57 
(55.54); H: 6.69 (6.70); N: 12.43 (12.14). 
3.4.2.1.2 Synthesis of T2a 
A pale yellow powder was recrystallized by layering hexane 
onto a DCM solution of the compound (89 mg, 63 %). Mp = 155 
- 157 °C. FTIR (ATR): 3134 cm-1 (C-H triazole stretch). 1H NMR 
(400 MHz, DMSO-d6): δ (ppm) = 8.87 (s, 1H, CH triazole), 8.44 
(d, 2H, 3J = 7.7 Hz, 2 × CH Ar), 7.61 (t, 2H, 3J = 7.5 Hz, 2 × CH 
Ar), 7.52 (t, 1H, 3J = 7.4 Hz, CH Ar), 4.66 - 4.60 (m, 1H, CH), 
2.12 (d, 2H, 3J = 13.1 Hz, CH2), 1.85-1.75 (m, 5H, 2 × CH2 + 
CH), 1.50 – 1.41 (q, 3H, 3J = 12.8 Hz, CH2 + CH), 1.31 – 1.21 (m, 1H, CH), (severe overlap with 
dissociated ligand signals). 13C NMR (101 MHz, DMSO-d6): δ (ppm) = 146.85 (C quat), 129.44 (C 
quat), 128.91 (2 × CH Ar), 127.84 (2 × CH Ar), 127.45 (CH Ar), 123.33 (CH triazole), 59.11 (CH), 
54.90 (CH2) 32.86 (CH2), 32.28 (CH2), 24.73 (CH2), 24.57 (CH2), (severe overlap with dissociated 
ligand signals). Confirmed with HSQC. ESI-MS: found: 597.1552 m/z [M – Cl]+ (calc. 597.1568 m/z). 
Elemental analysis: % Found (% calc.) for C28H34Cl2N6Pd·0.5H2O: C: 52.37 (52.47); H: 5.27 (5.50); 
N: 11.90 (13.11). 
T1a 
T2a 





3.4.2.1.3 Synthesis of T3a 
A pale yellow powder was obtained (0.053 g, 95 %). Mp =.232 
°C (turns brown), 239 – 240 °C (decomposes). FTIR (ATR): 
3469 (O-H stretch), 3130 (C-H triazole stretch), 1229 (C-N), 
1071 (C-O). 1H NMR (600 MHz. DMSO-d6): δ (ppm) = 8.76 (s, 
1H, CH triazole), 8.43 (d, 2H, 3J = 7.5 Hz, 2 × CH Ar), 7.61 (t, 
2H, 3J = 7.6 Hz, 2 × CH Ar), 7.52 (t, 1H, 3J = 8.0 Hz, CH Ar), 
5.22 (t, 1H, 3J = 5.0 Hz, OH), 4.58 – 4.55 (m, 2H, CH2), 3.89 – 3.86 (m, 2H, CH2), (severe overlap 
with dissociated ligand signals). 13C NMR (101 MHz, DMSO-d6): δ (ppm) = 146.92 (C quat), 129.43 
(C quat), 128.93 (2 × CH Ar), 127.88 (2 × CH Ar), 127.45 (CH triazole), 125.43 (CH Ar), 59.12 (CH2), 
54.28 (CH2). ESI-MS: found: 483.0766 m/z [M – 2Cl - H]+ (calc. 483.0769 m/z), 521.0526 m/z [M – 
Cl]+ (calc. 521.0526 m/z). Elemental analysis: % Found (% calc.) for C20H22N6O2Cl2Pd·0.25DCM: C: 
42.49 (42.15); H: 3.75 (3.93); N: 14.80 (14.57). 
3.4.2.1.4 Synthesis of T4a 
A pale yellow powder was obtained (0.121 g, 87 
%). Mp = 191 °C decomposes. FTIR (ATR): 
3422 cm-1 (O-H stretch), 3098 cm-1 (C-H 
triazole). 1H NMR (600 MHz, DMSO-d6): δ 
(ppm) = 8.79 (s, 1H, CH triazole), 8.43 (d, 2H, 
3J = 7.3 Hz, 2 × CH Ar), 7.61 (t, 2H, 3J = 7.5 Hz, 
2 × CH Ar), 7.53 (t, 1H, 3J = 7.3 Hz, CH Ar), 
4.73 – 4.67 (m, 5H, 2 × CH2 + OH), 3.90 (t, 4H, 3J = 4.8 Hz, 2 × CH2), 3.50 – 3.47 (m, 2H, CH2), 
(severe overlap with dissociated ligand signals). 13C NMR (101 MHz, DMSO-d6): δ (ppm) = 147.04 
(C quat), 146.18 (C quat), 129.50 (2 × CH Ar), 129.15 (2 × CH Ar), 127.49 (CH triazole), 125.39 (CH 
Ar), 67.81 (CH2), 67.80 (CH2), 51.50 (CH2), 51.46 (CH2), (severe overlap with dissociated ligand 
signals). HRMS: found: 571.1292 m/z [M – 2Cl - H]+ (calc. 571.1295 m/z), 609.1058 m/z [M – Cl]+ 
(calc. 609.1051), 643.0611 m/z [M – H]+ (calc. 644.0735), 650.1307 m/z [M – Cl + MeCN]+ (calc. 
650.1317), 685.1174 m/z [M – Cl + DMSO]+ (calc. 685.1198). Elemental analysis: % Found (% calc.) 
for C24H30N6O4Cl2Pd: C: 44.76 (44.77); H: 4.91 (4.70); N: 12.58 (13.05). 
3.4.2.1.5 Synthesis of T5a 
A pale yellow powder was 
crystallized from a layered 
solution of DCM and hexane 
(0.119 g, 90 %). Mp = 131 – 
132 °C. FTIR (ATR): 3447 cm-1 









triazole stretch). 1H NMR (600 MHz, DMSO-d6): δ (ppm) = 8.75 (s, 1H, CH triazole), 8.43 (d, 2H, 3J 
= 7.1 Hz, 2 × CH Ar), 7.61 (t, 2H, 3J = 7.6 Hz, 2 × CH Ar), 7.53 (t, 1H, 3J = 7.4 Hz, CH Ar), 4.70 – 
4.69 (m, 3H, CH2 + OH), 3.92 (t, 3H, 3J = 4.8 Hz, CH2), 3.56-3.55 (m, 2H, CH2), 3.51-3.49 (m, 2H, 
CH2), 3.46 (q, 2H, 3J = 5.1 Hz, CH2), 3.39 (t, 2H, 3J = 5.2 Hz, CH2), (severe overlap with dissociated 
ligand signals). 13C NMR (75 MHz, DMSO-d6): δ (ppm) = 129.50 (C quat), 128.95 (C quat), 128.54 
(2 × CH Ar), 127.49 (2 × CH Ar), 125.21 (CH Ar), 121.76 (CH triazole), 72.36 (CH2), 69.74 (CH2), 
69.53 (CH2), 67.87 (CH2), 67.84 (CH2), 49.66 (CH2), (severe overlap with dissociated ligand signals). 
ESI-MS: found: 659.1819 m/z [M – 2Cl - H]+ (calc. 659.1821 m/z), 697.1556 m/z [M – Cl]+ (calc. 
697.1577 m/z). Elemental analysis: % Found (% calc.) for C28H38N6O6PdCl2: C: 45.43 (45.05); H: 
5.47 (5.15); N: 10.16 (11.16). 
3.4.2.1.6 Synthesis of T6a 
A pale yellow powder was obtained (0.041 
g, 60 %). Mp = 123 – 124 °C. FTIR (ATR): 
3369 cm-1 (O-H stretch), 3096 cm-1 (C-H 
triazole stretch). 1H NMR (600 MHz, 
DMSO-d6): δ (ppm) = 8.81 (s, 1H, CH 
triazole), 8.44 (d, 2H, 3J = 7.5 Hz, 2 × CH 
Ar), 7.61 (t, 2H, 3J = 7.5 Hz, 2 × CH Ar), 
7.53 (t, 1H, 3J = 7.2 Hz, CH Ar), 4.54 – 4.49 (m, 3H, CH2 + OH), 3.36 (q, 3H, 3J = 6.4 Hz, CH2), 1.92 
– 1.84 (m, 3H, CH2), 1.43 – 1.38 (m, 3H, CH2), 1.35-1.24 (m, 4H, 2 × CH2), (severe overlap with 
dissociated ligand signals). 13C NMR (101 MHz, DMSO-d6): δ (ppm) = 147.04 (C quat), 129.48 (C 
quat), 129.14 (2 × CH Ar), 128.95 (2 × CH Ar), 127.45 (CH Ar), 124.88 (CH triazole), 51.41 (CH2), 
29.09 (CH2), 25.52 (CH2), 24.81 (CH2), (severe overlap with dissociated ligand signals). ESI-MS: 
found: 595.2024 m/z [M – 2Cl - H]+ (calc. 595.2024 m/z), 633.1762 m/z [M – Cl]+ (calc. 633.1780 
m/z). Elemental analysis: % Found (% calc.) for C28H38N6O2PdCl2·0.75DCM: C: 46.89 (47.20); H: 
5.28 (5.44); N: 10.97 (11.49). 
3.4.2.1.7 Synthesis of T7a 
A pale brown powder was obtained (114 mg, 76 %). Mp = 160 
°C decomposes. FTIR (ATR): 3113.98 cm-1 (C-H triazole). 1H 
NMR (400 MHz, DMSO-d6): δ (ppm) = 9.50 (s, 1H, CH triazole, 
8.07 (t, 2H, 3J = 7.9 Hz, 2 × CH Ar), 7.74 (t, 2H, 3J = 7.5 Hz, 2 
× CH Ar), ligand dissociation is so extensive that complex 
signals are mostly obscured. HRMS: found: 619.1668 m/z [M – 
H]+ (calc. 619.0234 m/z). Elemental analysis: % Found (% calc.) 
for C28H22Cl2N6Pd·4DCM: C: 39.66 (40.05); H: 2.89 (3.15); N: 8.40 (8.76). 
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3.4.2.1.8 Synthesis of T8a 
A pale brown powder was obtained (82 mg, 63 %). Mp = 213 °C 
decomposes. FTIR (ATR): 3131.64 cm-1 (C-H triazole). 1H NMR 
(300 MHz, DMSO-d6): δ (ppm) = ligand dissociation is so 
extensive that complex signals are mostly obscured. ESI-MS: 
found: 426.1011 m/z [M – L]+ (calc. 426.9670 m/z), found: 
603.1541 m/z [M – 2Cl]+ (calc. 604.1579 m/z). Elemental 
analysis: % Found (% calc.) for C32H30Cl2N6Pd: C: 56.22 
(56.86); H: 4.87 (4.47); N: 10.92 (12.43). 
3.4.2.1.9 Synthesis of T9a 
The precipitate was too fine to filter. The reaction 
mixture was thus divided into two centrifuge tubes 
and the samples centrifuged at 6000 rpm for 15 
minutes. The supernatant was siphoned off and 
fresh DCM (4 mL) was added. The process was 
repeated until the supernatant was clear. A bright 
orange powder was obtained (0.241 g, 90 %). Mp = 
304 – 305 °C decomposes with melting. FTIR (ATR): 3126 cm-1 (C-H triazole stretch), 1597 cm-1 
(N=O stretch), 1343 cm-1 (N=O stretch). 1H NMR (600 MHz, DMSO-d6): δ (ppm) = ligand dissociation 
is so extensive that complex signals are mostly obscured. ESI-MS: found: 638.9182 m/z [M – 2Cl]- 
(calc. 638.0653 m/z). Elemental analysis: % Found (% calc.) for C28H20N8O4PdCl2·0.125DCM: C: 
47.27 (46.89); H: 2.65 (2.83); N: 14.61 (15.55). 
3.4.3 Synthesis of N,N’-bidentate Pd(II) complexes based on 1-substituted-4-
pyridyl-1,2,3-triazolyl ligands 
3.4.3.1 General synthesis for N,N’-bidentate Pd(II) pyridyl-1,2,3-triazolyl complexes 
(MeCN)2PdCl2 (1 eq.) was dissolved in DCM (9.0 mL) at 25 °C. The ligand (1 eq.) was dissolved in 
DCM (1.0 mL) and added to the Pd-precursor. The reaction mixture was allowed to stir at 25 °C for 
2-4 hours after which the resulting precipitate was filtered off. The precipitate was washed with DCM 
(3 × 2 mL) to remove any residual ligand and Pd-precursor, followed by Et2O (3 × 2 mL) in order to 
remove the residual solvent. The product was then dried under vacuum overnight. 
T8a 
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3.4.3.1.1 Synthesis of N1b 
A pale orange powder was obtained (0.082 g, 82 %). Mp = 
279 – 280 °C decomposes with melting. FTIR (ATR): 3080 
cm-1 (C-H triazole). 1H NMR (400 MHz, DMSO-d6): δ (ppm) 
= 9.21 (s, 1H, CH triazole), 8.96 (d, 1H, 3J = 5.3 Hz, CH Ar), 
8.30 (dd, 1H, 3J = 7.6 Hz, 4J = 1.4 Hz, CH Ar), 8.15 (d, 1H, 
3J = 7.5 Hz, CH Ar), 7.69 (m, 1H, CH2), 1.91-1.88 (m, 2H, CH2), 1.30-1.24 (m, 10H, 5 × CH2), 0.85 
(t, 3H, 3J = 7.0 Hz, CH3). 13C NMR (101 MHz, DMSO-d
6): δ (ppm) = 149.49, 148.32, 147.36, 141.40, 
125.57, 125.52, 122.04, 52.19, 31.18, 24.11, 28.46, 28.36, 25.62, 22.07, 13.96. ESI-MS: found: 
459.01 m/z [M + Na]+ (calc. 459.0146 m/z), found: 442.08 m/z [M – Cl + MeCN]+ (calc. 442.0831 
m/z). Elemental analysis: % Found (% calc.) for C15H22Cl2N4Pd: C: 41.01 (41.35); H: 4.84 (5.09); N: 
12.40 (12.86). 
3.4.3.1.2 Synthesis of N2b 
A pale orange powder was obtained (0.078 g, 78 %). Mp = 304 °C 
decomposes. FTIR (ATR): 3087 cm-1 (C-H triazole). 1H NMR (400 MHz, 
DMSO-d6): δ (ppm) = 9.30 (s, 1H, CH triazole), 8.95 (d, 1H, 3J = 5.7 Hz, 
CH Ar), 8.30 (ddd, 1H, 3J = 7.6 Hz, 4J = 1.2 Hz, CH Ar), 8.12 (d, 1H, 3J = 
7.9 Hz, CH Ar), 4.72 (tt, 1H, 3J = 11.3 Hz, 4J = 3.9 Hz, CH), 2.21-2.18 (m, 
2H, CH2), 1.86-1.67 (m, 5H, 2 × CH2), 1.53-1.43 (m, 2H, CH2), 1.31-1.20 (m, 1H, CH). 13C NMR (101 
MHz, DMSO-d6): δ (ppm) = 149.50, 148.38, 147.21, 141.41, 125.49, 123.97, 121.90, 61.84, 32.36, 
24.48, 24.26. ESI-MS: found: 428.97 m/z [M + Na]+ (calc. 428.9676 m/z), found: 412.04 m/z [M – Cl 
+ MeCN]+ (calc. 412.0361 m/z), found: 371.01 m/z [M-Cl]+ (calc. 371.0095 m/z). Elemental analysis: 
% Found (% calc.) for C13H16Cl2N4Pd: C: 38.12 (38.49); H: 4.17 (3.98); N: 12.44 (13.81). 
3.4.3.1.3 Synthesis of N3b 
A pale orange powder was obtained (0.087 g, 87 %). Mp = 249 °C 
decomposes. FTIR (ATR): 3446 cm-1 (O-H stretch), 3091 (C-H stretch). 
1H NMR (600 MHz, DMSO-d6): δ (ppm): 9.20 (s, 1H, CH triazole), 8.98 
(d, 1H, 3J = 5.5 Hz, CH Ar), 8.30 (t, 1H, 3J = 7.5 Hz, CH Ar), 8.24 (d, 1H, 
3J = 7.7 Hz, CH Ar), 7.69 (t, 1H, 3J = 7.1 Hz, CH Ar), 5.22 (bs, 1H, OH), 
4.62 (t, 2H, 3J = 5.1 Hz, CH2), 3.85 (m, 2H, CH2). 13C NMR (151 MHz, DMSO-d6): δ (ppm): 149.50 
(CH triazole), 148.30 (C quat.), 147.16 (C quat.), 141.39 (CH Ar), 126.25 (CH Ar), 125.48 (CH Ar), 
121.97 (CH Ar), 59.26 (CH2), 55.05 (CH2). ESI-MS: found: 296.9956 m/z [M – 2Cl + H]+ (calc. 
296.9972 m/z), found: 371.9851 m/z [M – Cl + MeCN]+ (calc. 371.9845 m/z). Elemental analysis: % 
Found (% calc.) for C9H10Cl2N4Pd·H2O: C: 28.34 (28.04); H: 3.32 (3.14); N: 14.53 (15.27). 





3.4.3.1.4 Synthesis of N4b 
A pale orange powder was obtained (0.232 g, 88%). Mp = 202 - 
203 °C decomposes. FTIR (ATR): 3458 cm-1 (O-H stretch), 3090 
cm-1 (C-H triazole). 1H NMR (300 MHz, DMSO-d6): δ (ppm) = 
9.19 (s, 1H, CH triazole), 8.96-8.94 (m, 1H, CH Ar), 8.30 (dd, 1H, 
3J = 7.7 Hz, 4J = 1.4 Hz, CH Ar), 8.21-8.19 (dd, 1H, CH Ar), 7.68 
(dd, 1H, 3J = 8.9 Hz, 4J = 1.5 Hz, CH Ar), 4.55 (t, 2H, 3J = 4.9 Hz, CH2), 3.90 (t, 2H, 3J = 4.9 Hz, 
CH2), 3.49 (s, 4H, 2 × CH2). 13C NMR (101 MHz, DMSO-d6): δ (ppm) = 149.49 (CH triazole.), 148.26 
(C quat), 147.27 (C quat.), 141.39 (CH Ar), 126.18 (CH Ar), 125.54 (CH Ar), 122.07 (CH Ar), 72.19 
(CH2), 67.88 (CH2), 60.04 (CH2), 52.31 (CH2). ESI-MS: found: 376.9839 m/z [M – Cl]+ (calc. 376.9837 
m/z), 418.0099 m/z [M – Cl + MeCN]+ (calc. 418.0103 m/z). Elemental analysis: % Found (% calc.) 
for C13H16O2Cl2N4Pd: C: 38.12 (38.49); H: 4.17 (3.98); N: 12.44 (13.81). 
3.4.3.1.5 Synthesis of N5b 
A pale brown powder was obtained (0.072 g, 36 %). Mp 
= 160 – 161 °C decomposes. FTIR (ATR): 3535 cm-1 (O-
H stretch), 3099 cm-1 (C-H triazole stretch). 1H NMR 
(400 MHz, DMSO-d6): δ (ppm) = 9.16 (s, 1H, CH 
triazole), 8.98 (d, 1H, 3J = 5.2 Hz, CH Ar), 8.29 (td, 1H, 
3J = 7.7 Hz, 4J = 1.1 Hz, CH Ar), 8.23 (d, 1H, 3J = 7.3 Hz, CH Ar), 7.70 (td, 1H, 3J = 7.4 Hz, 4J = 1.4 
Hz, CH Ar), 4.77 (t, 2H, 3J = 4.8 Hz, CH2), 4.58 (t, 1H, 3J = 5.5 Hz, OH), 3.90 (t, 2H, 3J = 4.9 Hz, 
CH2), 3.60-3.57 (m, 2H, CH2), 3.53-3.50 (m, 2H, CH2), 3.49-3.44 (m, 2H, CH2), 3.40-3.38 (m, 2H, 
CH2). 13C NMR (101 MHz, DMSO-d
6): δ (ppm) = 149.51, 148.24, 147.26, 141.38, 126.10, 125.55, 
122.07, 72.30, 69.64, 69.51, 67.90, 60.19, 52.25. ESI-MS: found: 421.0098 m/z [M – Cl]+ (calc. 
421.0100 m/z). Elemental analysis: % Found (% calc.) for C13H18O2Cl2N4Pd: C: 30.79 (31.11); H: 
3.30 (3.73); N: 10.67 (10.36). 
3.4.3.1.6 Synthesis of N6b 
A yellow-orange powder was obtained (0.134 g, 89 %). Mp = 
220 – 221 °C decomposes. FTIR (ATR): 3472 cm-1 (O-H 
stretch), 3095 (C-H triazole stretch). 1H NMR (600 MHz, 
DMSO-d6): δ (ppm) = 9.22 (s, 1H, CH triazole), 8.96 (d, 1H, 3J 
= 6.0 Hz, CH Ar), 8.29 (t, 1H, 3J = 7.8 Hz, CH Ar), 8.16 (d, 1H, 
3J = 7.8 Hz, CH Ar), 7.68 (t, 1H, 3J = 7.2 Hz, CH Ar), 4.56 (t, 2H, 3J = 7.1 Hz, CH2), 4.34 (t, 1H, 3J = 
5.2 Hz, OH), 3.38 (q, 2H, 3J = 6.3 Hz, CH2), 1.90 (quintet, 2H, 3J = 7.1 Hz, CH2), 1.44-1.39 (m, 2H, 
CH2), 1.36-1.31 (m, 4H, 2 × CH2). 13C NMR (151 MHz, DMSO-d6): δ (ppm) = 149.44, 148.29, 147.32, 
141.35, 125.55, 125.47, 122.01, 60.50, 52.15, 32.18, 29.12, 25.48, 24.90. ESI-MS: found: 389.0191 
m/z [M – Cl]+ (calc. 389.0201 m/z), 406.0662 m/z [M – OH]+ (calc. 406.9856 m/z), found: 430.0455 





m/z [M – Cl + MeCN]+ (calc. 430.0467 m/z). Elemental analysis: % Found (% calc.) for 
C13H18Cl2N4Pd·0.25H2O: C: 36.12 (36.47); H: 5.41 (4.36); N: 14.16 (13.09). 
3.4.3.1.7 Synthesis of N7b 
A pale orange powder was isolated (0.316 g, 88 %). Mp = 252 °C 
decomposes. FTIR (ATR): 3593 cm-1 (C-H triazole). 1H NMR (300 MHz, 
DMSO-d6): δ (ppm) =  9.88 (s, 1H, CH triazole), 9.04-9.02 (m, 1H, CH 
Ar), 8.38 (dd, 1H, 3J = 7.8 Hz, 4J = 1.4 Hz, CH Ar), 8.19-8.16 (m, 1H, CH 
Ar), 7.94-7.90 (m, 2H, 2 × CH Ar), 7.78-7.66 (m, 4H, 4 × CH Ar). 13C 
NMR (75 MHz, DMSO-d6): δ (ppm) = 149.67, 148.28, 148.08, 141.62, 135.84, 130.65, 130.26, 
125.88, 124.28, 122.07, 121.22. ESI-MS: found: 362.9641 m/z [M – Cl]+ (calc. 362.963118 m/z), 
found: 405.9891 m/z [M – Cl + MeCN]+ (calc. 405.9892 m/z), found: 422.9167 m/z [M + Na]+ (calc: 
422.9206 m/z). Elemental analysis: % Found (% calc.) for C13H10Cl2N4Pd·0.75H2O: C: 37.60 (37.80); 
H: 2.27 (2.80); N: 14.10 (13.56). 
3.4.3.1.8 Synthesis of N8b 
A pale orange powder was obtained (0.196 g, 77 %). Mp = 327 °C 
decomposes. FTIR (ATR): 3117 cm-1 (C-H triazole). 1H NMR (300 MHz, 
DMSO-d6): δ (ppm) = 9.47 (s, 1H, CH triazole), 9.04 (d, 1H, 3J = 6.2 Hz, 
CH Ar), 8.35 (dd, 1H, 3J = 7.8 Hz, 4J = 1.3 Hz, CH Ar), 8.14 (d, 1H, 3J = 
7.5 Hz, CH Ar), 7.78-7.73 (m, 1H, CH Ar), 7.55-7.50 (m, 1H, CH Ar), 7.38 
(d, 2H, 3J = 7.8 Hz, 2 × CH Ar), 2.06 (s, 6H, 2 × CH3). 13C NMR (75 MHz, DMSO-d6): δ (ppm) = 
149.86, 148.26, 148.15, 141.44, 134.91, 134.55, 131.36, 128.88, 127.70, 125.83, 122.34, 16.89. 
ESI-MS: found: 434.0217 m/z [M – Cl + MeCN]+ (calc. 434.0205 m/z). Elemental analysis: % Found 
(% calc.) for C15H14Cl2N4Pd·H2O: C: 40.32 (40.43); H: 2.84 (3.62); N: 12.01 (12.57). 
3.4.3.1.9 Synthesis of N9b 
A pale yellow powder was obtained (0.093 g, 86 %). Mp = 335 °C 
decomposes. FTIR (ATR): 3135 cm-1 (C-H triazole), 1596 (C=N 
pyridine stretch), 1523 (N=O stretch), 1346 (N=O stretch). 1H NMR 
(600 MHz, DMSO-d6): δ (ppm) = 10.09 (s, 1H, CH triazole), 8.97 (d, 
1H, 3J = 5.5 Hz, CH Ar), 8.58 – 8.55 (m, 2H, 2 × CH Ar), 8.38 (td, 
1H, 3J = 7.9 Hz, 4J = 1.5 Hz, CH Ar), 8.21 – 8.18 (m, 3H, 3 × CH Ar), 7.75 (td, 1H, 3J = 7.3 Hz, 4J = 
1.3 Hz, CH Ar). 13C NMR (151 MHz, DMSO-d6): δ (ppm) = 149.62, 148.60, 147.94, 147.72, 141.69, 
139.90, 126.06, 125.79, 124.75, 122.28, 121.95. ESI-MS: found: found: 450.9749 m/z [M – Cl + 
MeCN]+ (calc. 450.9743 m/z). Elemental analysis: % Found (% calc.) for C13H9N5O2PdCl2·0.25DCM: 
C: 34.59 (34.17); H: 1.71 (2.06); N: 14.42 (15.04). 





3.4.4 The NMR study of the trans-Pd(II) 1-substituted-4-phenyl-1,2,3-triazolyl 
complexes 
All the 1H NMR experiments performed in this study were conducted on a 400 MHz Agilent NMR 
instrument at 25 °C, unless otherwise indicated. 
3.4.4.1 Addition of (MeCN)2PdCl2 to 4a in DMSO-d6 
4a (0.01 g, 0.042 mmol) was dissolved in DMSO-d6 (0.65 mL). The 1H NMR spectrum was recorded 
immediately. The sample was then removed from the spectrometer and added to 0.5 eq. 
(MeCN)2PdCl2 (0.0056 mg. 0.021 mmol). The 1H NMR spectrum of the resulting mixture was 
collected immediately. The process was repeated by adding two more equivalents of the Pd-
precursor. With the addition of the third equivalent of the Pd-precursor, the solution showed signs of 
saturation and required extensive heating to dissolve the Pd-precursor. 
3.4.4.2 Addition of (MeCN)2PdCl2 to 4a in DMSO-d6 followed by the dilution of the sample 
4a (0.014 g, 0.06 mmol) was dissolved in DMSO-d6 (0.65 mL). The 1H NMR spectrum was recorded 
immediately. The sample was then removed from the spectrometer and added to 0.5 eq. 
(MeCN)2PdCl2 (0.0077 g. 0.03 mmol). The 1H NMR spectrum of the resulting mixture was collected 
immediately. The process was repeated by adding two more equivalents of the Pd-precursor. With 
the addition of the third equivalent of Pd-precursor, the solution showed signs of saturation and 
required extensive heating to dissolve the Pd-precursor. The solution was then diluted by half by 
adding it to an additional 0.65 mL DMSO-d6. The NMR sample was prepared again and the 1H NMR 
spectrum collected immediately. This was repeated twice. 
3.4.4.3 Addition of (MeCN)2PdCl2 to 2a in DMSO-d6 followed by the dilution of the sample 
2a (0.01 g, 0.044 mmol) was dissolved in DMSO-d6 (0.65 mL). To this was added CDCl3 as an 
external standard in a sealed glass capillary. The 1H NMR spectrum was recorded immediately. The 
sample was then removed and added to 0.5 eq. (MeCN)2PdCl2 (0.0057 g. 0.022 mmol). The 1H NMR 
spectrum was collected immediately. The process was repeated by adding two more equivalents of 
Pd-precursor in the presence of the external reference. With the addition of the third equivalent, the 
solution showed signs of saturation and required extensive heating to dissolve the Pd-precursor. 
The solution was then diluted by half by adding it to an additional 0.65 mL DMSO-d6. The NMR 
sample was prepared again and the 1H NMR spectrum collected immediately. This was repeated 
twice. 
3.4.4.4 Titration of T2a in CDCl3 with DMSO-d6 
The 1H NMR spectrum of the DMSO-d6 was recorded in order to determine the H2O/DMSO ratio of 
the solvent. Through the integration of the resulting H2O and DMSO-d6 signals, it was found that the 
DMSO-d6 contained 25 % (v/v) H2O, thus the DMSO equivalents to be added was calculated for a 
75 % (v/v) DMSO solution. A NMR sample of T2a (0.01 g, 0.024 mmol) in CDCl3 (0.65 mL) was 





prepared and the spectrum acquired. To the sample was added one equivalent 75 % DMSO-d6 (2.25 
µL, 0.024 mmol). The sample was inverted 4 times in order to ensure thorough mixing of the DMSO-
d6 the metal-containing solution. The spectrum was acquired immediately. The process was 
repeated until 6 eq. DMSO-d6 added. The 12 eq. spectrum was obtained by adding 13.5 µL DMSO-
d6 to the sample and collecting the spectrum immediately after mixing. 
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Chapter 4: Biological evaluation of trans- 
and N,N’-bidentate Pd(II) complexes 
4.1 Introduction 
The development of a novel drug-like compound takes approximately 12 – 15 years from 
conceptualization to clinical application.1,2 With research costs exceeding $1 billion (approximately 
R13.5 billion), it becomes clear that the drug development process is not ideal when taking into 
account that only 10 % of compounds that enter clinical trials reach the market.2 
The drug discovery process is multi-faceted with various areas that are interlinked. Kerns et al. 
summed the process up in the form of a flow diagram (Figure 4.1).3 
 
Figure 4.1: The drug discovery process as outlined by Kerns et al.3 
As is visible from Figure 4.1, property assays play an important role within the early drug discovering 
process. Property assays involve the evaluation of five physiochemical properties: absorption, 
distribution, metabolism, excretion and toxicity (ADMETox). Without a good understanding of these 
properties for each potential drug-like molecule, the chances of that drug progressing beyond the 
laboratory are limited.4 
There is some debate within the literature as to whether the ADMETox properties of potential drug-
like molecules should be evaluated before the biological screening is performed, or whether it should 
be the other way around.5 The current trend is to evaluate certain aspects of the ADMETox 
properties, specifically properties that would influence absorption, and to perform the biological 
screening in between the property evaulations.1  
In general, the majority of Pd(II)-compounds for anti-cancer applications have not progressed into 
clinical trials due to two reasons, 1) that there is no real structure-activity-relationship established for 
these compounds and 2) that their mode of action is not yet understood. It is thus necessary to 





investigate libraries of compounds in order to determine a structure-activity-relationship and to 
investigate the mode of anti-cancer activity.4 
Within the field of bioinorganic chemistry, it has become practice to evaluate the interaction of 
potential anti-cancer compounds with DNA. Metal complexes can form covalent bonds to DNA, or 
interact with DNA in a variety of non-covalent manners6, as discussed in Section 4.2.3. 
This chapter summarizes the evaluation of the complexes described in Chapter 3 as anti-cancer 
agents and the investigations into their solubility and DNA binding modes. 
4.2 Results and Discussion 
4.2.1 Turbidimetric Assay 
Solubility is one of the key elements that influence the absorption properties of a compound, and it 
is thus prudent that the aqueous solubility of a potential drug-like compound is determined early 
within the discovery stages. Some would argue that the solubility of a compound should be 
determined prior to its biological evaluation.7 
Conventionally, one can define two types of solubility, thermodynamic solubility and kinetic solubility. 
The measurement of thermodynamic solubility involves the addition of the aqueous phase directly 
to the solid followed by a long incubation period (24 – 72 hours) in order to establish an equilibrium 
between the dissolved material and the undissolved material. Thermodynamic solubility is generally 
determined in late stage drug development rather than early drug discovery due to the fact that it is 
dependent on the crystalline form of the compound and can thus vary between batches.3 
In order to determine the kinetic solubility of a compound, the compound is dissolved in DMSO and 
the resulting solution added to an aqueous buffer solution. Equilibrium is not reached between the 
undissolved material and the dissolved material and the compound is allowed to precipitate out of 
solution.3 Kinetic solubility testing mimics the protocols typically applied when carrying out biological 
assays in which a stock solution in DMSO is prepared and then added to the aqueous buffered 
solution, thus making it more suitable for early drug discovery. After incubation (2 – 4 hours), the 
turbidity of the sample is assessed with UV-Vis spectroscopy by recording the extent of light 
scattering at 620a nm.3 
The kinetic solubility of the trans-Pd(II) phenyl-1,2,3-triazolyl complexes and N,N’-bidentate Pd(II) 
pyridyl-1,2,3-triazolyl complexes were determined with a turbidimetric assay, the details of which is 
outline in Section 4.4.2. The results are summarized in Table 4.2. As discussed in Chapter 3, the 
                                               
a The extent of light scattering caused by particulates in solution can be assessed with wavelengths ranging 
from 600 – 820 nm,49 depending on the absorbance of the particles themselves. It is protocol to assess the 
turbidity of drug-like molecules in solution at 620 nm, as few drug-like molecules absorb in this region.3,49,50 





trans-Pd(II) phenyl-1,2,3-triazolyl complexes undergo ligand dissociation/exchange in DMSO, thus 
in reality what we were determining was the kinetic solubility of the various species in solution. 
The degree of the solubility of the compounds is classified according to the criteria outlined in Table 
4.1. 
Table 4.1: The classification of compounds according to their solubility. 
< 10 µg/mL Sparingly soluble 
10 – 60 µg/mL Partially soluble 
> 60 µg/mL Soluble 
 
Table 4.2: A summary of the kinetic solubility obtained for the trans-Pd(II) and N,N'-bidentate Pd(II) complexes. 
Compound Functionality 
µM  
(2 % DMSO/PBS)a 
µg/mL  
(2 % DMSO/PBS)a 
25 °C 37 °C 25 °C 37 °C 
T1a Octyl 10 - 20 10 - 20 6.92 - 13.84 6.92 - 13.84 
T2a Cyclohexyl 5 - 10 5 - 10 3.16 - 6.32 3.16 - 6.32 
T3a Ethanol > 200 > 200 > 111.15 > 111.15 
T4a 2-(2-ethoxy)ethanol > 200 > 200 > 128.77 > 128.77 
T5a 2-(2-(2-ethoxy) ethoxy)ethanol > 200 > 200 > 146.39 > 146.39 
T6a Hexanol 80 - 120 80 - 120 53.44 - 80.16 53.44 - 80.16 
T7a Phenyl 20 - 40 5 - 10 0 - 3.10 3.10 - 6.20 
T8a 2,6-dimethyl phenyl 20 - 40 60 - 80 13.52 - 27.04 40.56 - 54.08 
T9a Nitrophenyl 0 - 5 0 - 5 0 - 3.55 0 - 3.55 
N1b Octyl 5 - 10 5 - 10 2.18 - 4.36 2.18 - 4.36 
N2b Cyclohexyl 20 - 40 40 - 80 8.11 - 16.23 16.23 - 32.45 
N3b Ethanol 40 - 80 > 200 14.70 - 29.40 > 73.51 
N4b 2-(2-ethoxy)ethanol 160 - 200 > 200 65.85 - 82.31 > 82.32 
N5b 2-(2-(2-ethoxy)ethoxy)ethanol >200 > 200 > 91.13 > 91.13 
N6b Hexanol 160 - 200 > 200 67.78 - 84.73 > 84.73 
N7b Phenyl 40 - 60 40 - 80 15.98 - 23.97 15.98 - 31.97 
N8b 2,6-dimethyl phenyl 10 - 20 40 - 80 4.28 - 8.55 17.11 - 34.21 
N9b Nitrophenyl 10 - 20 20 - 40 4.45 – 8.89 8.89 - 17.78 
(MeCN)2PdCl2 > 200 > 200 > 51.89 > 51.89 
Hydrocortisone >200 >200 > 72.49 > 72.49 
Reserpine 20 - 40 10 - 20 12.17 - 24.35 6.09-12.17 
a Percentage expressed as v/v. 
The results obtained for the controls, Hydrocortisone and Reserpine, agree with literature values8 
and thus the assay is validated. 
From the solubility results obtained it is clear that the complexes with the ethanol moieties (3, 4, 5 
and 6) are more soluble than their aliphatic and aromatic counterparts (1, 2, 7, 8 and 9) as was 





expected. It was also interesting to note that the T2a is less soluble than N2b although both have 
cyclohexyl moieties, and the reverse is observed for T1a versus N1b with the octyl moieties. For 
both the trans-Pd(II) phenyl-1,2,3-triazolyl and N,N’-bidentate Pd(II) pyridyl-1,2,3-triazolyl complexes 
it is also observed that an increase in temperature results in an increase in solubility, as expected. 
In general, all complexes are soluble at the MTT Assay test concentrations (0 – 20 µM) apart from 
those indicated in red in Table 4.2.  
Treatment of cells with the complexes of poor solubility were thus done with suspensions, just to 
assess whether they have some anti-cancer activity as nanosuspensions. The use of 
nanosuspensions as a drug delivery method has become an active area of research recently, as this 
allows for the utilization of previous disregarded drug candidates. The IC50 values of 
nanosuspensions are not reported as molar concentrations, due to the nature of the suspensions, 
but rather as mass/volume concentrations.9 
4.2.2 In Vitro cytotoxic evaluation 
The cytotoxicity of the trans-Pd(II) and N,N’-bidentate Pd(II) complexes was evaluated against 
advanced human breast cancer, MCF-7, and metastatic human breast cancer, MDA-MB-231, using 
a standard MTT Assay. The concentration range tested was 0 – 20 µM and the treatment time was 
kept constant at 48 hours. The results are summarized in Table 4.3. 
Among the trans-Pd(II) phenyl-1,2,3-triazolyl complexes, only T8a showed some anti-cancer activity 
at the concentration tested. It should be noted that since the trans-Pd(II) phenyl-1,2,3-triazolyl 
complexes dissociate in DMSO, it is suspected that what was being tested is a mixture of ligand, 
complex and various, thus far unidentified, Pd-species present in solution. 
The inactivity of the trans-Pd(II) phenyl-1,2,3-triazolyl complexes could possibly be explained by the 
dissociation of the complex in solution. As mentioned in Chapter 1, the main hypothesis for the 
inactivity for most Pd-compounds is their faster hydrolysis rates (105 times faster than for Pt).10 This 
can be overcome with strongly binding ligands. Since the trans-Pd(II) complexes described in this 
thesis appears to readily dissociate in DMSO, even before cell treatment takes place, the percentage 
of the original complex that might ultimately reach the cellular target is so small that, even if it is 
cytotoxic, the concentration is below detectable limits. 
Interestingly, the N,N’-bidentate Pd(II) pyridyl-1,2,3-triazolyl complexes were also inactive. This is 
slightly surprizing since analogous pyridine triazole complexes reported by Trivedi and colleagues.11 
showed reasonable activity. These complexes however have carbohydrate moieties incorporated 
into their ligand scaffolds and these play a role in cellular uptake. 
 





Table 4.3: A summary of the MTT Assay results obtained for the trans-Pd(II) and N,N'-bidentate Pd(II) complexes. 





Cyclohexyl T2a Inactive Inactive 
Ethanol T3a Inactive Inactive 
2-ethoxy ethanol T4a Inactive Inactive 
2-ethoxy-ethoxy-ethanol T5a Inactive Inactive 
Hexanol T6a Inactive Inactive 
Phenyl T7a Inactive Inactive 
2,6-dimethyl phenyl T8a 40.7 ± 1.1 Inactive 
4-nitrophenyl T9a Inactive Inactive 
Octyl N1b Inactive Inactive 
Cyclohexyl N2b Inactive Inactive 
Ethanol N3b Inactive Inactive 
2-ethoxy ethanol N4b Inactive Inactive 
2-ethoxy-ethoxy-ethanol N5b Inactive Inactive 
Hexanol N6b Inactive Inactive 
Phenyl N7b Inactive Inactive 
2,6-dimethyl phenyl N8b Inactive Inactive 
4-nitrophenyl N9b Inactive Inactive 
Cisplatin 19.6 ± 4.3
c 43.5 ± 3.0d 
a IC50: Concentration at which 50 % cell growth is inhibited 
b No growth inhibition observed at the maximum concentration tested (20 µM) 
c From Trávníček et al.12 
d From Canada et al.13 
It was then decided to evaluate the cytotoxicity of the ligands in order to see whether the free ligand 
itself has any anti-cancer activity. The results of the MTT Assays conducted with the ligands are 
summarized in Table 4.4. Since the complexes did not show any activity against MDA-MB-231, it 
was decided that the cytotoxicity of the ligands would only be evaluated against MCF-7, and should 
they show activity against the less aggressive MCF-7 cell line, only then would they be evaluated 
against MDA-MB-231. 
Owing to time-constraints, 9a and 8b were not evaluated for their cytotoxicity, but it was interesting 
to note that among the phenyl-1,2,3-triazole ligands there were some active compounds, while the 
pyridine analogues were completely inactive. This could possibly indicate that the phenyl ring in that 
position plays a role in the mode of cytotoxicity that cannot be replicated by the pyridine moiety. 
 
  











Octyl 1a 80.0 ± 1.2 Inactiveb 
Cyclohexyl 2a 33.3 ± 1.3 Inactive 
Ethanol 3a 24.5 ± 1.1 Inactive 
2-(2-ethoxy) ethanol 4a 65.2 ± 2.5 Inactive 
2-(2-(2-ethoxy) ethoxy) ethanol 5a Inactive -c 
Hexanol 6a Inactive - 
Phenyl 7a 13.0 ± 1.2 Cytotoxicf 
2,6-dimethyl phenyl 8a Inactive - 
4-nitrophenyl 9a - - 
Octyl 1b Inactive - 
Cyclohexyl 2b Inactive - 
Ethanol 3b Inactive - 
2-(2-ethoxy) ethanol 4b Inactive - 
2-(2-(2-ethoxy) ethoxy) ethanol 5b Inactive - 
Hexanol 6b Inactive - 
Phenyl 7b Inactive - 
2,6-dimethyl phenyl 8b - - 
4-nitrophenyl 9b Inactive - 
Cisplatin 19.6±4.3
d 43.5 ± 3.0e 
a IC50: Concentration at which 50 % cell growth is inhibited 
b No growth inhibition observed at the maximum concentration tested (20 µM) 
c Not tested 
d From Trávníček et al.12 
e From Canada et al.13 
f Cytotoxicity observed is not concentration dependent. 
When the compounds are arranged in order of decreasing cytotoxicity (Figure 4.2), it becomes more 
apparent that there is a structure-activity-relationship. 
 
Figure 4.2: The structures of the active ligands arranged in order of decreasing cytotoxicity. 
Since ligand 7a has the more planar structure due to the presence of a phenyl ring on each side of 
the 1,2,3-triazole ring, it was expected that the compound could perhaps intercalate with the DNA, 
thus preventing cell replication from taking place. Compounds 1a – 4a have only one aromatic ring 
compared to 7a. This is expected to reduce the possibility of these species from being DNA 





intercalators. It would appear that the flexibility of the N-bound substituent is playing a role in the 
cytotoxicity. 7a, whilst having the least flexible N-bound substituent, is the more active, and 1a, with 
the most flexible N-bound substituent, is the least active. 3a, 2a and 4a have similarly flexible N-
bound substituents and display higher IC50 values. The exact reason for the difference of activity is 
not clear and thus would require further investigation. From the results it is also clear that those 
complexes with highly flexible substituents are less active, showing higher IC50 values. 
It was also interesting to note that the ligand 8a does not show any cytotoxicity while its trans-Pd(II) 
complex T8a does show some activity. Since T8a dissociates in solution and the ligand itself is not 
active, it can be concluded that the activity could potentially be attributed to the small amount of 
intact complex present in solution or by any one of the other Pd-species present. 
It was however concerning to see that 7a has concentration independent cytotoxicity for the MDA-
MB-231 cell line. This could potentially indicate that the compound is not genotoxic enough in order 
to bring about cell death, but rather only supresses cell growth. This however requires further 
investigations. 
It was then decided to investigate the type of interaction the active compounds have with DNA by 
means of horizontal agarose gel electrophoresis and UV-Vis DNA titration studies. 
4.2.3 DNA binding studies 
The anti-cancer activity of most chemotherapeutic compounds can often be attributed to the direct 
interaction of the compound with DNA. This interaction usually results in the prevention of mitosis 
and ultimately leads to cell death.6,14 Cisplatin’s activity can be attributed to the fact that it cross-links 
DNA strands by preferentially binding to the guanine and cytosine base pairs.15–17 
Compounds can interact with DNA covalently or non-covalently. Among the non-covalent 
interactions there are three distinct ways in which compounds can interact with the DNA (Figure 4.3): 
1. Intercalation during which the compound enters the DNA helix and, through 𝜋-stacking 
interactions, positions itself between the base pairs. 
2. Groove binding during which the compound aligns itself in either the major or minor groove 
of the DNA helix through weak electrostatic interactions caused by hydrogen bonding. 
3. Electrostatic interaction whereby a positively charged compound interacts with the negatively 
charged phosphate backbone of the DNA.6 
In general, non-covalent interactions are preferred clinically since covalent interactions are 
irreversible, leading to an increase in toxicity due to non-selectivity and the appearance of 
secondary growths.18  
Drug-DNA interactions can be investigated with a variety of analytical techniques, including 
agarose gel electrophoresis, UV-Vis spectroscopy, circular dichroism, fluorescence 





spectroscopy, enzymatic assays and viscometry.6,14 These techniques are all sensitive to buffer 
composition, pH and temperature, and thus it is advised that direct comparisons are made.14 
 
 
Figure 4.3: The various modes of non-covalent DNA-drug interactions.b 
No single method can be used to unambiguously determine the DNA binding mode of the test 
compound and thus, for the purposes of this thesis, horizontal agarose gel electrophoresis and UV-
Vis spectroscopy were used to investigate the DNA binding modes of the compounds that displayed 
cytotoxicity in the MTT Assays. 
4.2.3.1 DNA migration study: Horizontal agarose gel electrophoresis 
The use of gel electrophoresis in the determination of DNA-drug interactions has gained increasing 
popularity in recent years.19–23  
Bacterial plasmids separate into two distinct bands in an electrical field. The first is the open circular 
(OC) band which has the lower electrophoretic mobility (thus appears near the top of the gel) and 
the second is the supercoiled closed circular (CCC) band, which has the higher electrophoretic 
mobility of the two bands (appears below the OC band). In some cases, a third band is observed 
between the OC and CCC bands, which is attributed to the linear plasmid DNA (L). Changes in the 
electrophoretic mobilities of the plasmid bands in the presence of the test compounds indicate 
                                               
b DNA structure template obtained from http://www.scienceclarified.com/scitech/Genetics/Genes-and-DNA.html 





interaction of the compounds with the DNA. DNA damage can also be assessed by a 
decrease/increase in a band’s intensity or in the extent of streaking of the bands through the gel.24,6 
This is a simple, robust method used to investigate preliminary DNA interactions, but the 
interpretation could be ambiguous in cases where more than one type of binding mode is observed.6 
However, by comparing the changes observed to those of known control compounds in the same 
system, an approximate idea of the DNA interaction mode can be obtained. 
A recent example of the use of horizontal gel electrophoresis in the characterization of DNA-drug 
interactions was published by Albert el al.24 
 
Figure 4.4: The horizontal gel electrophoresis of the palladacycles investigated by Albert et al.24 with pBluescript 
DNA using cisplatin and ethidium bromide (EB) as control compounds. Lane 1 of each gel shown does not contain 
test compound. Lanes 2 – 9 show increases in the concentration of the compound while the DNA loading remains 
constant.24 
From Figure 4.4 it is observed that neither palladacycle A nor B have the same effect as that of 
cisplatin on DNA. It is thus possible to concluded that the palladacycles are not cross-linking the 
DNA. Ethidium bromide, as a known intercalator, shows a slight decrease in the electrophoretic 
mobility of both the OC and the CCC band. The same trend is observed for A and, to a lesser extent, 
B, along with a general increase in streaking with an increase in concentration. It can thus be 
concluded from these gels that A and B could possibly be intercalators but that they are also 
contributing to indiscriminate DNA damage, as observed from the increase in band streaking.24 
A similar study was thus performed with the compounds prepared in the current work that displayed 
some cytotoxicity, namely 1a – 4a, 7a and T8a. The agarose gels were stained with ethidium bromide 
for visualization purposes after electrophoresis had taken place, in order to prevent competitive 
binding. Figure 4.5 shows the image obtained of the pBluescript migration study in the presence of 
ethidium bromide (EtBr), 7a, 2a, 4a and 3a. 






Figure 4.5: The photos obtained from the horizontal agarose gel electrophoresis of pBluescript (40 ug/mL), with 
(A) showing different concentrations of EtBr and compounds 7a, 2a, 4a and 3a as indicated and (B) with cisplatin, 
methylene blue, methyl green and compounds T8a and 1a. Each compound was investigated at three different 
concentrations, 10 µM (Lane 1), 100 µM (Lane 2) and 200 µM (Lane 3) as shown. 
From Figure 4.5A and Figure 4.5B, it can be seen that the DMSO has a limited influence on the DNA 
itself, causing a slight retardation in all three DNA bands. Since all the compound were prepared in 
DMSO-containing stock solutions, the resulting DNA interactions were analysed in reference to the 
DNA + DMSO band. Ethidium bromide was used as a classical intercalator control compound25, and 
causes retardation of all three plasmid bands. A decrease in the intensity of the CCC and L bands 
in the favour of the OC band is observed with an increase in concentration. A decrease in the 
intensity of the CCC band is due to DNA unwinding into the larger OC form, indicating that 
intercalation has taken place. 
None of the ligands investigated in Figure 4.5A altered the DNA migration as drastically as ethidium 
bromide, possibly indicating that the ligands have a lower affinity towards DNA than ethidium 





bromide. All the ligands cause a slight retardation in all three plasmid DNA bands and exhibit higher 
concentrations of L DNA than present in the control, indicating that the ligands could possibly cause 
double stranded DNA breaks.6  
7a and 4a display concentration dependent reduction in the amount of the CCC form and an increase 
in band smearing, indicating a fair amount of DNA degradation at higher concentrations. At higher 
concentrations, 4a has more of the CCC form than 7a, which could indicate the CCC band uncoils 
to the OC form at lower concentrations and recoils at higher concentrations. The uncoiling and 
recoiling of CCC DNA is usually attributed to the transition between negative supercoiled DNA 
(CCC-) and positive supercoiled DNA (CCC+).24,26 Due to the excessive smearing observed for 4a, 
it is not possible to definitively attribute the increase in the CCC form to the transition between CCC- 
and CCC+ forms. This could further be investigated by performing an unwinding experiment, in which 
the compound is incubated in the presence of CCC- alone and the formation of the OC band is 
monitored. 
 Ligands 2a and 3a do not entirely eradicate the CCC band, but a lower intensity of the CCC band 
with an increase in the OC band intensity indicates that the supercoiled DNA unwinds to the more 
relaxed OC form. The same trend is observed for ligand 1a in Figure 4.5B. 
In Figure 4.5B, cisplatin and methyl green (MG) were included as controls for intra-strand 
crosslinking27 and major groove binding,28 respectively. The DNA binding mechanism for methylene 
blue (MB) is under some debate, with some studies indicating semi-intercalative binding29 while 
others conclude that minor groove binding is observed.30 The current consensus is that methylene 
blue displays multimode binding, including intercalation and minor groove binding depending on the 
nucleotide sequence.31  
Cisplatin causes concentration dependent retardation of both the OC and CCC bands, along with 
slight increase in the electrophoretic mobility of the L band. With an increase in concentration, the 
CCC band becomes less intense in favour of precipitation in the wells, indicating the formation of 
high molecular weight aggregates forming due to intra-strand crosslinking.32 
MB also shows high molecular weight aggregates in the wells, possibly indicating the that DNA has 
been saturated with compound. A concentration dependent increase in electrophoretic mobility is 
observed for the OC band while the opposite is observed for the L band. At the highest concentration, 
200 µM, the CCC band has completely disappeared in favour of precipitation in the wells. 
The trends observed for MG are similar to that of MB but less intense. Smearing of the DNA is 
observed at higher concentrations indicating severe DNA damage. 
T8a behaves similarly to cisplatin, causing concentration dependent retardation of the OC and the 
CCC bands, while the electrophoretic mobility of the L band increases. Coalescence of the L and 
CCC bands are observed with a reversal of retardation observed for the coalesced band at 200 µM. 





Similar behaviour has been discussed in literature and is attributed to counter-twisting of the 
negatively supercoiled DNA to the positively supercoiled DNA.33 
From the DNA migration studies it can thus be concluded that ligands 1a - 4a and 7a show similar 
behaviour to that observed for EtBr, but to a lesser extent, thus possibly indicating that the ligands 
are weak intercalators or have weak electronic interactions with the DNA. T8a shows behaviour 
similar to that of cisplatin, thus indicating a cross-linking mode of action. It should be noted that T8a 
dissociates in solution and that it is a mixture of species responsible for the DNA interaction 
observed, and not the discrete complex alone, as discussed in Chapter 3. 
4.2.3.2 UV-Vis DNA binding study: Electronic absorption titration 
Electronic absorption spectroscopy is the most common method utilized for the investigation of drug-
DNA interactions. Practically, there are a number of methods that can be used to investigate the 
DNA-drug interactions. The DNA concentration can be kept constant and increasing amounts of 
compound can be added, thus the effect on the DNA spectrum is monitored.34 Alternatively, the 
compound concentration can be kept constant and increasing amounts of DNA can be added, thus 
monitoring the effect on the compound spectrum.20,23,35 These methods are known as electronic 
absorption titration experiments. 
Changes observed in the absorbance spectrum corresponds to certain types of drug-DNA 
interactions. Intercalation results in hypochromism in the absorbance spectrum, due to the coupling 
of the 𝜋∗-orbitals of the ligand and the 𝜋-orbitals of the base pairs, resulting in a decreased 𝜋 − 𝜋∗ 
transition energy.36 Intercalation can also result in bathochromism in some cases, which is attributed 
to a decrease in the energy gap between the HOMO and LUMO molecular orbitals after binding of 
the compound to the DNA.37 
Electrostatic and groove binding interactions both result in hyperchromism. This is considered to be 
due to the change that these interactions cause in the DNA structure. The partial unwinding of the 
DNA or distortion of the helix, results in the destabilization of the stacking interaction of the base 
pairs, resulting in an increase of absorbance.37,38 
The method used in this study is based on that published by Yang et al.39 in which aliquots of DNA 
are added to both the reference cell (containing the buffer solution) and the sample cell (containing 
a fixed concentration of compound). This results in the observation of changes in the compound 
spectrum alone, from which the binding constant can be calculated. 
The intrinsic binding constants, Kb, were calculated, where possible, by the model developed by 
Wolfe et al.40 
The Wolfe-model originates from the Benesi-Hildebrand method41, which was developed to describe 
host-guest interactions. This model assumes that the UV-Vis absorbance of the compound tested 
and its resulting, or apparent spectrum, upon DNA addition, obeys the Beer-Lambert Law. It also 





assumes that if reagent A (compound) is in great excess to reagent B (DNA), the absorption 
spectrum of reagent B will be negligible.41 Thus, by measuring the absorption spectra of the reaction 
before and after the formation of the product, the association constant of the reaction can be 
determined. The method unfortunately results in systematic deviations depending on the chosen 










Where [𝐷𝑁𝐴] denotes the DNA concentration in base pairs and 𝐾𝑏 represents the binding coefficient 
to be calculated. ∆𝐴 is the difference between the absorbance of two titrations, 𝐶𝑇 is the compound 
concentration, ∆𝜀 the difference in the extinction coefficient between two titrations and 𝑙 represents 
the path length of the sample. 
Schmechel and Crothers43 modified the Benisi-Hildebrand method in order to address the 
concentration scale problem. This was done by rearranging Equation 4.1 to use the extinction 
coefficients rather than the absorbance units. From each titration compound absorbance obtained, 
from which the extinction coefficient can be calculated. The difference between the extinction 
coefficient of the free compound and that of the spectrum obtained from the interaction of the 
compound with DNA, serves as an indication of the degree of drug-DNA interaction. The binding 
constant can be determined from a double-reciprocal plotc of the apparent extinction coefficient of 










Where 𝜀𝑎 denotes the apparent extinction coefficient, 𝜀𝑓 the free compound extinction coefficient and 
𝜀𝑏 the fully bound extinction coefficient. However, the double reciprocal plot is biased towards data 
points obtained at low DNA concentrations.42  
In order to correct for this, Wolfe et al.40 rearranged the double reciprocal plot to a half-reciprocald 
form. This was done by multiplying Equation 4.2 with the concentration of DNA,40 as shown by 
Equation 4.3. In this form, the binding constant can be easily calculated from the y-intercept equal 










                                               
c A double reciprocal plot refers to any plot in which the reciprocal of the dependent variable (in this case the 
change in extinction coefficients) is plotted against the reciprocal of the independent variable (the concentration 
of DNA). This method is generally employed in enzyme kinetics.42 
d A half-reciprocal plot is obtained from a double reciprocal plot when the independent variable is multiplied 
throughout and is no longer a reciprocal. 
(4.3) 
(4.2) 





This model is however not suited for compounds with more than one binding mode, in which case a 
linear relationship is not obtained and the binding constant cannot be calculated. The Wolfe-model 
is the prevalent method used to interpret electronic absorption titrations.44,19,45 
It should also be noted that if the compound displays multi-mode binding, the fit of the model to the 
experimental data will not be good. The Wolfe-model was designed to evaluate any interaction 
between a host (DNA) and a guest (compound), but not classify the type of interaction. The type of 
interaction is determined by comparing the binding constant calculated to that of a known binder, 
such of ethidium bromide (Kb = 1.3 × 106 M-1).29 
As an example, the study by Icsel et al.22 (Figure 4.6) followed the same assay and kinetic analysis 
and concluded that the binding constant is lower than that of the classical intercalators such as 
ethidium bromide, indicating the complex is probably not an intercalator. When combined with the 
information obtained from the other drug-DNA investigations, they concluded that the complex 
probably forms covalent bonds to the DNA, similar to that observed for cisplatin.22 
 
 
Figure 4.6: The UV-Vis spectra obtained by Icsel et al.22 for the absorption titration performed with trans-[PtCl2(2-
hepy)2] with increasing amounts of FS-DNA (fish sperm DNA). The arrow indicates the general change in 
absorption upon DNA addition and the inset shows the [𝑫𝑵𝑨] |𝜺𝒂 − 𝜺𝒇|⁄  vs [𝑫𝑵𝑨] plot, from which the Kb value 
was obtained, as indicated. 
The electronic absorption titrations were conducted at 25 °C rather than 37 °C. This is due to the 
fact that accelerated DNA denaturation was observed at 37 °C in the absence of the compounds 
investigated. The data was also corrected for the small dilution effect that is inherent in this assay, 
as is described in Section 4.4.4.2. 





The titration spectra of ligand 2a are shown in Figure 4.7, with the inset depicting the kinetic analysis 
of the Wolfe-model. Hypochromism is observed, as opposed to the hyperchromism which is 
observed for the example in Figure 4.6. The UV-Vis spectrum of the ligand alone shows two local 
absorption maxima at 307 nm and 327.5 nm respectively, as well as a shoulder around 247 nm. With 
an increase in the DNA concentration, a hypochromic shift is observed throughout the spectrum. 
The kinetic analysis was done with the absorbance at 327.5 nm. The binding constant determined 
(Kb = 0.06 × 106 M-1) is smaller than that of ethidium bromide (Kb = 1.3 × 106 M-1)29, indicating that 
the compound has a lower affinity for DNA than ethidium bromide and can be described as a weak 
intercalator. Similarly, ligand 3a showed hypochromism with an increase in the DNA concentration. 
Thus indicating an intercalative interaction, as shown in  
Figure 4.8. As evidenced by the kinetic plot inserted, the Wolfe-model does not fit this compound, 
as there are systematic errors in the data. This might suggest that multi-mode binding is taking place.  
 
Figure 4.7: The spectra obtained for the titration of 20 µM 2a with increasing amounts of 0.47 mM salmon sperm 
DNA. The arrows indicate the general change in absorption upon the addition of DNA. The inset shows the 
[𝑫𝑵𝑨] |𝜺𝒂 − 𝜺𝒇|⁄  vs [𝑫𝑵𝑨] plot, from which the Kb value was obtained, as indicated. The dotted line represents the 
spectrum of 2a in the absence for DNA. 
 






Figure 4.8: The spectra obtained for the titration of 20 µM 3a with increasing amounts of 0.47 mM salmon sperm 
DNA. The arrow indicates the general change in die absorption upon DNA addition. The inset shows the 
[𝑫𝑵𝑨] |𝜺𝒂 − 𝜺𝒇|⁄  vs [𝑫𝑵𝑨] plot. The dotted line shows the spectrum of 3a in the absence for DNA. 
It was interesting to note that 4a, while being less cytotoxic than both 2a and 3a, shows a higher 
affinity for DNA than 2a, displaying a binding constant of Kb = 4.35 × 106 M-1 (Figure 4.9). It should 
however be noted that there are slight systematic deviations in the kinetic plot for 4a, but the model 
fit is still acceptable. The Kb value is thus just an approximate indication of DNA affinity. 
The DNA titration of 1a resulted in the most drastic hypochromism observed for all the compounds 
investigated, as shown in Figure 4.10. This agrees with the higher binding constant (Kb = 6.39 × 106 
M-1) obtained for the ligand, despite the fact that the compound shower the weakest cytotoxicity 
among the ligands. There is also an isobestic point observed at 270 nm. This usually indicates that 
there are two different species in solution that are at equilibrium with one another.46 These species 
could be due to more than one binding site that is being occupied or a combination of bound and 
free species in solution, but more information is required. 
From the ligands discussed thus far it can be concluded that they display intercalative properties, as 
indicated by the binding constants obtained for some of the ligands, the hypochromism observed in 
the DNA titration studies and the results of the DNA migration studies. The other two compounds 
investigated, 7a and T8a, yielded unexpected results.  
The titration spectrum for T8a is shown in Figure 4.11. It was interesting to note that despite the 
significant effect the complex had on the plasmid DNA in the DNA migration study (Figure 4.5B), it 
displayed no significant hypochromism upon the addition of DNA. 
 






Figure 4.9: The spectra obtained for the titration of 20 µM 4a with increasing amounts of 0.47 mM salmon sperm 
DNA. The arrow indicates the general change in die absorption upon DNA addition. The insets show the 
[𝑫𝑵𝑨] |𝜺𝒂 − 𝜺𝒇|⁄  vs [𝑫𝑵𝑨] plot, from which the Kb value was obtained, as indicated. The dotted line shows the 
spectrum of 4a in the absence for DNA. 
 
Figure 4.10: The spectra obtained for the titration of 20 µM 1a with increasing amounts of 0.47 mM salmon sperm 
DNA. The arrow indicates the general change in die absorption upon DNA addition. The insets show the 
[𝑫𝑵𝑨] |𝜺𝒂 − 𝜺𝒇|⁄  vs [𝑫𝑵𝑨] plot, from which the Kb value was obtained, as indicated. The dotted line shows the 
spectrum of 1a in the absence for DNA. 
 






Figure 4.11: The spectra obtained for the titration of 20 µM T8a with increasing amounts of 0.47 mM salmon sperm 
DNA. The dotted line shows the spectrum of T8a in the absence for DNA. 
The lack of hypochromism was surprising considering the extent of DNA alteration observed in the 
DNA migration study. The lack of interaction prevented the calculation of a binding constant for T8a. 
However, it should be noted that the DNA migration study uses pBluescript plasmid DNA and the 
samples are incubated for 24 hours, while the DNA titration uses salmon sperm DNA and incubates 
for 5 minutes after each DNA addition. 
In order to evaluate the effect of the incubation time, 20 µM T8a was incubated with 20 µL salmon 
sperm DNA (0.47 mM) over 22 hours at 25 °C, with an absorbance spectrum collected every hour. 
The resulting spectra are shown in Figure 4.12. 






Figure 4.12: The spectra obtained for the interaction of 20 µM T8a with 20 µL 0.47 mM salmon sperm DNA over 22 
hours. The arrows indicate the general trend of the complex spectrum. 
Slight hypochromism was observed for the first 9 hours of incubation and slight hyperchromism for 
the final 11 hours of incubation. Hyperchromism is generally an indication of DNA denaturation or 
weak electronic interactions, but the changes in the spectrum are so small that the results can be 
deemed insignificant. Thus indicating that the incubation time is not the determining factor. 
The DNA migration study indicated that T8a binds DNA in a similar fashion to cisplatin, thus it would 
appear that T8a binds covalently to DNA. The lack of activity in the titration study can thus potentially 
be explained by the difference in DNA sources between the DNA migration and DNA titration studies. 
DNA migration studies are used to observe how the compound affects the tertiary structure of DNA6, 
i.e. how the double helix shapes itself. In order to visualize this, plasmid DNA is used as it separates 
into three distinct forms that can easily be distinguished from one another. Thus, any changes in the 
DNA structure are readily visualized. 
DNA titration investigations use linear DNA sources, such as salmon sperm DNA or calf thymus 
DNA.6 Since these DNA sources have only linear DNA strands in solution, they do not produce 
distinct bands in DNA migration studies, but rather one large smeared band, and are thus unsuitable 
for tertiary structure evaluations. They are however better suited towards the observation of 
secondary structure changes, such as those investigated in DNA titration studies, due to the fact that 
there is only one form (linear) in solution and that any changes observed in the absorbance spectrum 
would be due to changes in the secondary structure and not the tertiary structure. 





Cisplatin binds preferentially to guanine and cytosine base pairs15, thus it can be reasoned that if 
T8a displays similar behaviour to cisplatin, it might also display the same preferential binding 
character. The DNA migration studies are performed with pBluescript DNA, which consists of 50 % 
G + C base pairs, while salmon sperm DNA consists of 41 % G + C base pairs. Thus, should T8a 
display the same preferential binding character as cisplatin, it would thus bind more readily to the 
pBluescript DNA than to the salmon sperm DNA, allowing for greater DNA interaction in the migration 
study than in the titration study.  
Additionally, the DNA migration study allows for the evaluation of high compound concentrations. 
The electronic absorption study does not, due to the absorbance limit on the instrument. The 
differences in concentration might also explain the increased DNA interaction observed for T8a in 
the DNA migration study. 
Ligand 7a showed hypochromism upon DNA addition, but unlike the other compounds investigated, 
it did not reach saturation within 10 additions of DNA, but only after 30 additions (Figure 4.13). It was 
interesting to observe that at high DNA concentrations the hypochromic shift trend reversed, as 
indicated by the red arrow and spectra, and a slight bathochromic shift (red shift) is observed from 
252 nm to 258 nm, before the spectrum stabilizes. To the best of our knowledge, this has not been 
observed in the literature. This could potentially be attributed to DNA denaturation taking place in 
the sample cell. Denaturation is also observed in the DNA migration study for ligand 7a (Figure 4.5A). 
The absorbance at 252 nm was used for the kinetic investigations. Analysis according to the Wolfe-
model did not yield a straight line and thus the binding constant could not be calculated. This is 
possibly an indication of multi-mode binding, but would require further investigation. 






Figure 4.13: The spectra obtained for the titration of 20 µM 7a with increasing amounts of 0.47 mM salmon sperm 
DNA. The arrow indicates the general change in die absorption upon DNA addition. The dotted line shows the 
spectrum of 7a in the absence for DNA. 
Ligand 7a was the most cytotoxic compound among those tested, displaying cytotoxicity against the 
MCF-7 cell line comparable to that of cisplatin. It was thus interesting to note that the DNA binding 
studies conducted on 7a indicated that the ligand displayed a strong tendency towards multi-mode 
binding, while none of the other ligands displayed multi-mode binding character. Whether the 
increase in cytotoxicity can be attributed to the differences of the binding modes of the ligands 
investigated is unclear, but it may well be a contributing factor.  
Without a binding constant it is difficult to evaluate the DNA binding abilities of 7a and 3a, but 
percentage hypochromism (%H) can give a qualitative indication as to the DNA interaction. 
Percentage hypochromism is calculated according to Equation 4.2.47 
% 𝐻 =  (
𝐴𝑓𝑟𝑒𝑒 − 𝐴𝑏𝑜𝑢𝑛𝑑
𝐴𝑓𝑟𝑒𝑒
) × 100 
Where 𝐴𝑓𝑟𝑒𝑒 represents the absorbance of the ligand in the absence of DNA, and 𝐴𝑏𝑜𝑢𝑛𝑑 represents 
the absorbance of the fully bound ligand. 
Table 4.5 shows the resulting binding constants and percentage hypochromism obtained for the 
compounds investigated. 
(4.2) 





Table 4.5: A summary of the kinetic information obtained as compared to the MTT Assay results. 
 Functionality λ (nm) % H Kb × 106 (M-1) IC50 (µM)b 
1a Octyl 250 65.0 6.39 (± 2.81) 80.0 (± 1.2) 
2a Cyclohexyl 327.5 55.8 0.06 (± 0.01) 33.3 (± 1.3) 
3a Ethanol 243 5.46 -a 24.5 (± 1.1) 
4a 2-(2-ethoxy) ethanol 244 9.88 4.35 (± 1.28) 65.2 (± 2.5) 
7a Phenyl 252 50.5 -a 13.0 (± 1.2) 
a Could not be determined with Wolfe-Model kinetics 
b IC50 values evaluated against MCF-7 cancer cell lines. 
As expected, the higher the percentage hypochromism, the greater the binding constant obtained, 
however, the cytotoxicity does not agree with the expected trend. The greater the binding constant, 
the larger the IC50 value obtained, which indicates that the affinity of the ligand towards the DNA 
does not affect the cytotoxicity of the compound. It is thus possible that the DNA might not be the 
primary pharmacological target of the ligands.  
This is not unexpected as DNA is the main target for metal containing compounds, but organic 
compounds tend to interact more with proteins and other metabolites, as discussed in Chapter 1. 
Ligand 7a displays a high percentage hypochromism but a low IC50 concentration, thus differing from 
the other ligands evaluated. This might indicate that the multi-mode binding character of the ligand 
enables it to influence the DNA to a greater extent than the other ligands, ultimately leading to a 
higher cytotoxicity. 
4.3 Conclusion 
The complexes synthesized were subjected to a turbidimetric assay in order to determine their kinetic 
solubility, and it was found that the majority of the palladium complexes investigated show moderate 
solubility in a 2 % DMSO/PBS buffer solution.  
The cytotoxicity of the complexes was evaluated against two breast adenocarcinoma cell lines, MCF-
7 and MDA-MB-231. Only one complex, T8a, displayed moderate anti-cancer activity. Subsequently, 
the ligands were evaluated against MCF-7 and 1a, 2a, 3a, 4a and 7a displayed good to moderate 
anti-cancer activities. A structure-activity relationship was established in favour of the least flexible 
N-bound substituents. 
The DNA binding modes of the active compounds were investigated with two methods, a DNA 
migration study utilizing horizontal gel electrophoresis and a UV-Vis absorbance DNA titration. 
Ligands 1a, 2a, 3a and 4a displayed intercalative character and T8a displayed covalent binding in 
the DNA migration study. Ligand 7a could not be evaluated with the chosen kinetic model, but 
displayed some multi-mode binding character.  





The affinity of the ligands to the DNA did not reflect the IC50 concentrations obtained, thus indicating 
that the main target of these ligands might not be DNA, and thus warrants further investigation. 
It is also necessary to concede that the Wolfe-model is not suitable to describe the interaction of 
these ligands with DNA as evidenced by the ill-fitting R2-values obtained. When combined with the 
data obtained from the DNA migration study, it would appear that ligands 1a – 4a are weak 
intercalators, but additional information is required. It is suggested that a competitive DNA-EtBr 
florescence study be conducted for additional kinetic data. 
4.4 Experimental Procedures 
4.4.1 General Methods and Materials 
All starting materials used were obtained from Merck and Sigma-Aldrich and used without additional 
purification. Solvents used were obtained from Merck, Protea Chemicals, Kimix and Sigma-Aldrich 
and purified accordingly. THF, DCM, hexane, and diethyl ether were purified and degassed with 
PureSolv Micro purifiers. Acetonitrile, methanol and ethanol were distilled over the appropriate drying 
agents. Acetonitrile was distilled over phosphorous pentoxide and both methanol and ethanol were 
distilled over magnesium filings and iodine. The turbidimetric assay was performed in 96-well 
microplates and the absorbance measured on a Thermo Fisher Multiskan GO UV-Vis plate reader. 
MTT Assays were performed at the Department of Human Biology, UCT Medical School. DMEM 
medium and RPMI 1640 was purchased from Highveld Biological, UK. The MTT assay was 
performed according to the manufacturer’s instructions accompanying the MTT Assay Kit, obtained 
from Roche, USA. The IC50 values were calculated by fitting a variable slope curve to the data 
obtained, using GraphPad Prism 7 software. 
Overnight cultures of pBluescript E. coli was obtained from the Department of Microbiology, 
Stellenbosch University. The plasmid was isolated with a Zippy Plasmid Isolation Miniprep kit 
obtained from Inqaba Biotech and the concentration determined with a Thermo Fisher Scientific 
Nanodrop spectrophotometer. The agarose gels were viewed with a UV lamp at 254 nm and the 
photos obtained with a Sony Xperia M4 aqua camera in ISO mode. Images were processed with 
Image J freeware. 
UV-Vis DNA binding studies were performed with Invitrogen salmon sperm DNA solution (10 mg/mL) 
obtained from Life biotechnologies. All buffers used were prepared with a Metrohm 744 pH meter. 
UV-Vis investigations were performed on a Shimadzu UV-1800 UV spectrophotometer equipped 
with a CPS cell positioner and temperature control attachment. Binding constants were calculated 
with Origin Pro 8.5. 





4.4.2 Turbidimetric Assay 
The protocol for the turbidimetric assay has been published previously48 and was adapted slightly 
by using duplicate plates for the assessment of solubility at different temperatures. A 0.01 M pH 7.4 
Phosphate Buffered Saline (PBS) solution was prepared by dissolving one PBS tablet, obtained from 
Sigma-Aldrich, in 200 mL distilled water at 25 °C in order to yield a buffered solution containing 0.01 
M phosphate buffer, 0.003 M KCl and 0.14 M NaCl. The solution was allowed to equilibrate at 25 °C 
for one hour upon which the pH was confirmed with a pH meter. The solution was then filtered 
through a 0.45 µM Nylon syringe filter in order to remove any undissolved particulates. 
A 10 mM stock solution in DMSO of each test compound was prepared and filtered through a 0.45 
µM PVDF syringe filter prior to use. A preparation plate (96-well flat bottomed) was prepared by 
serially diluting the compound in order to achieve the desired concentrations (5.0 µM to 200 µM). 
The test plate was prepared by pipetting 196 µL DMSO into wells 1 – 6 and 196 µL PBS into wells 
7 – 12. Each compound was tested in triplicate thus a single plate could be used to evaluate two 
compounds. 4 µL of each compound concentration was pipetted from the preparation plate into the 
test plate in order to bring the total volume up to 200 µL and to ensure that a 2 % (v/v) DMSO/PBS 
solution is achieved. 
Test plates were prepared in duplicate and one plate was incubated at room temperature (25 °C) 
and the second at physiological temperature (37 °C). Both test plates were incubated for 2 hours 
upon which the UV-Vis absorbance readings were measured at 620 nm. The corrected absorbance 
readings were obtained by subtracting the blank readings from each concentration absorbance. 
4.4.3 MTT Assay 
MDF-7 oestrogen positive breast cancer cells were maintained in RPMI 1640 medium, and MDA-
MB-231 triple negative metastatic breast cancer cells were maintained in DMEM medium. Both 
media were supplemented with 10 % FBS, 100 U/mL penicillin and 100 µg/mL streptomycin. The 
cells were maintained at 37 °C in a 5 % CO2/air humidified incubator. 
Stock solutions of each compound were made by dissolving the compound in 100 % DMSO to yield 
a stock solution of 5 mM, and stored at room temperature for no more than seven days. Cells were 
seeded into 96-well microplates at 5000 cells/well for MCF-7 and 5500 cells/well for MDA-MB-231 
and allowed to settle for 48 hours. The cells were treated for 48 hours with a range of compound 
concentrations (5, 10,15 and 20 µM) and a blank vehicle test. 
Cytotoxicity was assessed with the addition of 10 µL MTT to each well followed by incubation at 37 
°C for 4 hours. After incubation, 100 µL of solubilizer (10 % SDS, 0.01 HCl) was added followed by 
overnight incubation at 37 °C. Cell viability was monitored using UV-Vis spectroscopy at 585 nm and 
calculated as a percentage of the mean vehicle control. 





4.4.4 DNA binding 
4.4.4.1 Horizontal gel electrophoresis 
Samples were prepared by combining pBluescript DNA (40 µg/mL, 10 µL) with compound stock 
solution in DMSO (34, 340 and 680 µM, 5 µl) in order to obtain samples with final concentrations of 
10, 100 and 200 µM (total volume 15 µL). The samples were incubated at 25 °C for 24 hours.  
An agarose gel was prepared by dissolving 0.8 g agarose in 100 mL 1× TBE (Tris/borate/EDTA) 
buffer with microwave radiation at 300 W in 30 second intervals until the agarose was completely 
dissolved. The agarose solution was then poured into the gel mould and allowed to set at room 
temperature for 30 minutes.  
After 24 hours the samples were centrifuged at 6000 rpm for 1 minute in order to ensure that any 
condensation droplets settled in the bottom of the microtubes. Loading buffer (2 µL) was added to 
each sample before being loaded into a prepared agarose gel. The samples were loaded in 15 µL 
quantities into the gel. Electrophoresis took place at 80 V for three hours in 1× TBE buffer. 
After three hours the gel was removed from the electrophoresis tank and stained in 100 mL 1× TBE 
buffer with ethidium bromide (10 mg/mL, 30 µL) for 15 minutes with constant linear agitation. After 
15 minutes of staining the gel was placed in 100 mL distilled water and destained for 5 minutes in 
order to remove any excess staining solution from the outside of the gel.  
The gel was viewed under a UV lamp at 254 nm. 
4.4.4.2 UV-Vis DNA binding study: Electronic absorbance titration 
A 200 µM stock solution of the test compound was prepared in DMSO and diluted with Tris-HCl 
buffer (pH = 7.2) to yield a final solution of 20 µM test compound in a 10 % DMSO/Tris-HCl solution. 
A 10 % DMSO/Tris-HCl reference sample was prepared and the UV-Vis spectrum collected from 
230 – 630 nm. Aliquots (5 – 20 µL) of salmon sperm DNA (0.43 – 0.47 mM) were added to both the 
sample cell and the reference cell respectively. The samples were stirred manually and placed in 
the spectrophotometer to incubate for 5 minutes at 25 °C before the absorbance spectrum was 
acquired. This process was repeated until the same spectrum was obtained for three additions of 
DNA, indicating that saturation has been achieved. This method as an inherent dilution factor that 
occurs with each addition of DNA to the sample cell. In order to minimize the dilution, a high 
concentration of DNA stock solution was used and the data obtained adjusted accordingly. 
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Chapter 5: Conclusions and Future 
Prospects 
5.1 General Conclusions 
The aim of this study was to synthesize a number of trans-Pd(II)-phenyl-1,2,3-triazolyl and N,N’-
bidentate Pd(II)-pyridyl-1,2,3-triazolyl complexes as potential anti-cancer agents.  
A modified microwave ‘click’ reaction using a sterically hindered copper catalyst, Cu(PPh3)3Br, 
resulted in the best yield of a number of known and novel 1-substituted-4-phenyl-1,2,3-triazole and 
1-substituted-4-pyridyl-1,2,3-triazole ligands.1 The organoazide substituents were chosen in such a 
way as to allow us to investigate the influence of sterics, electronics and ligand hydrophilicity. All 
ligands were fully characterized with various analytical techniques. 
Complexation of the 1-substituted-4-phenyl-1,2,3-triazole ligands to palladium, using (MeCN)2PdCl2 
as a precursor, yielded the trans-Pd(II)-phenyl-1,2,3-triazolyl complexes in moderate to good yields. 
Full characterization with various analytical techniques confirmed the PdL2Cl2 nature of these 
complexes. It was noted that the trans-Pd(II) complexes dissociated in DMSO and that the extent of 
dissociation is dependent on the N-bound substituents of the 1,2,3-triazole ring, with aromatic 
substituents leading to a greater extent of dissociation than the aliphatic and hydrophilic substituents. 
Since the cytotoxicity evaluation of these complexes relies on the solvation of the complex in DMSO, 
stability of the complex is important to ascertain the active species of the complex. The dissociation 
of the complex in DMSO means that the cytotoxicity evaluations conducted were done with a mixture 
of species in solution, as discussed in Chapter 3. 
Complexation of the 1-substituted-4-pyridyl-1,2,3-triazole ligands to palladium, using (MeCN)2PdCl2 
as a precursor, yielded the N,N’-bidentate-Pd(II)-pyridyl-1,2,3-triazolyl complexes in moderate to 
good yields. Full characterization using a variety of analytical techniques confirmed the successful 
synthesis of the complexes. 
The kinetic solubility of the palladium complexes synthesized was determined using a turbidimetric 
assay. It was found that all complexes were moderately soluble in a 2 % DMSO/PBS buffer solution 
except complexes T2a, T7a, T9a and N1b. Cytotoxicity of the insoluble complexes was thus 
evaluated as suspensions. 
The complexes synthesized were investigated as anti-cancer agents against breast cancer cell lines, 
MCF-7 and MDA-MB-231, and the cytotoxicity evaluated with an MTT assay. Complex T8a displayed 
moderate anti-cancer activity, IC50 = 40.7 (± 1.1) µM, while the remainder of the trans-Pd(II)-1-
substituted-4-phenyl-1,2,3-triazolyl complexes were inactive as anti-cancer agents. None of the 
N,N’-bidentate-Pd(II)-1-substituted-4-phenyl-1,2,3-triazolyl complexes displayed anti-cancer activity. 





It is proposed that low solubility and lability in solution contributes to the lack of anti-cancer activity 
observed. 
Subsequently, the cytotoxicity of the ligands was investigated against MCF-7 and 1a - 4a and 7a 
displayed good to moderate anti-cancer activities. A trend was observed in which an increase in the 
flexibility of the N-bound substituent resulted in decreased cytotoxicity. It was interesting to observe 
that the phenyl ring in the 1-substituted-4-phenyl-1,2,3-triazole ligands appear to be crucial for the 
cytotoxicity of the ligands, as none of the 1-substituted-4-pyridyl-1,2,3-triazole ligands displayed any 
anti-cancer activity. 
The DNA binding capabilities of the active compounds were investigated with two studies, a DNA 
migration study utilizing horizontal gel electrophoresis and a UV-Vis absorbance DNA titration. 
Ligands 1a - 4a displayed intercalative character in both studies and T8a displayed covalent binding 
in the DNA migration study. Ligand 7a displayed potential intercalative character as ascertained from 
the DNA migration study. The DNA titration study, on the other hand, revealed possible multi-mode 
binding characteristics. 
The affinity of the ligands towards DNA did not correlate with the results obtained for the MTT assays 
conducted. This would seem to indicate that the main target of these ligands might not be DNA, and 
this thus warrants further investigation. 
In summary, the aims and objectives, as outlined in Chapter 1, were achieved. A small library of 1,4-
disubstituted-1,2,3-triazole ligands were synthesized and complexed to a Pd-precursor to yield trans-
Pd(II)-1-substituted-4-phenyl-1,2,3-triazolyl and N,N’-bidentate-Pd(II)-1-substituted-4-pyridyl-1,2,3-
triazolyl complexes, respectively. The cytotoxicity of the complexes was evaluated against the MCF-
7 and MDA-MB-231 cancer cell lines, and it was found that only one complex, T8a, displayed 
moderate anti-cancer activity. A number of ligands, 1a - 4a and 7a, displayed moderate to good 
cytotoxicity against MCF-7 and their DNA interaction modes were investigated by utilizing UV-Vis 
spectrometry and horizontal gel electrophoresis. The active ligands displayed weak intercalation with 
the exception of 7a, which seem to display a multi-mode binding character. 
5.2 Future Prospects 
Owing to the continuous flow of experimental research, there are always opportunities for expansion. 
When the work presented in this thesis is considered, there are two areas in which future endeavours 
can be focussed, 1) changes pertaining to the chemical structure of the complexes investigated and 
2) the types of biological interaction studies pursued. 





5.2.1 Structural investigations 
In order to combat the ligand dissociation observed for the trans-Pd(II)-1-substituted-4-phenyl-1,2,3-
triazolyl complexes, a stronger metal-ligand bond is required. As mentioned in Chapter 1, the 
strength provided by a Pd-C bond has proven to provide the solution stability required.  
All the 1-substituted-4-phenyl-1,2,3-triazole ligands synthesized in this paper can be used to 
synthesize NHC-carbenes of the type published by Hong and co-workers2 as shown in Figure 5.1. 
The complexes investigated by these authors were applied in Suzuki-Miyuara cross-couplings but 
their biological applications have not been investigated. This would afford the opportunity for the 
investigation of the 1,2,3-triazolyl ligands in a trans-Pd(II) complex. 
 
Figure 5.1: The PEPPSI (pyridine-enhanced precatalyst preparation stabilization and initiation) type NHC-carbenes 
synthesized by Hong and co-workers.2 
Similarly, the 1-substituted-4-pyridyl-1,2,3-triazole ligands can be used to synthesize abnormal 
carbenes, as investigated by Albrecht and colleagues3 (Figure 5.2).In this case the complex 
investigated was an efficient water oxidation catalyst, but the biological application has not been 
investigated. This would result in the investigation of the ligand in a chelated position. 






Figure 5.2: An abnormal carbene complex investigated by Albrecht and colleagues3 as a water  oxidation catalyst. 
Alternatively, the N-bound substituent of the 1-substituted-4-pyridyl-1,2,3-triazole can be altered to 
include a bioactive molecule, such as a carbohydrate4 or folic acid. This would result in the complex 
being more readily available to enter the cellular matrix through a Trojan horse mechanism5. 
 
Figure 5.3: One of the carbohydrate containing 1,2,3-triazolyl Pd(II) complexes investigated by Trivedi and 
colleagues4 
Owing to the simple nature of the ligands that displayed anti-cancer activity, there is a myriad of 
structural changes that can be applied in an effort to include the palladium and increase the 
cytotoxicity. However, investigating the mode of action of the active ligands, especially ligand 7a, 
would also be prudent. 
5.2.2 Biological interactions 
The DNA binding observed in the DNA titration of 7a was not quantitative, possibly due to multi-
mode binding, as discussed in Chapter 4. In order to ascertain that DNA damage does occur, it is 
recommended that proteins from treated cells are extracted and a Western blot for PARP cleavage 
is performed.6 This should indicate whether DNA damage does indeed occur, or whether the 
interaction observed in the DNA migration and DNA titration studies is merely an artefact of the assay 
conditions. 
If PARP cleavage is observed, the DNA interaction of the ligand needs to be investigated with 
different methods. For quantitative purposes, it is advised to use a competitive ethidium bromide 
DNA fluorescence study, from which the binding constant can be calculated. During this assay the 
fluorescence spectrum of EtBr-DNA is recorded with the ligand being titrated into the sample.7–9  





Should the Western blot indicate that DNA damage does not take place, the mode of action of the 
ligand can be evaluated against a number of biological macromolecules. There are many examples 
of alternative biologically abundant molecules with which the ligand could potentially interact.  
The interaction of various heterocyclic ligands with bovine serum albumin (BSA) has been prevalent 
in literature recently.8,10–14 BSA is an abundant protein in the circulatory system which is responsible 
for the transportation of steroids, metal ion and drugs among others.8 This provides the opportunity 
to investigate the drug-protein interaction, rather than the drug-DNA interaction. 
Alternatively, the interaction of the ligand with topoisomerase would also provide some insights into 
the mode of interaction of the ligand. Topoisomerase is an enzyme which controls the coiling of DNA. 
Owing to the fact that the DNA titration and migration studies for 7a indicated that some form of DNA 
interaction is taking place, it might be worthwhile to investigate whether the change in DNA is due to 
an interaction with the topoisomerase.11,13,15–17 
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